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Abstract 
 
1,4-disubstituted-1,2,3-triazoles are widely researched organic structures which are 
generally biologically well tolerated and metabolically stable, making them ideal 
isostere for amide/peptidic bonds.  This project focuses on the development of 1,4-
disubstituted-1,2,3-triazoles based structures for both the treatment of prostate 
cancer and tuberculosis. 
A range of non-steroidal androgen receptor (AR) antagonists were designed and 
synthesised with a focus on producing compound which mimic clinically used AR 
antagonists Flutamide and Bicalutamide.  A robust and rapid methodology was 
developed to access a range of compounds which replace the amide group with the 
1,4-disubstituted-1,2,3-triazole whilst still also retaining the general structure seen 
in these gold standard AR antagonists.  Compounds inspired by Flutamide were 
accessed in high yield (45–87%) and screened at static concentrations of 20 and 40 
μM against androgen dependant (LNCaP) cells, the most three promising were 
found to display IC50 values of 40–50 μM and 42–69 μM against LNCaP and 
androgen independent (PC-3) cells, respectively.  These results are promising when 
compared to Bicalutamide itself (30 and 58 μM against LNCaP and PC-3 cells, 
respectively).  
The Bicalutamide inspired compounds, were synthesised in an optimised five step 
synthesis, and in isolated overall yields ranging from 41% to 85%.  Evaluation of 
these compounds against androgen dependant (LNCaP) and independent (PC-3) 
cell lines showed excellent IC50 values of 34–45 μM and 29–151 μM, respectively. 
In parallel to cellular evaluation in silico docking of all synthesised compounds was 
undertaken in various AR isoforms (wild type and T877A mutant).  The docked 
compounds were found to bind in either one of two main conformations, dependant 
on the interactions dominating the binding.  
Similarities between the compounds within this study and established 
antitubercular compounds, inspired a preliminary examination into the existing 
compounds potential antitubercular properties.  This preliminary study into the 
antitubercular activity of previously synthesised compounds, revealed twelve 
xx 
 
compounds which possessed promising activity with six possessing minimum 
inhibitory concentration (MIC) values <10 μg mL−1.  A further 21 compounds were 
synthesised with an additional six compounds displaying MIC values of ≤ 10 μg 
mL−1-.  In addition to the low MIC values displayed for these compounds they also 
displayed a total selectivity for the tuberculosis mycobacterium, when assayed 
against Staphylococcus aureus ATCC 13801, Bacillus subtilis, Pseudomonas 
aeruginosa PA01 and Escherichia coli HB101.    
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Plain English Summary 
 
1,2,3-Triazoles, particularly the 1,4-disubstituted-1,2,3-trizole, are useful tools for 
medicinal chemistry and drug discovery.  Their rapid synthesis, large amount of 
commercially available starting materials and ease of purification, mean that they 
often serve as excellent starting points for potential drug candidates.  This thesis 
commences by discussing prostate cancer, its physiology and current treatments, 
before summarising the construction and applications of 1,2,3-triazole-based 
structures. 
Three topics will be covered in the remaining chapters, each topic focusing on the 
application of 1,4-disubstituted-1,2,3-triazoles. 
Chapter 2 investigates the design and synthesis of a range of 1,4-disubstituted-
1,2,3-triazoles based on the common prostate cancer therapeutic Flutamide.  The 
synthesised compounds were evaluated for their ability to inhibit prostate cancer 
cell growth, and their in silico modelling data evaluated. 
Chapter 3 focuses on the design and synthesis of a range of 1,4-disubstituted-1,2,3-
triazoles, which aim to mimic the gold standard prostate cancer therapeutic, 
Bicalutamide (trade name Casodex®). 
Chapter 4 focuses on the biological and in silico evaluation of the synthesised 
Bicalutamide mimetics.  With the in silico modelling being undertaken with the 
wild type and T877A mutant AR isoforms. 
Chapter 5 begins with an introduction of tuberculosis, its physiology and current 
treatments.  This introduction will be followed by the design and synthesis of three 
libraries of novel compounds with the aim of inhibiting the growth of the 
Mycobacterium tuberculosis (Mtb). 
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“The true delight is in the finding out rather 
than in the knowing.” 
-Isaac Asimov 
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Chapter 1 
 
1 Introduction 
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 Prostate cancer 
Prostate cancer presents a major concern in society as it is the second most 
commonly diagnosed cancer and is the sixth-leading cause of cancer related death 
in men worldwide.[1]  The risk of prostate cancer increases significantly with age 
resulting in a rise in occurrence from 1 in 1000 to 1 in 12 when comparing a man 
in his forties to a man in his seventies (Figure 1-1).[2]   
 
 
Figure 1-1 Graph of increase 
 
Ethnicity also plays a large factor in a person’s likelihood of developing prostate 
cancer as can be seen in Figure 1-2 in a study done by Centres for Disease Control 
and Prevention (CDC) in the USA.  An African American man is much more likely 
to develop prostate cancer followed by Anglo-Saxon men, men of Hispanic 
descent, with Asian/Pacific Islander (A/PI) and American Indian/Alaska Native 
men displaying similar prevalence.  
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Figure 1-2 Graph of death rates by ethnicity, adapted from ref[3] 
 
The symptoms of prostate cancer are often non-specific and commonly include 
painful and frequent urination, blood in the urine, unexplained weight loss, and 
fatigue can also be indications of more widespread problems.  Once found to have 
prostate cancer, the prognosis depends heavily on the type and stage of the cancer 
along with the age and general health of the patient.  Overall the survival rate for 
prostate cancer is generally good with many patients dying with prostate cancer 
rather than dying of prostate cancer.  Although this may be a result of the higher 
incidence of prostate cancer among older men.  Prostate cancer also represents large 
cost to society with the cancer council Australia stating that, in the 2008–2009 
period the health system expenditure on prostate cancer was $347 million.[4]  
 
 Prostate cancer physiology 
The prostate is a small gland which surrounds the posterior urethra, as can be seen 
in Figure 1-3.  It is close to the lower ends of the ureters, the rectum and to many 
structures associated with erection of the penis.[5]  In a healthy male the prostate 
glands main role is secreting fluids which act to nourish and protect the sperm, 
aiding in reproductive capabilities.   
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Figure 1-3 Diagram showing location of prostate gland[6] 
 
Prostate cancer, as with all cancers, represents a disease which displays enhanced 
cell proliferation, relative to healthy cells, due to a range of different factors.  
Prostate cancer cells are primarily driven to grow by activation of androgen 
receptors (AR), within the cells binding androgenic hormones, such as testosterone 
and dihydrotestosterone (DHT), Figure 1-4.  Although healthy cells are also driven 
to grow by these same androgens, the cancerous prostate cells overexpress 
androgen receptors meaning they are more likely to interact with any androgens 
present in the blood, and proliferate extensively. 
 
 
Figure 1-4 Structure of Testosterone (left) and Dihydrotestosterone (right) 
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Androgens, are responsible for the development of the male physical characteristics 
during embryogenesis, sexual maturity at puberty, and a variety of other non-
reproductive related characteristics such as muscle and brain development.[7]  The 
androgen receptor (AR) is a member of steroid hormone receptor transcription 
factor super family, and is present in both healthy and cancerous cells.  As can be 
seen in Figure 1-5 once bound to an androgenic ligand; in this case testosterone, 
the AR undergoes a conformational change and through the help of several protein 
complexes such as heat shock proteins (HSP), transcription takes place.[8] 
Figure 1-5 shows a simplified description of the mode of action of the AR, it’s 
binding with androgens (DHT in this case) and its influence on cell growth.  In the 
absence of an appropriate ligand the AR is bound to a number of heat shock proteins 
(HSP); these HSP are a family of proteins that have a number of different roles in 
the body, in the case of prostate cancer they act as chaperones.[9]  With respect to 
Figure 1-5 this process is started by testosterone (Test) being transported into the 
cell cytoplasm, here it either binds with the AR (not shown), or in the presence of 
5α-Reductase is converted to DHT (shown in Step 1, Figure 1-5).[10]  Once 
converted, DHT binds to the AR, at the carboxyl-terminal steroid binding domain 
(shown in Step 2, Figure 1-5).[11]  Once the DHT and the AR are bound, the 
complex undergoes a conformational change, the HSP is released (shown Step 3, 
Figure 1-5), and the AR/DHT complex localises to the nucleus (shown 4, Figure 
1-5).  Once in the nucleus this complex then forms a dimer with another AR/DHT 
complex.[12]   This dimer then interacts with androgen response elements (ARE-
DNA) and ultimately results in cell growth.[13]   
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Figure 1-5 Simplified AR binding and transcription 
 
In prostate cancer, the AR pathway differs from that of a normal prostate cell, whilst 
both still use the same distinct signalling pathway, many of the androgen regulated 
genes such as cell cycle regulators ODCI, PCNA[14] and proliferation-associated 
genes such as BUB1, BUB3 and UBCH10;[15] become up-regulated during the 
development of prostate cancer,[16] resulting in the cancerous cell becoming much 
more responsive to androgens.  Thus eliciting an increased growth rate when 
compared to healthy prostate cells, in addition to an over expression of AR’s 
Prostate cancer cells first rely on their interaction with androgens to grow, but in 
general the cancer will often progress to what is known as castration-resistant 
prostate cancer (CRPC).  Also known as hormone-refractory prostate cancer, 
usually occurs when a person suffering from prostate cancer is undergoing 
androgen deprivation treatment (ADT).  After an amount of time (typically 12-33 
months) the cancer begins to shows signs of resistance to this therapy.[17]  Although 
not fully understood, CRPC is thought to develop resistance to therapy via a number 
of different pathways; (i) AR activation by androgens converted from adrenal 
androgens or synthesised intratumorally via a de novo route; (ii) the ARs become 
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hyper sensitive due to extreme over expression of AR proteins; (iii) the AR mutates 
becoming promiscuous, allowing cell proliferation to be activated by a wider 
variety of ligands.[18]  Until recently once a person is found to have CRPC the 
treatment changed from a curative style to one of palliative care, with recent study 
showing some combinations of pharmaceuticals being effective in the treatment of 
CRPC.[19]  
 
 The androgen receptor 
The AR, as demonstrated, plays an enormous part in the development of prostate 
cancer. The receptor itself is a phosphoprotein which functions as a ligand-
dependent nuclear transcription regulator.[12]  Figure 1-6 highlights how the AR 
protein is comprised of four major domains; the N-terminal domain (NTD), which 
contains the transcriptional activation domain, becoming activated when the AR 
binds with an androgen; also causing the AR/androgen complex to become 
localised in the cell nucleus.  The DNA binding domain (DBD), the region of the 
protein that interacts with DNA.[20]  The hinge region (H), which plays a part in 
many functions of the AR protein including, intranuclear mobility, nuclear 
translocational signal and binding of the AR to different ligands.[21]  The 
steroid/ligand binding domain (LBD), the region of the protein which interacts with 
the target androgens, and will eventually lead to the activation of the target genes.     
 
 
Figure 1-6 Structure of AR isoforms, AR-A and AR-B 
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The AR is also present in two isoforms; AR-A and AR-B, differing in the length of 
the NTD region.[22]  The AR-B isoform has an additional 187 amino acids at the 
start of the N-terminus, which are not found in the AR-A isoform.  The AR-B 
isoform has been suggested to be produced by the initiation of protein synthesis at 
the 188 site in AR-A.  Both of these isomers still retain their binding regions and 
thus ability to bind to androgens, and so both are targets for prostate cancer 
therapy.[23]   
 
 Detection of prostate cancer 
The treatments used to combat prostate cancer can often differ depending on a 
person’s age and stage to which the cancer has progressed at diagnosis.  Therefore 
detection of the cancer plays a crucial role in determining the severity, duration and 
type of treatments. 
Early detection of prostate cancer is incredibly important, and is key to high 
survival.  Considering the increase in prevalence of prostate cancer with relation to 
age, it is often recommended that men undergo a screening at age 40.  This can then 
be used to assess their individual risk of prostate cancer and work out a detailed 
monitoring strategy.  
The most common methods employed in the detection of prostate cancer are the 
digital rectal exam (DRE) and transrectal ultrasonography (TRUS).  Whilst these 
two physical evaluation techniques are widely employed they are limited in their 
ability to distinguish between benign prostate hyperplasia (BPH) and prostate 
cancer.[24]  In either case (BPH or prostate cancer), intervention or therapy must be 
sought.  Therefore, despite their lack of diagnostic power, these physical 
evaluations are crucial in the early detection of potential prostate cancer.  The 
inherent difficulty present with these physical methods of detection have led to the 
use of certain complimentary diagnostic tools being used, one such tool is the 
screening of biomarkers being used to detect prostate cancer, such as prostate-
specific antigen (PSA).[25]   
Cancerous prostate cells exhibit a ‘leakiness’ allowing PSA to leach from the 
cancerous cells ultimately elevating the normally low serum concentrations of 
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PSA.[26]  Elevated levels of PSA in the bloodstream generally anywhere above 4 
ng/mL, indicates abnormal prostate function,[26] following this a more conclusive 
method, such as a biopsy is performed, to confirm the tumour presence and allow 
for staging of the cancer.  The cancer may be staged using the Gleason scale,  a 
score (1-5) is assigned based on architecture of cancer tissue and of the cellular 
content of samples taken via biopsy,[27] with high scores presenting a higher risk 
than lower scores.[28]  Figure 1-7 shows the differing grades and architecture with; 
Grade 1 – small uniform cells, well defined and differentiated, Grade 2 – more 
space between cells, becoming less defined, Grade 3 – moderately differentiated, 
becoming less tightly packed, Grade 4 – poorly differentiated, signs of infiltrative 
masses, Grade 5 – distinct lack of differentiation, infiltrative masses, Grade 5 often 
points to the worst stages of prostate cancer.[29]   
 
 
Figure 1-7 Examples of tissue structure and Gleason score[29] 
 
Tumour-Node Metastasis (TNM) is another commonly employed system for 
staging prostate cancer, which defines the cancers progression by ranking three 
separate properties of the cancer (Table 1-1); (i) the tumour is given a number (1-
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4) based on depth of the tumour and how far the tumour has spread to the 
immediately surrounding areas; (ii) nodes are assigned a number (0-1) based on 
whether or not the cancer has spread to regional lymph nodes; (iii) metastasis is 
ranked (0-1) with M0 indicating no metastasis and M1 indicating metastasis with 
levels ranging from M1a-c based on severity of the cancers spread.[30] [31]  
 
Table 1-1 Stages of the TNM system of tumour staging 
TMN Classification 
T1 
A doctor cannot feel the 
tumour or see it with imaging 
N0 
Cancer has not spread to 
lymph nodes 
T2 
A doctor can feel the cancer 
during DRE and see it using 
imaging 
N1 
Cancer has spread to regional 
lymph nodes (inside the 
pelvis) 
T3 
The cancer has begun to 
spread outside of the prostate 
M0 
The cancer has not 
metastasised beyond the 
regional lymph nodes 
T4 
The cancer has spread to 
tissues such as the rectum, 
bladder or pelvic walls  
M1 
The cacner has metastasised 
to distant lymph nodes, 
bones, or other distant organs 
 
 Prostate cancer therapies 
 
 Surgery 
Surgery is one of the front line treatments for prostate cancer and boasts a relatively 
high survival rate when compared with other treatment options.[32]  Surgical options 
for the treatment of prostate cancer (radical prostatectomy) involve either the 
attempted removal of all or some of the prostate gland in an attempt to remove the 
afflicting tumour.  Surgical intervention can possess innate risks due to the position 
of the prostate gland and its relatively complex surroundings.  Prostate removal is 
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rife with intricacies and can result in decreased bladder control and erectile 
dysfunction which can have negative impacts on the patients quality of life.[33]     
 
 Radiotherapy 
Radiotherapy is currently one of the more common methods of treating prostate 
cancer and can be used to avoid invasive surgical treatments if the cancer is detected 
at an early stage.[1]  Radiotherapy can be split into two distinct forms based on 
where the radiation source is located; external beam or brachytherapy.  External 
beam radiotherapy uses an externally generated beam of radiation, commonly X-
ray, to bombard  cells with high levels of radiation.[34]  This bombardment with 
radiation results in the damaging of the DNA of the cancerous cells either by direct 
breakage of single and double stranded DNA or by DNA damage caused by 
charged particles such as OH• radicals generated in situ  by the radiation.[35]  This 
mechanism relies on the inability of cancerous cells to repair the damage while 
healthy cells can recover. 
Brachytherapy is a less common form of radiotherapy in which a radioactive ‘seed’ 
is placed in, or in close proximity to, the prostate tumour effectively applying a 
small amount of radiation concentrated at the cancerous site.[36]  The radioactive 
‘seeds’ can be made of a variety of different radioactive materials depending on the 
half-life and emission type wanted.  Commonly used radioactive materials include 
125I a γ-emitter with half-life of 59 days, 103Pd a γ-emitter with a half-life of 17 days 
and 192Ir which emits a combination of β and γ radiation and has a half-life of 73 
days, or a combination of several.[37]  Brachytherapy commonly uses both γ- and β-
emitters.  Both of these radiotherapy techniques have benefited from the continual 
advances made in medical imaging with both often being utilised with the 
assistance of real-time imaging to help deliver the radiation to the correct areas.[34]    
 
 Hormone therapy 
As ~90% of androgens originate from the testes,[38] thus in its simplest form 
hormone therapy involves the castration, or removal of the testes.  This procedure 
is often called orchiectomy and can be used to essentially deprive the cancer of the 
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androgens needed to fuel its growth.  Hormone therapy, in the form of administered 
drugs, can take form in either one of three applications; primary therapy, 
neoadjuvant therapy (given before main therapy) or adjuvant therapy (given after 
main therapy).  Primary hormone therapy often referred to as ‘androgen blockade’ 
refers to the use of Androgen Deprivation Therapy (ADT) whereby an Androgen 
Receptor Antagonist (ARA) is administered in an effort to limit the binding 
between the body’s natural hormones and the androgen receptors presented by the 
cancerous cells, thus limiting the cancers growth.[39]  When used as either adjuvant 
or neoadjuvant, hormone therapy acts as a secondary treatment, with the aim of 
reducing the tumour size to either allow for, or aid, a main treatment such as 
radiotherapy or surgical intervention.[40]   
 
 
Figure 1-8 Simplified agonist/antagonist diagram 
 
Hormone therapies generally rely on the administration of pharmaceuticals which 
act as an AR antagonist.  Agonist and antagonist are terms used to describe an 
administered pharmaceutical and the biological effect they have upon binding to 
their target receptor.  Agonistic compounds bind to the receptor and illicit the 
natural reaction e.g. DHT binds to the AR which then signals for increased cell 
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growth, whereas; antagonistic compounds bind to the receptor but generally do not 
illicit any response.  In the case of prostate cancer an agonistic compound would 
further cause the cancer to grow whereas an antagonistic compound would slow or 
stop the growth of the cancer (Figure 1-8). 
 
1.2.3.1 Steroidal Treatments of Prostate Cancer 
The majority of therapeutics for hormone therapies available today are based on 
non-steroidal compounds, however this has not always been the case.  Due to their 
involvement in prostate cancer function, steroidal molecules were an obvious 
choice to start compound development from.  Many steroids have been used over 
the years to either combat the prostate cancer or improve a patients quality of life.[41]  
Oestrogen plays an important part in the treatment of prostate cancer, as previously 
mentioned castration is often used in an effort to deprive the cancer of the hormones 
needed to fuel its growth.  Castration can refer to either surgical removal of the 
testes (previously discussed) or in a more subtle approach castration can refer to 
the administration of pharmaceuticals, in this case the synthetic oestrogen 
diethylstilbestrol (DES, Figure 1-9).[42]   
 
 
Figure 1-9 Structure of diethylstilbestrol 
 
DES exerts its effects by suppressing the amount of luteinising hormone (LH) the 
pituitary secretes.[43]  LH acts upon the Leydig cells, which are found in the 
testicles, by causing them to produce testosterone.  When DES supresses the 
amount of LH produced, it in turn supresses the production of testosterone, able to 
reduce it to near orchiectomy (castration) levels.[42]  Whilst DES is able to 
effectively lower androgenic hormone levels, it is not without its side effects, which 
include nausea, fluid retention, heart failure, deep vein thrombosis, pulmonary 
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embolism and gynecomastia.  It is due to these many serious side effects that DES 
is not used today.[44]    
1.2.3.2 Flutamide (1) 
Flutamide (Figure 1-10, 1) is a non-steroidal androgen antagonist (or anti-
androgen), it was the first clinically used non-steroidal androgen antagonists.[45]  
Flutamide (1) acts to essentially inhibit the binding of androgens to the AR, by 
preferentially binding to the AR itself.  Although Flutamide (1) has some affinity 
for the AR, its metabolite 2-hydroxyflutamide (2, Figure 1-10) which has the 
greatest antagonistic effect having an affinity that is threefold higher than that of 
its parent Flutamide (1).[46]   
 
 
Figure 1-10 Structure of Flutamide (1) and 2-hydroxyflutamide (2) 
 
Flutamide (1) is metabolised in the liver to 2-hydroxyflutamide (2) via cytochrome 
P450 (CYPs), commonly involved in drug metabolism.[47]  In the case of Flutamide 
(1) the CYPs are thought specifically to be CYPs 3A4 and 1A2.[48]  Flutamide (1) 
suffers the drawback of having a relatively short half-life of ≈6 h and thus can 
require up to three doses daily of ≈250 mg, making patient compliance difficult.   
1.2.3.3 Bicalutamide (3) 
Bicalutamide (3) (Figure 1-11) is another anti-androgen that acts in much the same 
way Flutamide (1) does, by agonistically binding to the AR it blocks the androgens 
from binding and thus can ‘starve’ the cancer of the needed androgens.   
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Figure 1-11 R & S Bicalutamide (3 & 4) 
 
Bicalutamide (3) has an affinity that is roughly 2–4 times higher than 2-
hydroxyflutamide,[49] and is currently the most commonly used anti-androgen in 
the treatment of prostate cancer.  This can partly be put down to its relatively long 
half-life (of ≈ 1 week) when compared with Flutamide (1).  Thus to maintain a 
therapeutic concentration in the blood, Bicalutamide (3) requires only one daily 
dose of 50 mg.  The AR antagonism of Bicalutamide (3) is mostly due to the (R)-
eutomer (enantiomer having desired activity), however Bicalutamide (3) is 
administered in a racemic mixture; both eutomer  and distomer (enantiomer lacking 
desired activity) are metabolised in the liver with the distomer (4S) being 
metabolised and eliminated up to 100× faster than the eutomer (4R).  Although both 
R & S enantiomers undergo metabolism via glucuronidation (coupling with a unit 
of glucuronic acid, 5) the difference in rate of metabolism is due to the location of 
glucuronidation.  The distomer is converted to the glucuronide derivative (6) 
immediately via the α-hydroxyl, whilst the aryl ring of the eutomer is first oxidised 
then converted to the glucuronide derivative (7) before being excreted (Figure 
1-12).[50]  
 
 
Figure 1-12 Metabolism of Bicalutamide (3) enantiomers 
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This fast clearing from the body puts unwanted stress on the patients liver which 
can be problematic for patients already experiencing hepatic impairment due to 
illness or prostate cancer therapies.[51]  Bicalutamide (3) is synthesised as a racemic 
mixture of it R & S enantiomers, this is due to the synthesis of Bicalutamide (3) not 
easily lending itself to a pathway which results in an enantiomerically pure 
product.[52]  As can be seen in Scheme 1-1, the first synthesis of Bicalutamide (3), 
published in 1988 proceeds via a racemic epoxide intermediate making control of 
the stereochemical outcome difficult.[53] 
   
 
Scheme 1-1 First synthesis of Bicalutamide 
 
Whilst Bicalutamide (3) is the most commonly used AR antagonist it is not without 
side effects, although only minor compared to other treatment options, these 
include hot flushes, gastrointestinal disorders, hepatic changes, pruritus (itching) 
and gynaecomastia. 
1.2.3.4 Nilutamide (8) 
Nilutamide (Figure 1-13, 8) is a hydantoin based non-steroidal AR antagonist, 
although less commonly used than Flutamide (1) and Bicalutamide (3).[54]  
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Figure 1-13 Structure of nilutamide 
 
Nilutamide (8) acts in much the same way Bicalutamide (3) and Flutamide (1) do, 
in that it blocks the androgen receptor essentially cutting off the androgens from 
binding and eliciting the growth response.  In terms of binding affinity, Nilutamide 
(8) has an affinity which is roughly 50% that of Bicalutamide (3) and twice that of 
Flutamide (1).[55]  Nilutamide has a half-life of 56 h which is comparable to that of 
Bicalutamide (3),[56] meaning that it can be given as a once daily dosage.  
Nilutamide (8) displays only mild side effects such as hot flashes, loose stools and 
problems adapting from light/dark environments.[54]  Payen et al.[57] synthesised a 
range of nilutamide derivatives which feature a range of different modifications, 
shown in Figure 1-14 are the two most active derivatives that were synthesised. 
 
 
Figure 1-14 Nilutamide derivatives 
 
 Chemotherapy 
Note that in the context of this thesis, chemotherapy for the treatment of prostate 
cancer will be discussed independent to androgen blockade therapy.  Chemotherapy 
involves the treatment of cancer with small molecular drugs that do not operate via 
hormone receptors.  Unlike surgery and radiotherapy, chemotherapy is a systemic 
treatment, meaning that it is not localised to the immediate area of the cancer and 
instead circulated throughout the body.  As with hormonal therapies, chemotherapy 
can also be administered as primary, adjuvant and neoadjuvant therapies depending 
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on the timing and whether they are aimed to be curative or help reduce the size of 
a tumour before further treatment is applied i.e. surgery/radiotherapy.  Most 
chemotherapeutics are often not cell specific and act to damage cells with a high 
proliferation rate. Thus cancerous cells as well as hair and stomach cells are 
attacked, this often leads to the severe side effects associated with chemotherapy 
treatment such as; nausea, vomiting, alopecia and gastrointestinal upset.  Although 
chemotherapeutics are often placed under the same umbrella term they actually 
encompass a wide variety of compounds which are often group according to their 
mode of action (Figure 1-15),[58]  with some acting to damage the DNA of cells 
which cancer cells are relatively poor at repairing when compared to normal cells; 
whilst other aim to interfere with cell division, halting the dividing cell and often 
leading to apoptosis.[59]  It should be noted that two chemotherapeutic agents which 
are related or operate via similar pathways may have vastly differing side effects.[58]  
 
Classification of chemotherapy drugs 
Class Group Example 
Alkylating 
agents 
Platinums, nitrogen mustard 
derivatives, 
oxazophosphorines 
 
Anti-
metabolites 
Pyrimidine analogues, anti-
folates 
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Figure 1-15 Classification of typical chemotherapy drugs 
 
Despite chemotherapy’s notoriety, it is rarely used in the treatment of prostate 
cancer; this is due to the relatively slow growth rates of the cancerous prostate cells.  
Up until the 1990’s, prostate cancer was even considered unresponsive to 
chemotherapy.  Though chemotherapy is now often reserved for when the prostate 
cancer has progressed to CRPC.[60]  Only recently has treatment of CRPC become 
standard with some agents showing survival benefits of months; the first treatment 
for CRPC was the dual use of docetaxel and prednisone (12 and 13, respectively, 
Figure 1-16) published by Tannock et al.[19] before this much of the treatment of 
CPRC was done using a combination of mitoxantrone (14, Figure 1-16) and 
prednisone.[58]  The combination of mitoxantrone/prednisone improved the quality 
of life and reduced the pain caused but it did not add any time to life of the recipients 
however the dual treatment with docetaxel/prednisone trialled by Tannock et al. 
Mitotic 
inhibitors 
Vinca alkaloids, taxanes 
 
Topoisomerase 
inhibitors 
Topoisomerase-I inhibitors, 
topoisomerase-II inhibitors 
 
Anti-tumour 
antibiotics 
Anthracyclines, bleomycin, 
mitoxantrone 
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showed an increase in the median survival of the patients.  Increase from 16.5 
months for those on the mitoxantrone/prednisone combination, to 18.9 months for 
those on the newly proposed docetaxel/prednisone regime. 
 
 
Figure 1-16 Structure of Mitoxantrone, Docetaxel and Prednisone 
 
 Triazoles 
Triazoles are a class of molecules pertaining to a five membered aromatic ring 
containing two carbon atoms and three nitrogens (Figure 1-17).  Triazoles have 
begun to garner an amount of interest within medicinal chemistry due to their 
unique properties, ease of synthesis and the relatively mild conditions under which 
they can be formed, meaning they can be installed in the presence of a wide range 
of functional groups. 
   
 
Figure 1-17 Structural classes of triazoles 
 
Shown here (Figure 1-17) are all the possible isomers of the basic triazole core.  
Each of these isomers possesses unique properties due to the relative configuration 
of the carbon and nitrogen positions, and the respective sp2 or sp3 hybridisation of 
the nitrogen atoms.[61]  Although all the triazoles isomers can be found in medicinal 
chemistry,[62] this thesis will focus exclusively on the 1H-1,2,3-triazole;  and so will 
be the only isomer discussed in any detail.  The  disubstituted-1,2,3-triazole 
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comprises a large group of related compounds which were first reported in 1893 by 
Michael after having synthesised them from acetylenedicarboxylate and phenyl 
azide.[63]  In 1963, Huisgen undertook a study of the mechanism by which this 
family of compounds was formed and as such has been labelled as the Huisgen 1,3-
dipolar cycloaddition reaction (Figure 1-18).[64]  The Huisgen cycloaddition 
generally involves the stirring of an azide an alkyne at elevated temperatures (e.g. 
>150 °C) resulting in a [3+2] cycloaddition, though this is non-specific and often 
results in a mixture of the 1,5 and 1,4-disubstituted triazole isomers (Figure 
1-18).[65]  
 
 
Figure 1-18 Huisgen 1,3-dipolar cycloaddition and 1,5 and 1,4-disubstituted triazole variants 
 
In 2002, work by Sharpless et al. found that the addition of copper (I) sped the 
reaction up by several orders of magnitude and gave only the 1,4-disubstituted 
regioisomer.[66]  This reaction was then coined the copper (I) catalysed azide-alkyne 
cycloaddition (CuAAc), and has spread throughout many areas of science.  The 
CuAAc reaction is tolerant to a large variety of functional groups, can often be 
undertaken at room temperature and can be catalysed using a large variety of Cu(I) 
catalysts.[66]  The use of CuAAc (or ‘click’ chemistry) has become one of the most 
commonly used reactions across not only chemistry, but also other disciplines, for 
an account refer to the literature.[67] Several mechanisms of this reaction were 
proposed,[66] though recent work by Fokin et al. has led to the following mechanism 
(Scheme 1-2).[68] 
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Scheme 1-2 Proposed dinuclear mechanism for CuAAc 
 
Here the copper coordinates to the alkyne followed by copper acetylide formation 
(1), helped by interaction with another copper (I) species.  This copper acetylide 
complex then cyclises with the azide via a bimetallic core, before finally forming 
the 5-membered triazole ring, with a vinyl cuprate species.[68]  This undergoes 
protonation giving the triazole in the 1,4-configuration and regenerates the Cu(I) 
catalyst.  This newly proposed mechanism avoids the strained six membered ring 
in previously proposed mechanisms.[66]   
The 1,5-regioisomer of the 1,2,3-triazole can be accessed through the use of 
[Cp*RuCl] containing catalysts (Figure 1-19), first published by Zhang et al,[69] 
these will not be heavily mentioned in this document, the reader is referred to the 
literature.[70]  
 
 
Figure 1-19 Common Ru based catalysts 
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 Triazoles as an amide isostere 
Triazoles have long been considered as a non-classical isostere for amide bonds,[71] 
as can be seen in Figure 1-20.  The geometry of the 1,4- and 1,5-triazoles resembles 
closely that of the trans and cis-amide bonds respectively, closely resembling the 
angle of separation between the R and R’ groups (Figure 1-20).  The incorporation 
of the triazole as an amide mimetic however results in an increase in peptide length 
of ≈1.2 Å, although several peptidomimetics have shown this extension does not 
negatively influence the biological activity of the final peptide.[72] [73]   
 
 
Figure 1-20 Comparison of disubstituted 1,2,3-triazoles and cis/trans-amides 
 
The 1,4-triazole is of particular interest as it not only mimics the general geometry 
well but also provides hydrogen bond capabilities similar to the trans-amide it is 
employed to mimic.[74]  Two of the nitrogens present in the heterocycle free to 
participate in hydrogen bonding, as well as this comparable hydrogen bonding 
capabilities the triazole also possesses a similar dipole moment.  For this reason 
1,2,3-trizoles have been employed to some extent in the synthesis of triazole 
bearing amino acid chains in which, the amide bond linking the two amino acids 
has been replaced with a triazole whilst the pseudo-peptides still display similar 
self-assembly properties[75] and biological activity.[73]  
Triazoles as an amide isostere have also shown some resistance to proteolysis[76] 
when combined with the triazoles ability to proficiently mimic an amide bond, 
preserving the natural function of the parent molecule.  This resistance to 
proteolysis can in some cases confer a longer half-life to the triazole containing 
drug mimetic.[73]     
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 Current applications of 1,2,3-triazoles  
‘Click chemistry’ offers a powerful, reliable and highly selective tool for drug 
discovery, and whilst ‘click chemistry’ refers to a broad range of reactions, as 
previously mentioned only the CuAAc will be discussed in detail.  Due to the speed 
with which compounds can be synthesised, the large amount of suitable 
azides/alkynes and the often simple purification; it comes as no surprise that many 
novel 1,2,3-triazoles are constantly shown to be useful leading pharmacophores.  
Recent reviews by Kolb & Sharpless,[77] Hou et al.[78] and Agalave et al.[79] have 
highlighted some of these recent applications. 
1.3.2.1 1,2,3-Triazoles in anticancer therapeutics 
With cancer presenting a major public health concern, it comes as no surprise that 
1,2,3-triazoles have found application in this field.  Work by Fray et al.[80] has 
shown a series of 1,2,3-trizole human methionine aminopeptidase type 2 (involved 
in angiogenesis) inhibitors (Figure 1-21).  The compounds being shown to inhibit 
cell growth at low concentrations (<5 μM) and as such are of interest for anticancer 
treatments, as cancers must rapidly build a network of blood vessels to support 
rapid proliferation.[81] 
 
 
Figure 1-21 Most active 1,2,3-triazole based compounds investigated by Fray et al. 
 
Work by Pisaneschi et al.[82] focused on a range of radiolabeled 1,2,3-traziole 
containing compounds based on a 3-cyanoquinoline core.  These compounds were 
shown to allow positron emission tomography data to be collected, whilst still 
retaining the antitumor activity displayed by the parent Pelitinib (against A431 
cells, a model epidermoid carcinoma cell line).[83]  
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Figure 1-22 Pelitinib vs the radiolabelled 1,2,3-triazole containing compound synthesised by Pisaneschi et al. 
 
Work done by Yoon & Ryu focused on a series of lavendustin mimetics, 
incorporating a 1,2,3-trizole portion.[84] A number of the synthesised compounds 
showed good inhibitory power (when tested at a static concentration of 10 μM) 
against both HCT116 a colon cancer cell line, and CCRF-CEM a leukaemia cell 
line (Figure 1-23). 
 
 
Figure 1-23 Anticancer compounds synthesised by Yoon & Ryu 
 
These are just a few representative examples.  For more applications of triazoles in 
anticancer studies the reader is referred to the literature.[85], [86], [87], [88], [89]  
1.3.2.2 Antifungal and antibacterial 
Utilising the CuAAc reaction to join fluconazole (an antifungal) and bile acids, 
Aher and co-workers were able to synthesise a series of compounds which showed 
high levels of antifungal activity (MIC ranging from 3.12 to 6.25 μg mL−1) against 
the Candida species (Figure 1-24).[90]     
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Figure 1-24 Fluconazole/bile acid conjugates synthesised by Aher et al. 
 
Work by Vatmurge et al. focused on 1,2,3-triazole linked bile acid/β-lactam 
conjugates,[91] with the majority of compounds exhibiting significant antifungal 
activity and moderate antibacterial activity. 
 
 
Figure 1-25 Example of bile acid/ β-lactam conjugate, synthesised by Vatmurge et al. 
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1.3.2.3 HIV protease inhibitors 
With HIV posing such a serious threat, claiming more than 20 million lives since 
1981,[92] it is no surprise that 1,2,3-triazoles have been investigated as potential 
anti-HIV agents.  Work by Whiting et al. has investigated the use of 1,2,3-triazoles 
to ‘click’ together azide/ alkyne containing fragments,[93] and has led to the 
discovery of a range of novel HIV-1 protease inhibitors (crucial in the virus’ 
lifecycle) (Figure 1-26). 
 
 
Figure 1-26 HIV-1 protease inhibitors synthesised by Whiting et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 Project aims 
 
This project seeks to determine if 1,2,3-isosterism is a viable approach to replace 
the amide unit in common molecular therapies for prostate cancer.  To answer this 
question the following aims will be targeted 
 
1. Design a range of compounds which mimic the general structure of Flutamide 
(1), which incorporate a 1,4-disubstituted-1,2,3-triazole core.  Synthesise these 
designed mimetics via a rational pathway which allows for quick generation of 
a range of further analogues.  Evaluate the biological activity of the synthesised 
compounds in their ability to inhibit the growth of both LNCaP and PC-3 cell 
lines, at two static concentrations.  The most active compounds will then be 
further tested to obtain IC50 values.  Provide further information into the 
possible mode of action of the synthesised compounds by undertaking in silico 
evaluation, providing a possible comparison with the obtained biological 
evaluation data. 
 
2. Design a compound which mimics the general structure and functionalization 
of Bicalutamide (2), whilst incorporating the previously used 1,4-
disubstituted-1,2,3-triazole core.  Devise a general synthetic pathway through 
which this compound and subsequent analogues can be accessed.  Obtain IC50 
data for the synthesised compounds, along with in silico docking data. 
 
3. Design a range of analogues of the previously synthesised Bicalutamide (3) 
mimic, incorporating a range of different ‘head’ and ‘tail’ regions.  Synthesise 
designed compounds utilising the already developed methodology.  Evaluate 
both the biological activity and in silico properties of the synthesised 
compounds. 
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Chapter 2 
 
2 Synthesis and biological evaluation of 
Flutamide mimetics 
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 Chapter overview 
This chapter begins with the design of a range of 1,4-disubstituted-1,2,3-triazoles, 
which mimic the general structure of Flutamide (1).  These compounds will be 
designed with a focus on a scaffold which allows for structural elaboration and 
rapid derivatisation.  The design, synthesis and biological evaluation of a range of 
compound sets will be discussed.  This chapter concludes with a discussion of in 
silico docking of all compounds into the wild type and T877A of the human 
androgen receptor ligand binding domains (hARLBD). 
 
 Design of Flutamide mimetic 
This work focuses on the replacement of the amide group in common prostate 
cancer therapeutics with a 1,2,3-triazole, and observe the affect the replacement has 
on the biological activity of the compounds compared to the parent.  Flutamide 
whilst not active as Bicalutamide served as a starting point allowing for the easy 
inclusion of a triazole core, whilst also allowing for the investigation into the effect 
the inclusion of the triazole would have on the activity of a known compound.  A 
synthetic pathway was devised (Scheme 2-1), which allows modifications to either 
tail (red) or head (blue) region with relative ease; note that throughout this thesis 
the terms ‘tail’ and ‘head’ will be used, whilst these are common terminology in 
molecules which exhibit amphiphilic character, their use in this work is simply to 
allow ease of differentiation between two ends of the same molecule.  This strategy 
allows for the use of an overall general methodology, and access to a broad range 
of potential compounds.  The synthesis will focus on a ‘click’ reaction with a 
terminal alkyne and phenyl azide, the phenyl azide will be accessed via the 
corresponding anilines. 
 
 
Scheme 2-1 Retrosynthetic design of basic Flutamide (1) mimetics 
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As seen above in Scheme 2-1, the proposed synthetic pathway allows for the use of 
a wide range of terminal alkynes.  This approach allows for modification of the tail 
region of the molecule; without the need for extensive synthesis as there are a large 
number of alkynes commercially available.  Through the use of different anilines a 
wide range of aryl azides can be accessed.  Though the major focus of this work 
will be on electron-withdrawing substituents (typically CN, NO2, CF3, etc.) as these 
are more common in prostate cancer therapeutics.  
 
    Synthesis of a model compound 
 
 Synthesis of aryl azide, head region 
A model aniline was chosen for the optimisation of the phenyl azide formation.  In 
this case 4-nitro-3-(trifluoromethyl) aniline (Scheme 2-3, 14) was chosen.  4-Nitro-
3-(trifluoromethyl) aniline was chosen as it correlates to the aryl region present in 
Flutamide (1). 
A vast array of methods exist for the conversion of an aniline to an aryl azide, 
though all typically proceed via diazotisation of the aniline followed by addition of 
an azide source.  An example of this by Zhou et al. is shown in Scheme 2-2. 
 
 
Scheme 2-2 Literature example of amine to azide conversion.[94] 
 
Based on the literature a range of different conditions were trialled, to facilitate the 
conversion of 14 to the desired product 15 (Scheme 2-3), as seen detailed in Table 
2-1.  
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Scheme 2-3 Aryl azide formation 
 
Table 2-1 Optimisation of aryl azide formation 
Entry Reactants Azide 
Source 
Solvent Temp 
(°C) 
Time 
(h) 
Yield (%) 
1 NaNO2 NaN3 o-
Dichlorobenzene 
0 3 - 
2 t-BuONO TMS-N3 MeCN 21 16 - 
3 HCl, NaNO2  NaN3 EtOAc:H2O (8:1) 0 3 Mixturea 
4 HCl, NaNO2  NaN3 MeCN:H2O (8:1) 0 3 94 
5 HCl, NaNO2  NaN3 MeCN 0 2 90 
a observed as a mixture of 15 and 16 
 
The use of sodium nitrite and sodium azide in dichlorobenzene resulted in no 
conversion of starting material 14, to the desired product 15 (Entry 1, Table 2-1).  
This is thought to be due to solubility issues encountered when using 
dichlorobenzene as the solvent and the NaNO2 salt.  The use of tert-butyl nitrite and 
trimethylsilyl azide (TMS-N3) in MeCN (Entry 2, Table 2-1) again resulted in no 
conversion of starting material to product 15.  This lack of conversion could be due 
to the stock of trimethylsilyl azide having degraded over time, as the reagent used 
had been store for an extended period of time.  Although TMS-N3 had been shown 
to effect the required change, its relative instability and danger made it a less 
desirable alternative, thus a more stable reagent was investigated.  A mixture of two 
products was observed when using an EtOAc:H2O (8:1) solvent mixture (Entry 3, 
Table 2-1), the mixture of compounds was found to be the desired aryl azide 
product 15, and an unwanted aryl ether 16, as shown in Scheme 2-4.  
33 
 
 
 
Scheme 2-4 Formation of product 15 and 16 
 
The formation of 16 was thought to arise by the interception of 17 (Scheme 2-4) by 
ethanol, generated in situ by acid promoted hydrolysis of ethyl acetate.  Due to this 
unwanted side reaction, a combination of sodium nitrite and sodium azide was used 
in a solvent mix of MeCN:H2O:HCl (12 M) (8:1:1).  These conditions afforded the 
product (15) in excellent yield (94%) and purity after 3 hours (Entry 4, Table 2-1).  
The formation of the desired aryl azide was confirmed by 1H NMR, the 
disappearance of the aniline peak at δ 4.8 ppm, and the downfield shift of the aryl 
protons (Figure 2-1).  This was also supported by the appearance of a peak at ≈2100 
in the FT-IR spectrum, indicating the formation of the desired azide moiety. 
 
 
Figure 2-1 1H NMR of 15 
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This reaction was repeated using a modified solvent system of MeCN:HCl (12 M) 
(8:1) (Entry 5, Table 2-1), with the aqueous component being entirely contributed 
by the HCl component.  These modified conditions gave a slightly faster reaction 
time (2 hours vs 3 hours) whilst still maintaining the excellent yield and purity; this 
faster reaction time is thought to be due to the more concentrated reaction solution.  
With these optimised conditions in hand a range of aryl azide bearing different 
functional groups typically seen in AR antagonists were synthesised (Scheme 2-5).  
The synthesised azides were obtained in good to excellent yields as can be seen in 
Table 2-2.  It should be noted that when using these optimised conditions all 
reaction mixtures required only a simple aqueous work-up to afford analytically 
pure product.   
 
 
Scheme 2-5 Optimised conditions for the formation of desired aryl azide 
 
The range of aryl azides synthesised were aimed to assess the effect that the 
electronics of the ‘head group’ would have on the synthesis and biological activity 
of the final compounds.  The choice of aryl azides was largely influenced by the 
current pharmaceuticals in clinical use, these being Flutamide, Bicalutamide and 
Nilutamide with all of these bearing aromatic rings which bear electron-
withdrawing substitutions.  As such a variety of aryl azides where chosen, each 
with differing substitutions and electron-withdrawing abilities.      
 
Table 2-2 Synthesised aryl azide products 
Compound 
Number 
Structure 
Yield 
(%) 
Compound 
Number 
Structure Yield (%) 
35 
 
15 
 
94 21 
 
95 
18 
 
62 22 
 
95 
19 
 
67 23 
 
82 
20 
 
84 24 
 
68 
 
These compounds (Table 2-2) represent a cross section of substituents which are 
inspired by commonly observed compounds investigated for their ability to treat 
prostate cancer.  It should be noted that, in general, the more electron deficient 
anilines gave better yields for their conversion to the corresponding aryl azides.  
This increased yield can be explained by examining the mechanism through which 
this reaction takes place (Scheme 2-6). 
 
Scheme 2-6 Mechanism for conversion of amine to azide 
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It should be noted that the use of 4-nitroaniline in this mechanism is to better 
highlight the stability afforded by such, resonance stabilised withdrawing 
substituents.  Protonation of the nitrite anion, which then undergoes nucleophilic 
attack by the aniline, resulting in the elimination of water.  The intermediate then 
undergoes another dehydration, resulting in the aryl diazonium intermediate; this 
intermediate is then attacked by the azide anion in a SnAr fashion.  In this example 
the withdrawing group acting via resonance promotes the nucleophilic attack before 
eventual elimination of the diazo-moiety as nitrogen gas.  In the case of anilines 
which lack this electron deficient nature, this resonance stabilisation is not present, 
which may explain the differences in yields observed. 
 
 Optimisation of ‘click’ reaction 
With azides 15 to 24 synthesised an appropriate alkyne was next chosen to optimise 
the CuAAc reaction.  Phenylacetylene (25) provided a readily available and 
relatively cheap alkyne with which to optimise the conditions.  The lack of any 
functionality present on phenylacetylene meant that the ‘click’ reaction conditions 
could be optimised without fear of any unwanted side reactions which could arise 
from a more complex alkyne bearing molecule.  Aryl azide 20 was chosen for the 
optimisation of the ‘click’ reaction due to its ability to be synthesised on a large 
scale and its relatively benign functional groups.  Azide 20 was also a powder at 
room temperature making it easy to handle. 
 
 
Scheme 2-7 Chosen CuAAc partners 
 
Examination of the literature revealed a myriad of catalysts and conditions for the 
CuAAc reaction and thus a choice of reaction conditions.  As shown in Table 2-3, 
the majority of the catalysts and conditions employed, afforded the desired product 
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in high yield and relatively short reaction times.  The most common catalyst system 
is CuSO4/ascorbic acid, this operates by the Cu(II) provided by the CuSO4 being 
reduced to Cu(I) in situ by the ascorbic acid.  The use of the CuSO4/ascorbic acid 
system, in an ethanol/water solvent mix at room temperature for 24 hours (Entry 
1, Table 2-3), afforded almost no conversion of starting materials to product 26.  It 
was thought that the ethanol may be having an adverse effect on the reaction and 
as such the majority of the remaining optimisation focused on a purely aqueous 
solvent system, although compounds 20 and 25 are insoluble in water this was not 
seen as problematic as the reaction is essentially done ‘on’ water, so the solubility 
of the compounds does not affect the final outcome.  The use of CuSO4 as a source 
of Cu(II) and ascorbic acid as a reducing agent (only needed when using a Cu(II) 
source), in an aqueous system, heated to 100 °C using microwave irradiation (Table 
2-3, Entry 2); gave the desired product 26 in excellent yield (89%) and high purity 
(>95%).  The formation of the desired triazole 26 was confirmed by 1H NMR 
specifically the appearance of the characteristic triazole-H peak at 8.14 ppm (Figure 
2-2).  The successful formation of target triazole 26 was also confirmed by an 
obtained crystal structure (Figure 2-3). 
 
Table 2-3 Optimisation of CuAAc conditions for model compound 
Entry Catalyst  
(10 mol%) 
Solvent Temp (°C) Time (h) Yield (%) 
1 CuSO4[a]  EtOH:H2O 
1:1 
21 24 Trace 
2 CuSO4[a] H2O 100[b] 0.5 89 
3 CuCl H2O 100[b] 0.5 90 
4 CuO[a,c] CHCl3 21 24 83 
5 CuSO4[a] H2O 100[b] 0.3 83 
6 CuSO4[a] H2O 100[b] 0.25 79 
[a] Ascorbic acid used as reducing agent [b] reaction performed using microwave irradiation 
[c] CuO nanoparticles used 
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Figure 2-2 1H NMR of triazole 26 
 
 
 
Figure 2-3 Crystal structure for triazole 26 
  
In the interest of thoroughness, even after the discovery of such suitable reaction 
conditions, a variety of catalyst and conditions were still investigated.  When using 
CuCl as a source of Cu(I), in an aqueous system, heated to 100 °C using microwave 
irradiation (Entry 3, Table 2-3), yields and purity similar to that observed in Entry 
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2, were obtained.  The use of CuO nanoparticles (Entry 4, Table 2-3) to catalyse 
the CuAAc reaction,[95] proceeded in high yield and purity, the extended reaction 
time was undesirable and as such was left in favour of other faster conditions.  The 
effect that the time of reaction has on the conditions trialled in Entry 2 was also 
investigated (Entry 5 and 6, Table 2-3), however due to the already short reaction 
time the drop in yield was deemed an unworthy trade, as such the conditions 
detailed in Entry 2 of Table 2-3 were chosen as those that would be used for the 
remainder of this study.       
It should be noted that Entries 2 and 3 of Table 2-3 show almost identical yields in 
the same reaction times, however the CuSO4/ascorbic acid catalyst system proved 
to be superior in this application.  Although CuCl is already in the catalytically 
active Cu(I) form, the material had to be purified prior to use, this was due to the 
autoxidation of the Cu(I) to the Cu(II) species.  Although this reaction can be 
minimised by diligent storing of the purified CuCl under a nitrogen atmosphere, 
the CuSO4/ascorbic acid combination is known to exceptionally stable and as such 
an aqueous solution can be made and is shelf stable for large periods of time.  
Through the use of microwave irradiation the reaction was able to be carried out in 
30 minutes allowing for rapid generation of target compounds. 
With the optimisation of the key ‘click’ reaction completed, the reaction conditions 
were then applied to the reaction of phenylacetylene and the range of azides (15 to 
24) in hand (as outlined in Scheme 2-8).  This afforded a range of 1,4-disubstituted-
1,2,3-triazole ‘click’ products (26 to 33) in good to excellent yield and purity (Table 
2-4). 
 
 
Scheme 2-8 CuAAc of aryl azide and phenylacetylene 
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Table 2-4 Synthesised 1,4-disubstituted-1,2,3-triazoles 
# Structure 
Yield 
(%) 
# Structure 
Yield 
(%) 
26 
 
89 30 
 
52 
27 
 
75 31 
 
68 
28 
 
57 32 
 
87 
29 
 
61 33 
 
90 
 
Similar to the phenyl azide formation, the more electron deficient aryl azides 
proved, in general, to be the higher yielding coupling partners, with azide 15 and 
22 both giving yields of >90% in the ‘click’ reaction.  When nitro-azide 23 was 
reacted with phenylacetylene, to give triazole 30, the reaction proved to be low 
yielding which is in opposition for the trend of the more electron deficient aryl 
azides giving better yields.  Although triazole 30 was obtained in only moderate 
yield, it was still obtained in excellent purity.  
 
 Synthesis of Flutamide mimetics 
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Following the synthesis of the series of phenylacetylene derived 1,4-disubstituted-
1,2,3-triazoles, and the optimisation of the ‘click’ reaction conditions, a new alkyne 
coupling partner was chosen.  2-Methyl-3-butyn-2-ol (34) was chosen; as it 
afforded a product which closely resembled 2-hydroxyflutamide (2) (Scheme 2-9, 
2); the metabolite of Flutamide (1), and biologically active compound.   
 
 
Scheme 2-9 Comparison of proposed product and 2-hydroxyflutamide (2) 
 
The reason for the need to create a mimetic which resembles the active metabolite 
is due to the fact that in cellular testing the oxidation by CYP450 will not take place 
and thus any pro-drugs administered will not be converted to their active forms.   
 
 
Scheme 2-10 CuAAc of 34 and general azide 
 
Table 2-5 Synthesised Flutamide (1) mimetics 
# Structure 
Yield 
(%) 
# Structure 
Yield 
(%) 
35 
 
45 39 
 
64 
42 
 
36 
 
70 40 
 
65 
37 
 
76 41 
 
87 
38 
 
75 42 
 
74 
 
Utilising the optimised reaction conditions 2-methyl-3-butyn-2-ol was coupled 
with the already synthesised range of azides (15 to 24), to afford a range of products 
(Scheme 2-10 and Table 2-5) which closely resemble Flutamide (1) and fit the 
overall aim of investigating the replacement of the amide bond with a 1,2,3-triazole.  
All triazoles (35 to 42) were accessed in good to excellent yields (45–87%) with no 
additional modification of the conditions needed.  
 
 Synthesis of an amino acid derived scaffold 
With the target Flutamide (1) mimetic compounds 35 to 42 synthesised, a new 
synthetically versatile scaffold was proposed (Scheme 2-11); utilising a protected 
propargyl glycine core (43).  The carboxylic acid of the Fmoc protected propargyl 
glycine core was first transformed into the protected methyl ester via an EDCI 
mediated coupling with methanol.  This protection was required as previous work 
to perform CuAAc reactions on small molecules containing carboxylic acids had 
proved unsuccessful, and the literature in general shows poor yield for reactions in 
which a carboxylic acid is present.[96]  With the protected methyl ester 44 
synthesised in moderate yield, the compound was then subjected to CuAAc with 
both aryl azide 15 and 22.   
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Scheme 2-11 Synthesis of synthetically versatile scaffolds 45 and 46 
 
The choice of azides 15 and 22, respectively; is due to the fact that these two azides 
best represent the electron-withdrawing ‘head’ groups commonly encountered in 
the clinical pharmaceuticals Flutamide (1) and Bicalutamide (3).  These compounds 
(45 and 46) were kept protect and evaluated with the Fmoc and methyl ester intact.  
Though they represent a scaffold that could easily undergo derivatisation via 
deprotection. 
 
 Biological evaluation 
With several libraries of compounds synthesised (26 to 46), the biological activity 
was investigated.  The compounds were first tested for their ability to inhibit the 
growth of LNCaP cells at two static concentrations (20 and 40 μM).  Due to the 
size of the library to be tested, this type of evaluation was undertaken as a 
preliminary screen, identifying compounds which may require IC50 determination.  
The choice of LNCaP cells is due to LNCaP cells being androgen responsive cells, 
meaning that they require androgens to grow and have not progressed to the 
androgen independent stage.[97] [98]  Thus giving a potential preliminary indication 
on the ability of the compound to act as an AR antagonist. 
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The figure below (Figure 2-4) shows the activity of the compounds given as the 
LNCaP growth percentage inhibition when administered at the two varying 
concentrations, with a 2 nM solution of DHT used as a positive control (i.e. 100% 
growth).  The percentage inhibition of Bicalutamide (3) at 20 and 40 μM was also 
measured to allow the activity of the synthesised compounds to be compared and 
evaluated.  Although these compounds were designed to mimic Flutamide (1); 
Bicalutamide (3) was still chosen as it is the more commonly used of the two AR 
receptor antagonists, and is the clinical gold standard for AR antagonist treatment 
of prostate cancer.[49]   
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Figure 2-4 Percentage inhibition values for synthesised compounds, phenyl ‘head groups in green, alcohol ‘head’ group in 
blue and propargyl glycine derivatives in yellow 
 
Evaluation of these compounds to screen their ability to stop androgen stimulated 
growth in LNCaP cells gave a wide variety of results, as can be seen in Figure 2-4.  
Overall, whilst the majority of the compounds only gave a minimal reduction in 
growth (typically 5-10%), relative to DHT control, compounds 39, 40, 41 and 42 
all displayed moderate activity with bis-trifluoromethyl triazole 39 even surpassing 
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Bicalutamides (3) ability to supress cell growth at a concentration 40 μM (Figure 
2-8).    
 
 
Figure 2-5 Percentage inhibition of synthesised compounds 
 
As can be seen in Figure 2-5, compounds 30, 31 and 34 all gave negative inhibition 
values at both concentrations.  These negative values indicate that the compound 
was acting as an agonist, causing the LNCaP cells to grow at an accelerated rate 
when compared to the DHT positive control.  Whether these compounds are 
themselves agonists or act synergistically with DHT is unknown, and is considered 
outside the scope of this project. 
 
 
Figure 2-6 Structure of compounds exhibiting agonistic activity 
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It is interesting to note that the only compounds to exhibit agonistic activity are 
those which bear the phenyl ‘tail’ region, also interestingly these are the compounds 
which bear head groups which most closely resemble the electron withdrawn ring 
found in Flutamide (1).  The remainder of the compounds which contain the phenyl 
tail region (27, 28, 29 and 32) all exhibit weak activity between 4–15% inhibition, 
with differences between the percentage inhibition at the two concentrations 
showing no clear trends.  For example the percentage inhibition of compound 28 
increased by 6% when the concentration was increased from 20–40 μM; whereas 
in the case of 32 there was a 7% decrease when going from the lower to higher 
concentration (Figure 2-7). 
 
 
Figure 2-7 Inhibition values for 27, 28, 29 and 32, at both concentrations 
 
Compounds 35 to 42, designed as mimetics of 2-hydroxyflutamide (2), overall 
showed greater activity than their phenyl ‘tail’ counter parts.  Whilst compounds 
35 and 36 showed similar activity when compared to the phenyl ‘tail’ counterparts, 
the rest all showed a marked improvement.  Compounds 38, 39 and 42 no longer 
exhibit the agonistic behaviour of their phenyl ‘tail’ counter parts and are now 
instead amongst the most potent of the compounds tested, with 39, the triazole 
possessing the propanol ‘tail’ and the bis-trifluoromethyl ‘head’ showing to have a 
larger percentage inhibition than Bicalutamide (3) at the 40 μM concentration 
(Figure 2-8). 
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Figure 2-8 Comparison of compound 39 and Bicalutamide (3) 
 
As with the phenyl ‘tail’ containing compounds, the Flutamide (1) mimetics 
containing the more electron withdrawn ‘head’ also showed greater percentage 
inhibition when compared with those that lacked such substituents. 
Amino acid derived compounds 45 and 46, both showed low percent inhibition 
values at both the concentrations.  The activity shown by 45 and 46 is promising 
however as the tested compounds were designed as intermediates, showing the 
possible versatility afforded when performing CuAAc with the synthesised aryl 
azides. 
With the majority (14 out of 17) compounds showing a positive inhibition value, 
the best three representative compounds were selected (39, 40 and 42) and the IC50 
values for these compounds were obtained for both LNCaP and PC-3 cells.  The 
evaluation of IC50 for PC-3 cells was added in the interest of thoroughness, as this 
cell line is used to represent hormone independent prostate cancer.  The IC50 
determines the concentration needed to inhibit 50% of the cell growth compared to 
a positive control (i.e. cells with no inhibitor present). 
 
 
Figure 2-9 IC50 values of compounds 39, 40, 42 and Bicalutamide (3) 
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All three compounds exhibit relatively similar IC50 values when tested against 
LNCaP cells, with all three needing higher concentrations than Bicalutamide (3).  
When tested for their ability to inhibit PC-3 cell growth, compounds 40 and 42 both 
show an increase in the obtained IC50 values, which is relatively similar to the IC50 
value for Bicalutamide (3).  This increase is expected as the PC-3 cells grow 
independent of binding in the AR.  Compound 39 exhibits an increase in 
concentration of only 2 μM when comparing the IC50 values for LNCaP and PC-3 
cell lines, this relatively similar activity against both LNCaP and PC-3 indicates 
that compound 39 and bis-trifluoromethyl azide 24 may be good lead compounds, 
and derivatisation fragments, respectively. 
This library of compounds provides a good starting point due to their rapid 
synthesis, simple starting materials and retention of a large portion of biological 
activity. 
 
 In silico docking studies 
To offer support and additional insight into possible reasoning for the biological 
activity exhibited by the tested compounds, molecular modelling was undertaken.  
As will be mentioned throughout this document in silico studies cannot predict the 
inhibitory power of a molecule however it can predict likely conformations within 
the chosen binding site and thus can be used to guide further structural elaboration.  
The compounds would be docked into the hARLBD (human androgen ligand 
binding domain), for this study two different LBD (ligand binding domain) would 
be selected.  The wild type LBD and the T877A mutant, which is similar to the wild 
type but exhibits a point mutation in which a threonine (THR877) has been replaced 
with an alanine (ALA877).  It should be noted that the LNCaP cell line possesses 
the same T877A mutation, as such docking compounds into this mutant can be used 
to correlate IC50 data to binding in the LNCaP cell line.  For testing of the wild type 
AR biologically, primary prostate cancer cells would have to be obtained from a 
patient, and ethics obtained.  This was considered to be outside the scope of this 
study as the vast majority of the literature examines LNCaP and PC-3 cells only.  It 
is important to note that although docking can be used to predict possible 
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interactions it cannot predict inhibitory power.  In cells, binding to the receptor can 
occur but not necessarily result in growth inhibition.  Binding in the AR is 
accompanied by, amongst other things, conformational changes in the helix-12 
(H12) region, in which the H12 region closes over the LBD, reinforcing ligand-
receptor interaction.[99]  This conformational change is not included in the 
predictions of the software, nor is it commonly done in literature, thus in silico 
docking studies only provide a small glimpse at a much larger overall picture.  It 
should be noted that the docking studies were independently carried out by Drs 
Anna Lohning and Stephanie Schweiker, but data interpretation was carried out in 
collaboration. 
When selecting structure files for use in the in silico docking studies, the space 
available for the compounds to be docked is dictated by the bound ligand present 
in the original structure file.  Initially the wild type structure 2AMB.pdb was 
selected, which incorporates the ligand tetrahydrogestrinone (47, Figure 2-10).[100]  
However upon review this structure file was replaced with the 2PNU.pdb structure 
file, which incorporates the much larger ligand EM744 (48, Figure 2-10), this larger 
original ligand means that there is now a larger area that the molecules being 
docked may inhabit.  The structure file chosen for the T877A mutant was 
2OZ7.pdb, which possessed cyproterone acetate (49, Figure 2-10) as the bound 
ligand. 
 
 
Figure 2-10 Docked ligand structures for 2AMB.pdb, 2PNU.pdb and 2OZ7.pdb, respectively 
 
With the structure files selected, the results for the docking simulations were 
obtained with the results providing an image of the confirmation and key 
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interactions of the ligand within the binding site, also called the ligands docked 
pose.  A binding score (pKD) was also obtained, which ranks ligands based on their 
binding interactions, with higher scores indicating better binding.  It should be 
noted that pKD values exist on a log scale, so a difference of 1 unit is in fact equal 
to a difference of an order of magnitude.   
Figure 2-11 shows the pKD scores for compounds 26 to 46, along with the reference 
Bicalutamide (3).  Compounds 45 and 46 (Figure 2-4) were synthesised utilising 
the S-enantiomer only, however for the purposes of the molecular modelling the 
binding scores were calculated for both enantiomers, with interest in seeing if there 
was any significant difference between the pKD for each. 
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Figure 2-11 pKD scores for modelled compounds 
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As seen in Figure 2-11, the majority of the compounds synthesised all possessed 
vastly different pKD values, with most sitting between values of 3-7.  Interestingly, 
the S-enantiomer for both compounds 45 and 46 gave higher pKD values than the 
corresponding R-enantiomers.  In general the bulky Fmoc compounds (45 and 46) 
scored highest in the wild type site, note that for the remained of this discussion the 
2PNU site will be referred to as the wild type and 2OZ7 as the mutant; followed by 
the Flutamide (1) mimetics (35 to 42) and then the aryl ‘tail’ containing compounds 
(26 to 33), whereas for the mutant site the Flutamide (1) mimetics (35 to 42) scored 
highest followed by the aryl ‘tail’ compounds (26 to 33) and then the Fmoc 
compounds (45 and 46).  The docked poses for the aryl ‘tail’ compounds 26 to 33 
where shown to adopt one of two orientations within the wild type LBD (Figure 
2-12 and Figure 2-13).  Compounds 27, 28 and 31 all were shown to dock in the 
first orientation, forming two key hydrogen bond interactions between the triazole 
nitrogens and T877.  In this orientation the aryl ‘tail’ sits in a hydrophobic pocket 
and the ‘head’ groups are directed up towards TRP741, with the bis-trifluoromethyl 
‘head’ group of 31 rotated slightly to better accommodate its size.  In general these 
three compound exhibited higher pKD values for their binding into the wild type 
LBD, with 28 being the highest (pKD = 4). 
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Figure 2-12 Wild type LBD docked poses for compounds 27 (atom colours), 28 (red) and 31 (violet) 
 
The remaining compounds 29, 30, 32 and 33, shown in Figure 2-13, all adopt a 
second confirmation, in which the substituents present on the ‘head’ groups are 
stabilized by forming hydrogen bonds with the polar guanidinium cation present in 
the arginine amino acid residue ARG752.    
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Figure 2-13 Wild type LBD docked poses for compounds 29 (atom colours), 30 (magenta), 32 (cyan) and 33 (orange) 
 
The compounds which docked with the wild type LDB in this second confirmation 
generally showed lower pKD scores, the scores also show lower pKD score for the 
more bulky di-substituted 32 and 33 when compared to the compounds 29 and 30 
which bear the same CN/NO2 but lack the bulky CF3 moiety.  It was though that an 
interaction between the hydrogen bond donating guanidine and the hydrogen bond 
accepting CN/NO2 , was leading to these higher pKD scores (Figure 2-14). 
 
 
Figure 2-14 Hydrogen bonding between NO2/CN aryl substitutions and guanidinium groups 
 
When docked within the mutant site, all aryl ‘tail’ compounds (27–33) exhibit 
similar orientation as seen in Figure 2-15, with the functionalised ‘head’ region 
siting close to glutamine residue GLN711 and arginine residue ARG752; it appears 
this orientation allows for stabilisation by maximising hydrogen bonding 
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opportunities with the GLN711 and ARG752 residues.  When comparing between 
the wild type and mutant LBD it seems the compound in general bind stronger in 
the wild type LBD.  
 
 
Figure 2-15 Mutant LBD docked poses for compounds 27 to 33 
 
Within the alcohol ‘tail’, Flutamide (1) mimic series, one of two possible 
orientations within the wild type LBD were observed, similar to the aryl ‘tail’ 
containing compound.  Compound 35 which had an un-substituted phenyl ring, 36 
and 37 which have a single para-chloro and para-cyano substituent respectively and 
compound 39 which possesses the 3,5-trifluromethyl substitution; these four 
compounds were all positioned with the aryl ‘head’ positioned close to TRP741 
(Figure 2-16). 
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Figure 2-16 Wild type LBD docked poses for compounds 35 (atom colours), 36 (red), 37 (cyan), 38 (orange), 39 (violet), 
41 (green) and 42 (brown) 
 
Again 35, 36, 37 and 39 were stabilised by hydrogen bond interaction between 
THR877 and both the triazole and hydroxyl groups of the ligands.  The remaining 
ligands (38, 41 and 42) were oriented to allow hydrogen bonding between the 
hydroxyl group of the ‘tail’ and amino acid residue THR877.  Also dominating the 
interaction was hydrogen bonding between the substituents located on the ‘head’ 
groups and the guanidine group present in amino acid residue ARG752.  Shown in 
Figure 2-17 is the docked pose encountered for compound 40, this compound 
shows only one source of stabilisation, through that of an H-bond between the 
hydroxyl ‘tail’ and amino acid residue ASN703.  This relatively weak docking is 
portrayed in its pKD scores (3.7 and 3.6 for 2PNU and 20Z7, respectively), which 
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are in general weaker than the other hydroxyl ‘tail’ compounds which exhibit two 
or more H-bonds in their docked poses. 
 
 
Figure 2-17 Compound 40 docked into the wild type LBD, highlighting destabilisation 
 
When docked into the mutant LBD the ‘hydroxyl’ tail containing compounds were found in a different orientation 
as seen in Figure 2-18 and  
Figure 2-19, this change in orientation is due to the loss of a hydrogen bond, which 
occurs in the mutant when the residue THR877 is changed to ALA877.  As a result 
of this loss of H-bonding ability, compounds 35 and 36 were observed to hydrogen 
bond to amino acid residue LEU704 through their hydroxyl groups.  Compounds 
37 and 38 being slightly longer interacted with amino acid residue ASN705, and 
through this were also in position to exploit hydrogen bonding between the 
substitutions present in their ‘head’ groups (CN for 37 and NO2 for 38), and the 
amino acid residues GLN711 and ARG752. 
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Figure 2-18 Mutant LBD docked poses for compounds 35 (atom colours), 36 (red), 37 (cyan), 38 (orange) 
 
Figure 2-19 shows the effect that the di-substitution present in the ‘head’ region of 
the molecule can have on the docked pose of these compounds.  The bulkier 
compounds 39, 41 and 42 all showed little interaction with any amino acid residues, 
positioned instead to accommodate the bulky trifluoromethyl substituents, with 
compound 40 being the only di-substituted compound to show hydrogen bonding 
in the mutant LBD, with the hydroxyl ‘tail’ bonding to the amino acid residue 
ASN705. 
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Figure 2-19 Mutant LBD docked poses for compounds 39 (red), 40 (atom colours), 41 (orange), 42 (violet) 
 
Shown in  
Figure 2-20 are the docked poses for the two isomers of compound 45, when 
docked into the wild type LBD.  Whilst the S-enantiomer shows no hydrogen 
bonding, the R-enantiomer shows two hydrogen bonds being formed between two 
of the nitrogens in the triazole ring, and amino acid residue THR877.  This 
difference in hydrogen bonding is however not shown in the pKD values of the two 
compounds, with (S)-45 scoring higher (8.0) than compound (R)-45 (5.8). 
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Figure 2-20 Wild type LBD docked poses for both isomers of 45, S (atom colours), R (orange) 
 
The mutant LBD was shown to be more accommodating of compounds (S)-45 and 
(R)-45, as seen in Figure 2-21.  The compounds took on a new conformation within 
this LBD now essentially being U-shaped bending back onto themselves, this is 
possibly due to the lack of the THR877 residue and as such lack of hydrogen 
bonding that it facilitated.  When docked, both compounds where shown to 
participate in hydrogen bonding, with the S-enantiomer (S-45) showing hydrogen 
bonding between the carbonyl oxygen present in the methyl ester and the amino 
acid residue GLN711.  This S-enantiomer (S-45) also showed an unusual stabilising 
bond formed between the fluorine of the trifluoromethyl ‘head’ group and ALA877.  
The R-enantiomer of compound 45 was shown to form three hydrogen bonds, one 
of which was similar to that observed in the S-enantiomer, being formed between 
the oxygen of the ester and amino acid residue GLN711.  The remaining two 
hydrogen bonds were formed between the carbonyl oxygen present in the 
62 
 
carbamate of the Fmoc protecting group, forming one bond with of the amino acid 
residues TRP741 and GLN711.    
 
 
Figure 2-21 Mutant LBD docked poses for both isomers of 45, S (atom colours), R (orange) 
 
When the two enantiomers of compound 46 were docked into the wild type LBD, 
as seen in Figure 2-22, they both adopted similar conformations with the ‘head’ 
groups sitting up towards amino acid residue GLN738 (although no interactions 
were observed with this residue), and the Fmoc group sitting close to residue 
GLN711.  The two enantiomers are held in this conformation by central hydrogen 
bonds formed with amino acid residue THR877.  In the case of the S-enantiomer 
both hydrogen bonds are being formed between the nitrogens in the triazole and 
amino acid residue THR877, with this enantiomer showing no other sites of 
hydrogen bonding.  The R-enantiomer forms the central hydrogen bonds with 
amino acid residue THR877, through one of the nitrogens in the triazole and the 
carbonyl oxygen in the ester. 
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Figure 2-22 Wild type LBD docked poses for both isomers of 46, S (atom colours), R (orange) 
 
When docked within the mutant LBD, the compounds again exhibited the U-shaped 
conformation (Figure 2-23), due to the replacement of the THR877, with that of the 
ALA877 residue.  Although in this case the compounds are in oriented in opposing 
directions with the open end of the U in the S-enantiomer facing towards GLN711 
in the case of the R-enantiomer the open end is facing towards ALA877.  In this 
conformation the S-enantiomer displays hydrogen bonding between the CN 
substituent of the ‘head’ group and GLN711 and ARG752.  The R-enantiomer 
being in the opposite direction, displays hydrogen bonding through both the 
carbonyl oxygen of the carbamate, bonding to amino acid residues TRP741 and 
GLN711; and the carbonyl oxygen of the methyl ester, bonding to amino acid 
residue GLN711.  
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Figure 2-23 Mutant LBD docked poses for both isomers of 46, S (atom colours), R (orange) 
 
In the interest of thoroughness and to gain a better insight into any possible overlap 
in binding between the synthesised compounds and commercial compounds 
molecular modelling was undertaken on an additional three compounds.  The 
compounds selected, shown in Figure 2-24, comprised of Flutamide (1), 
Bicalutamide (3) and Enzalutamide (also known as MDV3100).  
 
 
Figure 2-24 Structure of Flutamide (1), Bicalutamide (3) and enzalutamide 
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When docked into the wild type LBD (Figure 2-25) Bicalutamide (3) and 
enzalutamide both adopted a similar orientation.  In both cases, the aryl ring 
containing the cyano and trifluoromethyl substitutions, exhibit hydrogen bonding 
with either GLN711 or ARG752 amino acid residue through the mentioned cyano 
substitution.  The remaining region of these two molecules orients itself so that it 
is pointing towards the THR877 amino acid residue.  In this wild type LBD 
Flutamide (1) orients in such a way that the substituted aryl ring is sitting near 
amino acid residue TRP741, and a single hydrogen bond is formed between the 
carbonyl oxygen present in the amide bond, and the amino acid residue THR877.      
 
 
Figure 2-25 Wild type LBD docked poses for Flutamide (1) (red), Bicalutamide (3) (purple) and enzalutamide (atom 
colours) 
 
The compounds exhibit a horizontal flip in orientation when docked into the mutant 
LBD (Figure 2-26).  Bicalutamide (3) and Enzalutamide again exhibit relatively 
similar conformations and hydrogen bonding, as before the hydrogen bonding 
occurs between the nitrogen of the cyano substitution.  In this LBD the remainder 
of the compound have moved orientation no longer pointing upward towards amino 
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acid residue THR877, now instead sitting down in the hydrophobic pocket created 
by the amino acid residue LEU704, created by the isobutyl tail present in leucine.  
In the mutant LBD Flutamide (1) exhibits no hydrogen bonding and sits in a 
relatively central position within the space. 
 
 
Figure 2-26 Mutant LBD docked poses for Flutamide (1) (red), Bicalutamide (3) (purple) and enzalutamide (atom colours) 
 
 Conclusion 
The design and synthesis of a range of novel triazole-derived AR antagonists has 
been accomplished.  A number of the synthesised compounds have shown 
significant activity when tested at against both LNCaP and PC-3 cells lines (39, 40 
and 42).  The obtained results suggest that the aryl ‘head’ region is of great 
importance for the activity of the synthesised compounds.  The synthesised 
compounds were docked into both the wild type and mutant (T877A) ligand 
binding domains, utilising in silico evaluation, and where found to display good 
interactions within the LBD.  As suggested by the in silico studies, the activity seen 
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when tested against the LNCaP cells may be due to the binding of the compounds 
with the AR, but this is certainly not the case for PC-3 cell lines. 
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3 Synthesis of Bicalutamide mimetics 
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 Chapter overview 
This chapter begins with the design of a synthetic route to access an analogue of 
Bicalutamide (3) bearing a 1,4-disubstituted-1,2,3-triazole.  From this the rational 
design and synthesis and optimisation of a range of compounds, in which a variety 
of ‘head’ and ‘tail’ regions will be utilised is carried out. 
  
 Synthesis of Bicalutamide mimic 
With the Flutamide (1) based triazoles showing promising retention of biological 
activity (Chapter 2), focus was turned towards the synthesis of a triazole based 
mimic of the structurally more complex anti-androgen, Bicalutamide (3) (Figure 
3-1).  This mimetic would not only aim to incorporate the familiar 1,4-disubstituted 
1,2,3-triazole as a replacement for the amide bond, but would keep all other 
functionalities present in Bicalutamide (3) (Figure 3-1) 
Keeping in mind that analogues of these compounds would be required, a synthesis 
which allowed for easy variations of both aryl rings, was developed. 
 
 
Figure 3-1 Proposed Bicalutamide (3) mimic 
 
The retrosynthetic analysis of target compound 50 was undertaken and it was 
envisioned that 50 could be afforded from a relatively simple and concise synthesis 
(Scheme 3-1), and allow for simple generation of further analogues. 
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Scheme 3-1 Retrosynthetic analysis of 50 
 
It was planned that 50 could be accessed from a CuAAc reaction between any of 
the previously synthesised aryl azides (15 to 24) and novel alkyne 51.  Alkyne 51 
could be accessed by subjecting the ketone (52) to a 1,2-Grignard addition using 
ethynylmagnesium bromide.  Compound 52 which contains both the key sulfonyl 
group and the prerequisite ketone could be accessed from thioether 53, this synthon 
can be accessed from an SN2 style coupling of thiophenol (55) and chloroacetone 
(54), which is commercially available or readily accessed via the α-chlorination of 
acetone.  This proposed synthesis allows for large amounts of structural variation 
to be incorporated with minimal changes to the synthetic pathway required.  For 
example a change of either the azide or thiol (55) units will give a broad range of 
analogues.  
 
 Formation of thioether 53 
The first step in this synthetic pathway involved the α-chlorination of acetone, 
giving 54.  Although this product is readily available from commercial sources, its 
unsuitability to be stored for extended periods, high reactivity with water and its 
relatively simple synthesis meant that it was decided that synthesising this 
component in situ was the best option.  Chloroacetone (54) is obtained by reacting 
anhydrous acetone with sulfuryl chloride, a commonly used chlorinating agent, 
useful for converting C–H Æ C–Cl when adjacent to activating substituents (in this 
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case the carbonyl group).[101]  Although chloroacetone is able to be isolated, for the 
purpose of this pathway it was instead treated as a reactive intermediate and no 
isolation/purification was undertaken, instead the subsequent α-functionalization 
was done in one pot.  
 
 
Scheme 3-2 Synthesis of chloroacetone intermediate, and subsequent SN2 with 4-fluorothiophenol 
 
As previously mentioned the chloroacetone intermediate (54) is obtained by 
treating anhydrous acetone with sulfuryl chloride, paying attention to keep the 
reaction under an inert N2 atmosphere.  The reaction is cooled and the sulfuryl 
chloride added slowly, before allowing the reaction to warm to room temperature.  
After stirring for 4 hours the reaction is again cooled, before a non-nucleophilic 
base (NEt3 in this case) is added in excess to ensure no residual hydrochloric acid 
generated by the sulfuryl chloride is present.  This is followed by addition of 4-
fluorothiophenol (55), the reaction is then allowed to warm to room temperature 
and stir for an additional 16 hours.  Thioether 53 was obtained in high yield (94%) 
after an aqueous workup and subsequent purification by column chromatography.  
It should be noted that the crude product was generally of high purity and this 
process was able to be scaled up to multi-gram quantities (up to 15 g).    
 
 Oxidation of thioether (53) 
With thioether 53 in hand the next planned synthetic step was the oxidation of the 
thioether to a sulfone group (Scheme 3-1).  The oxidation of thioether 53 to sulfone 
52, proceeds through the sulfoxide intermediate 56 (Scheme 3-3).  This allows for 
the possibility of a mixture of products to be observed including either solely 
sulfoxide product (56), solely sulfone product (52) or a mixture of the two.  
Searching of previous literature showed that in general careful control of the 
equivalents of oxidant was needed to obtain purely sulfoxide product,[102] along 
72 
 
with the use of transition metals such as molybdenum and vanadium.[103]  With this 
in mind it was assumed that by using excess oxidant, sulfone (52) should obtained 
as the major product. 
 
 
Scheme 3-3 Oxidation of thioether 53 to sulfone 52 
 
Although the required oxidation appeared relatively simple, a range of different 
oxidants and conditions were examined, before a set of conditions were discovered 
that afforded the desired sulfone 52 in high yield and purity.   
 
 
Scheme 3-4 Oxidation of thioether (53) to sulfone (52) 
Table 3-1 Conditions trialled for oxidation of thioether to sulfone 
Entry Solvent Oxidant 
Time 
(h) 
Temp 
(°C) 
Conv  
(%) 
1 CH2Cl2 m-CPBA (3 eq) 16 21 >99a 
2 MeCN:H2O KMnO4 (3 eq) b 3 21 0 
3 AcOH H2O2 (3 eq) 16 21 Mixc 
4 MeCN:H2O H2O2 (3 eq) d 3 50 0 
5 MeOH:THF:H2O Oxone (3 eq) 16 21 >99 
a Conversion determined from 1H NMR 
b CuSO4 was added 
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c Complex mixture of products obtained 
d (NH4)2MoO4 was added 
 
The use of excess m-CPBA (Table 3-1, Entry 1) provided quantitative conversion 
of 53 to 52, determined via 1H NMR, with no trace of sulfoxide 56.  However 
separating 52, m-chlorobenzoic acid and residual m-CPBA from the target 
compound proved to be extremely difficult.  After a range of different work-up 
procedures and separation techniques were investigated these conditions were 
discontinued.  The use of KMnO4 as an oxidant with CuSO4 as an additive (Entry 
2, Table 3-1) has been used to affect a wide range of general oxidations.[104]  
However for this scaffold no oxidation of stating material was observed, and the 
starting material was recovered.  This lack of oxidation could be due to the chosen 
system simply being too mild to effect the wanted change.  The use of hydrogen 
peroxide using glacial acetic acid (57) as the solvent was employed (Entry 3, Table 
3-1); upon treatment of acetic acid with hydrogen peroxide the oxidant peracetic 
acid (58), is formed (Scheme 3-5).[105]  Peracetic acid is a weaker oxidant than other 
peroxyacids such as m-CPBA,[106] whilst also having the benefit of the by-product 
of the reaction being acetic acid, which can easily be removed in an aqueous 
workup.  As such it was hoped that it would be strong enough to oxidise the 
thioether to the required sulfone, but prove easier to purify than m-CPBA had been.   
 
 
Scheme 3-5 Formation of peracetic acid using hydrogen peroxide, compared to Oxone 
 
In this instance the oxidation proceeded but a complex mixture of products was 
obtained, this mixture of products seemed to be the result of the incomplete 
oxidation of the thioether of 53, resulting in the complex spectra seen in Figure 3-2.   
 
74 
 
 
Figure 3-2 Spectra for mixture of 53, 56 and 52 
 
The use of hydrogen peroxide, this time with the use of ammonium molybdate as 
an additive (Entry 4, Table 3-1).  This system has been shown to effect a wide 
range of selective oxidations and as such was trialled for the oxidation of the 
starting thioether (53) to the desired sulfone (52).[107]  Unfortunately these 
conditions gave no conversion and upon workup only starting material was 
recovered.  The final attempt at the desired oxidation (Entry 5, Table 3-1), uses the 
common oxidant, Oxone®, a potassium salt of the compound peroxymonosulfuric 
acid (Scheme 3-5).  Use of Oxone® in a solvent mixture of equal parts 
MeOH:THF:H2O gave a quantitative conversion of the starting material to the 
desired sulfone, and after a simple aqueous workup the target compound was 
obtained in >95% purity. 
 
 1,2-Grignard addition to ketone 52 
The next step in the planned synthetic pathway was the 1,2-Grignard addition of 
ethynylmagnesium bromide, to ketone 52, giving 51 (Scheme 3-6).  
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Scheme 3-6 Grignard addition to ketone 
 
The carbon bound to the magnesium in the Grignard reagent is nucleophilic, as 
such it is able to attack sufficiently electrophilic carbons such as those present in, 
imine, ketones, nitriles, etc.[108]  The 1,2-addition of the Grignard reagent to ketones 
(Scheme 3-7), is theorised to proceed through a six membered intermediate, as 
suggested by Muruyama et. al., although other mechanisms have been suggested 
for more hindered Grignard reagents, this six membered intermediate is 
common.[109]   
 
 
Scheme 3-7 General mechanism of 1,2-Grignard addition to ketone 
 
As seen in Scheme 3-8, upon treating compound 52 with the chosen Grignard 
reagent, ethynylmagnesium bromide, there was no observed formation of the 
alkyne product, after workup only starting material was returned. 
 
 
Scheme 3-8 Attempted Grignard addition 
 
It was thought that perhaps the Grignard reagent was acting as a base and simply 
deprotonating 52 to form the corresponding enolate and a molecule of acetylene, 
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which simply leaves the reaction as a gas (Scheme 3-9).  Upon acidic workup the 
starting ketone (52) is regenerated via protonation of the enolate (Scheme 3-9).  
 
 
Scheme 3-9 Reformation of starting material after deprotonation with Grignard reagent 
 
This theory is also reinforced after comparing the relative pKa of 52 with similar 
ketones.  With each subsequent step in the reaction pathway described in this study 
the pKa of the compound’s decrease drastically (Figure 3-3).  As the α-protons are 
becoming more acidic and as such it is more likely for the Grignard reagent to 
simply act as a base, resulting in enolate formation, rather than the intended 1,2-
addition of the ethynyl group. 
 
Figure 3-3 pKa of compounds, taken from Bordwell pKa table[110] 
 
To counteract this unwanted reaction, the reaction pathway was revised, with the 
Grignard addition now to be attempted with thioether (53) prior to oxidation to 
sulfone (52) (Scheme 3-10).  
 
 
Scheme 3-10 Grignard addition to 53 
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Table 3-2 Trialled conditions for the Grignard addition to 53 
Entry Additives Temp (°C) Time (h) Yield (%)a 
1 None 21 16 0 
2 None 50 62 16 
3 ZnCl2 21 16 0 
4 CuBr2 70 16 0 
5 Ce2(SO4)3 50 72 34 
6 CeCl3 75 16 36 
7 LaCl3∙2LiCl 21 16 73 
a isolated Yield 
 
The solvent of choice was THF, this was due to a number of reasons.  Grignard 
reagents are generally formed and used in ethereal solvents, as they are known to 
be stabilised by the ethereal oxygen present, promoting disaggregation of the 
Grignard species and encourage nucleophilic attack.[111]  Finally the 
ethynylmagnesium bromide is purchased as a 0.6 M solution in THF, so in the 
interest of compatibility the reaction solvent was kept the same as that which the 
reagent is supplied in.  Undertaking the reaction at room temperature for 16 hours 
(Entry 1, Table 3-1), shows no conversion of thioether (53) to the desired product 
60, the reason for the lack of reaction is unknown.  Nevertheless repeating this 
reaction with an extended reaction time (62 hours) and at an elevated temperature 
(50 °C) (Entry 2, Table 3-2), gave only a small increase in yield (16%).  Attention 
was turned away from providing the system with more energy, and was now 
focused on increasing the electrophilicity of the carbonyl carbon thus making it 
more susceptible to nucleophilic attack by the Grignard reagent.  Transition metal 
based Lewis Acids were added to the reaction in hopes of promoting the attack by 
drawing electron density away from the carbonyl carbon (Scheme 3-11).[112]  For 
this purpose ZnCl2 (Entry 3, Table 3-1), a common additive for 1,2-Grignard 
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reactions[113] and CuBr2 (Entry 4, Table 3-1), a somewhat uncommon additive 
which typically promotes 1,4-additions;[114] were chosen.  However both proved 
unsuccessful in promoting this reaction, as such alternative Lewis acids were 
sought out. 
 
 
Scheme 3-11 Lewis Acid promoted Grignard addition 
 
After searching of the literature it was found that lanthanide based additives such 
as CeCl3, NdCl3, PrCl3 and LaCl3∙2LiCl have been shown to promote 1,2-Grignard 
additions.  These reagents often result in high yields, with their prominent use in 
substrates that are prone to enolisation.[115]  As shown by Imamoto, Takiyama, 
Nakamura, Hatajima & Kamiya, 1989, in which the use of CeCl3 greatly aids the 
addition of n-butylmagnesium bromide to the readily enolizable 1,3-diphenyl-2-
propanone (Scheme 3-12). 
 
 
Scheme 3-12 CeCl3 promoting 1,2-Grignard addition, Imamoto et al., 1989 
 
It is thought that these lanthanide additives act in either of two ways, (i) by forming 
an organo-lanthanide species which exhibits greater reactivity than the parent 
Grignard reagent whilst also being a weaker base, as has been observed for organo-
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cerium species.[116]  The second possible mode of action is by acting as a Lewis and 
increasing the reactivity of the carbonyl as previously described.  The use of the 
cerium based reagents, Ce2(SO4)3 and CeCl3, to promote the desired Grignard 
addition (Entry 5 & 6, Table 3-2) showed a marked improvement in yield (34% 
and 36%, respectively), however the yields obtained were still lower than was 
deemed acceptable.  The relatively low activity of the Ce2(SO4)3 could be due to 
solubility issues, with Ce2(SO4)3 being only slightly soluble in THF.  Whilst the 
low activity of Ce2(SO4)3 may be due to solubility, the low activity of CeCl3 was 
thought to possibly be due to the highly hygroscopic nature of the CeCl3 salt.  
Although the CeCl3 salt can be commercially purchased, it must be dried before 
use, this requires high temperatures and large amounts of thionyl chloride, and 
moreover CeCl3 is highly hygroscopic making storage of the anhydrous material 
difficult.  Due to the difficulty with preparing these compounds and the relatively 
low yields another lanthanide based additive was investigated, specifically the use 
of LaCl3∙2LiCl to promote the 1,2-Grignard addition (Entry 7, Table 3-2).  Unlike 
many of the other lanthanide halides such as CeCl3, LaCl3∙2LiCl is highly soluble 
in THF (commercially available as the 0.5M solution in THF) and thus often proves 
highly active where other lanthanide based reagents have failed.[117]  It is thought 
that the LaCl3∙2LiCl acts as a Lewis acid,[118] promoting the 1,2-addition to the 
ketone (Figure 3-4).  As can be seen the use of LaCl3∙2LiCl resulted in a 
significantly improved yield (73%) (Entry 7, Table 3-2). 
 
 
Figure 3-4 Lanthanide Lewis acid activated intermediate (simplified for clarity) 
 
 Evaluation of divergent pathways 
With the successful formation of alcohol 60, there was now a choice between two 
options for how this synthesis could proceed.  As seen in Scheme 3-13, the target 
compound 50 could be synthesised in either one of two ways.  
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Scheme 3-13 Overview of two pathways to access 50 
 
Pathway 1, Scheme 3-13, first employs an oxidation of 60 to give product 51, able 
to then undergo a CuAAc with the previously synthesised azides, presented in 
chapter 2.  Pathway 2, begins with the CuAAc with azide 22, to give product 60, 
which can then be oxidised (Oxone®) to give the desired target Bicalutamide (3) 
mimetic, 50.  Both pathways are equally feasible, however Pathway 1 features the 
oxidation of the thioether to sulfone, prior to any potential derivatisation.  This 
means that the oxidation may be done on a large scale of compound 60, allowing 
for rapid generation of analogues.  Pathway 2 however employs the oxidation after 
the CuAAc, which mean that an individual oxidation would need to be undertaken 
for each subsequent triazole product formed.  This subsequent oxidation also limits 
the potential functional groups which can be present on the aryl “head” group, as 
any groups which are sensitive to oxidation would be unable to be used without 
first protecting.  Therefore in the interest of efficiency Pathway 1 was the obvious 
choice. 
 
 
Scheme 3-14 Oxidation of 60 to 51 
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The oxidation of 60 to 51 proceeded when subjected to the same optimised 
conditions that were used for the formation of 52, again in excellent yield (98%) 
and purity after a simple aqueous workup. 
With compound 51 in hand it was decided that a CuAAc with aryl azide 22 would 
be undertaken to provide 63 (Scheme 3-15), the choice of azide 22 resulted in a 
compound which closely mimicked the functionality present in Bicalutamide (3).   
Using the optimised conditions discussed in chapter 2, the target 63 was 
successfully obtained, and this was shown by the presence of the triazole proton 
peak in the crude 1H NMR spectroscopy.  The purification of 63 proved to be 
extremely easy, with only a simple aqueous workup, followed by, the crude solid 
being precipitated from chloroform using petroleum spirits, giving the analytically 
pure final compound 63 in good yield (78%). 
 
 
Scheme 3-15 Formation of target compound 63 
 
Although it was clear that Pathway 1 (Scheme 3-13) was the most efficient route to 
target compound 63, in the interest of thoroughness the synthetic process in 
Pathway 2 (Scheme 3-13) was also undertaken to compare yield.  The CuAAc 
between alkyne 60 and azide 22 proceeded giving 64 in excellent yield (86%, 
Scheme 3-16).  After a simple aqueous workup and subsequent precipitation from 
chloroform using petroleum spirits, 64 was obtained in >95% purity.   
 
 
Scheme 3-16 Alternate pathway to target 63 
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With the thioether 64 successfully synthesised the subsequent step was the 
oxidation of the thioether, giving the final sulfone 63.  This oxidation was 
undertaken using the already optimised conditions, as can be seen the oxidation 
again proceeded in high yield (85%, Scheme 3-17). 
 
Scheme 3-17 Last step oxidation giving 63 
 
 Design of Bicalutamide inspired compound library 
With the target compound 63 successfully synthesised attention was turned to 
designing a range of other compounds which could be synthesised.  This would 
allow investigation into effects key ‘tail’ and ‘head’ groups may have on both the 
biological activity of the compounds (Figure 3-5), and on their docking abilities 
when calculated in silico (presented in Chapter 4). 
  
 
Figure 3-5 'Tail' and 'Head' sections of Bicalutamide (3) mimic 
 
The modular approach to the synthesis of 63, meant that changes could be made to 
the azide ‘head’ region easily, by simply substituting a different azide in place of 
22 for the CuAAc with 51, a new analogue of the Bicalutamide (3) mimetic 63 
could be synthesised (Scheme 3-18).  
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Scheme 3-18 Synthesis of 'head' region derivatives 
 
So with this ease of derivatisation in mind a range of novel compounds were 
identified.  These compounds were designed to investigate the effect that different 
substitution would have on the compounds in silico docking and the compounds 
biological activity.  The first proposed derivative was the NO2, CF3 variant (65), of 
the original Bicalutamide (3) mimic synthesised (63) 
 
 
Figure 3-6 Target analogue 65 
 
Given the prevalence and previous success of the 4-nitro-3-trifluoromethyl 
substituent in PC therapy, 65 was thought to be an excellent analogue to access.  As 
previously discussed, -nitro groups can often undergo different binding with 
receptors than –cyano groups; in conjunction with the different binding attributes 
this modification was easily apparent as it would result in a product which bore the 
other common aryl group found in AR antagonists used in the treatment of prostate 
cancer (Figure 3-6).  As such 65 was proposed as the first compound in this library.  
Compounds 66 and 67 (Figure 3-7) were proposed to investigate the possible 
binding an acid moiety may have with the guanidinium group present in the 
arginine amino acid residue observed in the AR (Figure 3-8). 
 
 
Figure 3-7 Benzoic acid derivatives 
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Due to the possible interactions by the NO2 group with the guanidinium group of 
amino acid residue ARG752 within the hARLBD; shown in the previous in silico 
docking studies.  It was thought that by replacing this NO2 group with a carboxylic 
acid a stronger ligand-receptor interaction may be able to be achieved.  Both 
carboxylate and guanidine units possess a similar trigonal planar structure, giving 
rise to guanidine-carboxylate complementarity, in addition to an ion pairing effect.  
This complementarity has been used to encourage a range of different 
interactions.[119] [120]   
 
 
Figure 3-8 Possible interactions between acid derivative 
 
The ethyl ester containing 62 was incorporated to investigate what effects the 
replacement of normally polar carboxyl ‘head’ group, with removal of the acidic 
proton, would have on the in silico binding and biological activity.  Alongside these 
targets which vary the ‘head’ region, an analogue which would allow interactions 
at the ‘tail’ of the molecule to be investigated was proposed. 
 
 
Figure 3-9 Proposed fluorine 'tail' lacking targets 
 
One area of interest in the ‘tail’ region of the molecule was the fluorine atom present 
on the aryl ring.  The incorporation of  fluorine into medicinal compounds has only 
been a relatively recent advent, up until the 1970’s much of medicinal chemistry 
was focused on biologically active natural products.[121]  Recently drug candidates 
with one or more fluorine atoms have become common place, with fluorine often 
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being incorporated to; stop metabolism of vulnerable sites,[122] and increase 
lipophilicity or increase the binding strength of the molecule with its target site, 
among others.[123]  With this in mind it was decided that analogues which lacked 
this fluorine substitution in the ‘tail’ would be synthesised (68 and 69, Figure 3-9).  
Again these possessed the –nitro bis-trifluoromethyl and –cyano bis-
trifluoromethyl combinations found in common prostate cancer therapeutics.  In 
conjunction with compounds 68 and 69, a target was designed that would allow for 
easy derivatisation of the ‘tail’ section.  Due to the ever increasing use and 
versatility of palladium cross coupling reactions, it was thought that a scaffold 
which could take advantage of this, would be extremely useful.  With this objective 
in mind compounds 70 and 71 were proposed, possessing an aryl bromide moiety 
(Figure 3-10). 
 
 
Figure 3-10 Bromine containing analogues 
 
Scaffolds 70 and 71 as mentioned, were selected due to the potential versatility they 
afford, after a literature search it is apparent that a wide range of functionalities can 
be accessed from this central starting material.  Phan and co-workers demonstrated 
a Suzuki–Miyaura reaction in which a sulfonyl scaffold containing an aryl bromide 
was coupled with an phenylboronic acid, via the use of a Merrifield resin-supported 
salen-type palladium(II) complex (Scheme 3-19).[124]  Although the resultant bi-
aryl product is not particularly interesting, this procedure could in theory, be 
applied to more useful boronic acids.        
 
 
Scheme 3-19 Suzuki-Miyaura investigation done by Phan et al. 
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Utilising a similar scaffold Corpet and co-workers coupled an alkynyl bromide to 
an activated aryl bromide, in a reaction reminiscent of a Sonogashira cross-coupling 
(Scheme 3-20).[125]    
 
 
Scheme 3-20 Cobalt catalysed cross-coupling demonstrated by Corpet et al. 
 
Again utilising Co(II)Br and zinc dust, Qian and co-workers have demonstrated the 
successful amination of aryl halides (Scheme 3-21).[126]  Although this is just a 
handful of reactions it becomes apparent that the aryl bromide scaffolds 70 and 71 
provide an excellent starting point for the generation of future compound libraries.  
 
 
Scheme 3-21 Cobalt catalysed amination demonstrated by Qian et al. 
 
 Synthesis of designed compounds 
With the compounds of interest identified the next step was their synthesis.  The 
first compound designed was 65.  Target compound 65 could easily be accessed by 
performing a CuAAC between the already synthesised precursor alkyne (51) and 
the 4-nitro-3-trifluoromethyl azide (15) previously synthesised in chapter 2 
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(Scheme 3-22).  The cycloaddition proceeded smoothly and in high yield (84%), 
giving 65 with good purity. 
 
 
Scheme 3-22 Synthesis of 65 
 
With 65 successfully synthesised attention was turned towards compounds 66 and 
67.  To synthesise compounds 66 and 67 a new benzoic acid derived azide was 
needed, this azide could be accessed from 4-aminobenzoic acid (64).  Applying the 
azide formation conditions optimised in the previous chapter (Scheme 3-23) 4-
aminobenzoic acid (73) could be converted into the desired azide quickly and in 
high yield (93%).  Fortuitously, azide 73 rapidly precipitated from the reaction 
mixture, which after a simple filtration and washing, with water and petroleum 
spirits, gave analytically pure azide 73.   
 
 
Scheme 3-23 Synthesis of benzoic acid derived azide 73 
 
With this azide in hand the CuAAc could be performed, however when examining 
the literature and from previous experience, it is clear to see that there are few 
reports of these CuAAc reactions being performed in the presence of carboxylic 
acids.  This was found to be the case in this instance too, as when the CuAAc was 
undertaken using azide 74 only trace amounts of the desired product 67 were 
formed (Scheme 3-24). 
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Scheme 3-24 CuAAc of 73 and 51 
 
Due to the poor formation of 67 it was decided that the acid moiety could be 
accessed retrospectively from the proposed ethyl ester containing compound 66.  A 
Fischer esterification utilising ethanol was carried out,[127] providing azide 74 in 
excellent yield (86%, Scheme 3-25). 
 
 
Scheme 3-25 Ethyl ester Protection of acid 
 
The desired CuAAc between the alkyne 51 and the now protected benzoic acid 
azide 74, proceeded in a moderate yield (67%, Scheme 3-26).  This lower yield was 
thought to be due to the extra lipophilic bulk present on 74, as it may limit the 
solubility when placed in the aqueous reaction solution. 
 
 
Scheme 3-26 Formation of target compound 66 
Carboxylic acid 67 was then accessed by simple hydrolysis of the ethyl ester 
present in 66.  Stirring 66 in the presence of KOH (12M) in aqueous THF, followed 
by an acidic workup, gave target compound 67 in good yield (71%, Scheme 3-27) 
and excellent purity.   
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Scheme 3-27 Hydrolysis of ethyl ester protecting group 
 
With compounds 66 and 67 successfully synthesised, attention was turned to the 
synthesis of 68 and 69, the analogues which lacked the aryl fluoride ‘tail’.  Utilising 
the established synthetic strategy outlined previously, but this time utilising 
thiophenol (Scheme 3-28).  Alkyne 78 could be accessed in good yield (53% 
overall, 4 steps) although there was an overall drop in yield when compared to 51, 
the material was still obtained in a synthetically useful amount. 
 
 
Scheme 3-28 Synthesis of scaffold lacking fluorine 'tail' 
 
With alkyne 78 synthesised (Scheme 3-28) the required CuAAC were undertaken 
with azides 15 and 22 to afford compounds 68 and 69 good yield (78% for both, 
Scheme 3-29). 
 
 
Scheme 3-29 Fluorine 'tail' lacking compounds, 68 and 69 
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Finally brominated alkynes 70 and 71 were synthesised in much the same way as 
68 and 69, this time utilising 4-bromothiophenol, to obtain alkyne 82 (Scheme 
3-30). 
 
 
Scheme 3-30 Aryl bromide 'tail' containing compounds 
 
With aryl bromide containing alkyne 82 in hand the next step was the CuAAc 
reaction between this alkyne and azides 15 and 22, to give the two products.  As 
previously seen the already optimised CuAAc conditions provided the target 
compounds 70 and 71 in good yield (65% and 71% respectively, Scheme 3-31) 
 
 
Scheme 3-31 Synthesis of target triazoles 70 and 71 
 
With the envisioned library successfully synthesised, the six target compounds 50, 
65, 66, 67, 68 and 69 had their biological data assessed.  It should be noted that 
compounds 70 and 71 were not biologically evaluated, but instead synthesised to 
show synthetic versatility of the developed synthon, and for possible use in 
generation of further compound libraries. 
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 Conclusion 
The rapid synthesis of a range of 6 Bicalutamide (3) mimetics, incorporating a 1,4-
disubstituted-1,2,3-triazole has been developed.  The developed synthetic pathway 
allows for a range of analogues in which both the ‘head’ and ‘tail’ regions of the 
compounds can easily be varied, to support the capability to generate libraries of 
analogues the developed synthetic pathway is tolerant of a large number of 
functional groups.  In addition to this range of compound for biological testing, an 
aryl bromine containing analogue was synthesised allowing for the generation of 
future analogues. 
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 Chapter overview 
This chapter focuses on the evaluation of the compounds previously synthesised in 
Chapter 3.  These compounds will be tested biologically against both the LNCaP 
and PC-3 prostate cancer cell lines, and their IC50 data will be discussed.  Finally 
this chapter will close with a discussion on the in silico modelling data, when these 
compounds are docked into both the wild type and T877A mutant AR isoform.  The 
in silico data will be discussed with a focus on pKD values and the conformations 
adopted by the compounds. 
  
 Evaluation of Bicalutamide mimetics 
 
 Biological evaluation 
With six representative compounds in hand (63, 65, 66, 67, 68 and 69), their 
biological activity was assessed in both LNCaP and PC-3 cell lines.  Due to the 
smaller set of compounds in this study, the IC50 values were obtained directly 
without the preliminary screening at a static concentration, as outlined previously 
in Chapter 2.  A sample of Bicalutamide (3) was also submitted for determination 
of IC50 to allow for comparison of these novel compounds to a known anti-cancer 
drug, this would provide an excellent comparison and can account for potential 
variation from literature values. 
   
 
Figure 4-1 IC50 values for Bicalutamide (3) reference 
 
Compounds 63 and 65 possess IC50 values of 45 and 36 μM, respectively, when 
tested against the LNCaP cell line, comparable to the IC50 value of Bicalutamide 
(3) when tested against the same cell line (IC50 = 30 μM, Figure 4-1).  Interestingly 
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these two compounds both exhibit the inability to affect growth of the hormone 
independent (PC-3) cell line, whereas Bicalutamide (3) is still active, albeit 
markedly decreased, IC50 = 58 μM. 
 
 
Figure 4-2 IC50 values for compounds 50 and 65 
 
Both compounds 66 and 67 (Figure 4-3) showed no activity within the 
concentration window chosen (upper limit 300 μM).  The reason for this is 
unknown, although it was speculated that the lack of activity shown by compound 
67 may be caused by the compound being unable to cross the cell membrane, 
possibly due to carboxylic acid head group.  Even with the reason unknown, this 
highlights the importance of the substituent on the ‘head’ region.  Note that despite 
the lack of biological activity displayed by 66 and 67, they were still evaluated in 
silico as a matter of interest. 
 
 
Figure 4-3 IC50 values for compounds 66 and 67 
 
Similar evaluation of  68 and 69 (Figure 4-4), lacking the aryl fluoride moiety, 
showed moderate biological activity with IC50 values of 151 and 114 μM when 
tested against LNCaP and PC-3, respectively.  Compound 68 the analogue of 65, 
displayed weak inhibition of LNCaP cell growth (IC50 = 151 μM, Figure 4-4) when 
compared to Bicalutamide (3), and showed a moderate improvement in activity 
against PC-3 cells (IC50 = 114 μM), though these are still inferior the value 
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possessed by Bicalutamide (3).  Interestingly, compound 69 showed excellent 
biological activity against both LNCaP and PC-3 cell lines (Figure 4-4).   
 
 
Figure 4-4 IC50 values for compounds 68 and 69 
 
Compound 69 possessed an IC50 value of 34 μM when tested against LNCaP cells, 
this is comparable to both the Bicalutamide (3) reference (30 μM) and its fluorine 
‘tail’ containing counterpart 65 (36 μM).  However, compound 69 showed slightly 
increased biological activity against PC-3 cells, with an IC50 value of 29 μM, this 
is a dramatic difference when compared to Bicalutamide (3) and 65 which exhibit 
IC50  values of 58 and >300 μM, respectively.  Interestingly both compounds 68 
and 69 show a lower IC50 value for PC-3 cells than they do for LNCaP, this is 
encouraging as the PC-3 cell line is hormone independent and significantly harder 
to treat.[128]  This inhibitory activity towards PC-3 cells, also suggests that these 
compounds may not be AR antagonists as PC-3 cells lack the androgen receptor, 
however the mechanism of action is still to be determined. 
 
 In silico evaluation 
Despite some ambiguity regarding the interactions of these compounds with the 
AR; in parallel with the cellular evaluations these compounds were evaluated in 
silico.  The compounds were docked into the T877A mutant only, and pKD values 
determined.  As previously mentioned (Chapter 2) pKD values are essentially a 
binding score given to each compound, these scores rank ligands based on their 
binding interactions, with higher scores indicating stronger binding.  Note that as 
the compounds (50, 65, 66, 67, 68 and 69) are racemic, each enantiomer was docked 
to investigate if there was an obvious difference in pKD.  Again it should be noted 
that while in silico can be used to predict possible interactions it cannot predict 
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inhibitory power.  Enantiomers of each compound were docked into the hARLBD 
of 2OZ7.pdb and their pKD score obtained. As can be seen when comparing 
between sets of compounds there is a large degree of variance as pKD values are 
logarithmic, an increase of 1 refers to a difference of 1 order of magnitude.  
Although there is a large difference in pKD values between enantiomer sets (e.g. 
R/S 69 vs R/S 68), when comparing the two different enantiomers from the 
compound the pKD values are often close (e.g. R-69 vs S-69).  This lack of major 
difference between enantiomers of the same set suggests that at a fundamental 
level, one enantiomer is not dominating the biological activity.    
 
 
Figure 4-5 pKD values for all docked compounds and isomers 
 
The docked poses for the S-enantiomer of compound 63 bound into the mutant LBD 
(Figure 4-6), shows compound 63 orienting with the cyano, trifluoromethyl head 
group lying between amino acid residues ARG752 and GLN711.  Compound 63 
displays additional interactions with three of the amino acid residues, forming an 
overall five binding sites.  The first interaction seen is between one of the sulfonyl 
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oxygen’s and the carboxylic acid moiety present in the asparagine amino acid 
residue ASN705.  The second interaction is between two of the fluorine’s present 
in the trifluoromethyl group and a hydrogen located on the glutamine residue 
GLN711.  The third interaction seen with compound 63 is between the cyano group 
and the guanidine moiety present from amino acid residue ARG752, with the cyano 
forming two hydrogen bonds with the guanidine.   
 
 
 
Figure 4-6 Docked pose for S isomer of 63 (pKD = 6.0) 
 
The docked posed for the R-enantiomer of compound 63 shows a very similar 
orientation within the mutant LBD (Figure 4-7), however this enantiomer displays 
a  slightly lower pKD value overall, possibly due to the lower number of contacts 
(5 vs 4), with four hydrogen bonds present, two at each end of the binding domain.  
Similar to the S-enantiomer the one of the sulfonyl oxygen’s interacts with the 
primary amide present within ASN705.  Unlike the S-enantiomer however one of 
the nitrogens present in the triazole ring also interacts with this amino acid residue, 
due to the inversion of stereochemistry.  Again the cyano group present in the 
‘head’ of compound 63 maintains the interactions with the guanidine present in 
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ARG752, however in this enantiomer the interactions between the trifluoromethyl 
and amino acid residue GLN711 are absent. 
 
 
 
Figure 4-7 Docked pose for R isomer of 63 (pKD = 5.7) 
 
Interestingly, when the cyano group of 63 is replaced with the nitro group present 
in 65 a largely different binding mode is observed.  The docked pose obtained for 
the S-enantiomer of 65 (Figure 4-8), shows the compound adopting a somewhat 
bent conformation, with the ‘head’ region sitting close to GLN711 and the ‘tail’ 
section curved around pointing up towards the same GLN711 residue.  This bent 
conformation allows for pi-stacking interaction between the ‘tail’ section and the 
N-phenyl triazole, and shows relatively few interactions.  The only interactions 
coming from the nitro and trifluoromethyl located on the ‘head’ region interacting 
with amino acid residue GLN711. 
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Figure 4-8 Docked pose for S isomer of 65 (pKD = 5.3) 
 
The R-isomer of 65 displays a similar bent conformation, this time however with 
the change in stereochemistry the molecule is rotated.  The trifluoromethyl group 
present on the ‘head’ now no longer forms hydrogen bonds with the GLN711 
residue, meaning the only hydrogen bonds seen are between the nitro group and 
GLN711.  Interestingly, this rotation and lack of hydrogen bonds is not entirely 
detrimental as this enantiomer now displays increased hydrophobic interactions, as 
a result of this the R-enantiomer of 65 displays a greater pKD even with a reduced 
amount of hydrogen bonds (pKD = 5.8 vs 5.3, Figure 4-5).   
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Figure 4-9 Docked pose for R isomer of 65 (pKD = 5.8) 
 
The docked poses for the S & R-enantiomers of 66 (Figure 4-10 and Figure 4-11) 
are remarkably similar, though significantly different to those discussed previously, 
as such will be discussed together and referred to as 66.  The docked poses for 66 
shows the compound in a bent conformation similar to that observed with both 
enantiomers of 65.  This bent confirmation is most likely due to the increased length 
afforded by the ethyl ester, forcing the compound to adopt a conformation which 
requires less space lengthwise.  This conformation could also be aided by pi-
interactions between the aryl ‘tail’ section and the triazole/’head’ sections.  
Interestingly 66 orients itself in the opposite direction to that observed with the 
other compounds, with the sulfone dominating the interactions at the base of the 
binding pocket.  This change in direction may possibly be due to the ‘head’ of the 
compound no longer being able to hydrogen bond with either GLN711 or ARG752, 
with GLN711 now forming a hydrogen bond with a sulfonyl oxygen.  The now 
lipophilic ethyl ester ‘head’ section sits in a pocket created by LEU880, LEU704 
and ASN705.  Even with a low number of hydrogen bonds present (only one bond) 
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the S & R-enantiomers display a relatively high pKD value (6.4 and 5.8, 
respectively). 
 
 
Figure 4-10 Docked pose for S-isomer of 66 (pKD = 6.4) 
 
 
Figure 4-11 Docked pose for R-isomer of 66 (pKD = 5.8) 
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The docked pose for the S-isomer of 67, sitting with the ‘head’ carboxylic acid 
close to the GLN711 and ARG752 residues, and the ‘tail’ section sitting down 
towards the ANS705, LEU880 and LEU704 residues.  Within the LBD S-67 binds 
at a number of different sites, forming a total of seven hydrogen bonds.  As was 
hoped the carboxylic acid present on the aryl ‘head’ of the compound formed four 
hydrogen bonds, with three of these forming between the acid and ARG752, and 
one bond forming between the acid and GLN711.  On top of these four bonds 
formed by the carboxylic acid ‘head’ another three bonds were formed between the 
body of the compound and the asparagine residue ASN705.  One formed from the 
triazole N3, and two other formed from the tertiary alcohol.  Even with this high 
level of hydrogen bonding, a strong but not as strong as hoped pKD value of 5.6 
was obtained for the S-isomer of 67.  
 
 
 
Figure 4-12 Docked pose for S-isomer of 67 (pKD = 5.6) 
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The docked pose for the R-isomer of 67 (Figure 4-13) shows the compound 
orienting much the same way as the S-isomer, with the same four hydrogen bonds 
being formed between the carboxylic acid ‘head’ and amino acid residues ARG752 
and GLN711.  However now due to the inversion of stereochemistry the tertiary 
alcohol no longer sits close to the ASN705 residue meaning this hydrogen bond is 
absent.  Possibly due to the lack of this hydrogen bond, the triazole now also no 
longer forms hydrogen bonds with this ASN705 residue.  This lack of hydrogen 
bonding is somewhat made up for by a bond formed between one of the sulfonyl 
oxygen’s and the ASN705 residue, as the oxygen’s of the sulfonyl group have a 
large dipole, and this could be promoting the formation of the hydrogen bond 
(Scheme 4-1). 
   
 
Scheme 4-1 Dipole characteristic of sulfone 
 
It is interesting to note that even with the lower number of hydrogen bonds this 
isomer still obtains a higher calculated pKD value, with a score of 6.2. 
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Figure 4-13 Docked pose for R-isomer of 67 (pKD = 6.2) 
 
Given the positive in silico interactions observed for 67, this gives some validity to 
the earlier hypothesis that the lack of biological activity observed for these two 
compounds may in fact be due to its poor membrane permeability.  Although as 
previously mentioned pKD and in silico studies can only hint at possible binding 
strength and interactions, to fully understand this issue further biological testing 
would be needed. 
When docked into the binding site of 2OZ7.pdb, the S-enantiomer of compound 68 
adopted a similar conformation and binding mode to that of (S)-63; its fluorine 
containing analogue.  Overall 68 exhibits four hydrogen bonds within the binding 
domain.  The first of these hydrogen bonds was observed between one of the 
sulfonyl oxygen’s and the carboxylic acid moiety of ASN705, much like that 
observed with 63.  The ‘head’ region of (S)-68 adopts much the same interactions 
as (S)-63, with two of the fluorine’s present in the trifluoromethyl group forming 
hydrogen bonds with the GLN711 residue and the cyano group again forming 
hydrogen bonds with the guanidine moiety present in ARG752.  When comparing 
the pKD values for (S)-63 and (S)-68 they are remarkably similar (6.0 vs 6.1, 
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respectively) although this may be expected, due to the similar structures of the 
compounds, however this is not reflected in the IC50 values determined for each 
compound. 
 
 
Figure 4-14 Docked pose for S isomer of 68 (pKD = 6.1) 
 
The docked pose of (R)-68 forms four hydrogen bonds within the binding domain 
(Figure 4-15), as seen with the S-enantiomer it has a conformation and binding 
mode very similar to its fluorine containing counterpart (R)-63. When compared to 
(S)-68 the triazole ring of (R)-68 has been flipped now forming a hydrogen bond 
between one of the nitrogens present and ASN705.  The ‘head’ region of (R)-68 
has been flipped when compared to (S)-68, with the trifluoromethyl group now no 
longer interacting with GLN711 but instead sitting up towards a pocket by TRP741, 
MET745, and MET742.  As is seen with the majority of the cyano containing 
compounds, the cyano present in (R)-68 forms a hydrogen bond with the guanidine 
of ARG752.    
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Figure 4-15 Docked pose for R isomer of 68 (pKD = 6.1) 
 
The docked pose for (S)-69 shows an orientation which differs from the bent 
conformation seen with its fluorine containing analogue (S)-65.  Here (S)-69 adopts 
a conformation similar to both enantiomers of both 63 and 68, in which the ‘tail’ 
section resides close to ASN705 and LEU880 and the ‘head’ section again sits close 
to ARG752 with the nitro group present interacting with the guanidine moiety.  
Overall (S)-69 forms two hydrogen bonds, one being formed by the  nitro group 
present on the ‘head’ region interacting with the guanidine present in ARG752, and 
the other being the formed by oxygen from the sulfonyl group interacting with 
ASN705, as had been observed with compounds 63 and 67.  The small number of 
hydrogen bonds compared to other compounds is shown in the pKD value for (S)-
69, being relatively small at only 5.2.  This small value is inconsistent with the 
biological data as the racemic mixture of 69 submitted for testing had the highest 
level of inhibition for both LNCaP and PC-3 cell lines.    
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Figure 4-16 Docked pose for S isomer of 69 (pKD = 5.2) 
 
In contrast to (S)-69, (R)-69 adopts the same bent conformation previously seen 
with both enantiomers of the nitro containing compound 65, as a result the two 
enantiomers of 69 differ greatly in both docked pose and pKD value (S = 5.2, R = 
4.3).  This bent conformation again displays pi-stacking between the aryl ‘tail’ 
section and the triazole/aryl ‘head’ region, however this enantiomer now only forms 
a single hydrogen bond within the binding domain, seen between the sulfonyl 
oxygen and ASN705.  This impact the rest of the molecule as the nitro ‘head’ group 
now no longer interacting with the guanidine present from ARG752.  This lack of 
interaction between the nitro and guanidine units, is somewhat interesting as this 
would likely be quite a robust interaction.  Even though the in silico data suggests 
weak binding within the LBD, the racemic mixture of 69 that was sent for testing 
in fact displayed  the lowest IC50 values, even besting Bicalutamide’s (3) activity 
with respect to the PC-3 cell line.  This modelling data coupled with the IC50 data 
suggests that 69 may not be blocking the androgen receptor, but may be acting via 
a different pathway.  Although without further investigation this can only be 
speculated.     
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Figure 4-17 Docked pose for R isomer of 69 (pKD = 4.3) 
 
 Conclusion 
The biological testing of the previously synthesised compounds suggests that 
whether the synthesised compounds are active against LNCaP, PC-3 or both cell 
lines, is dictated to some extent by the ‘tail’ aryl group present on the compound.  
The fluorine lacking analogues 68 and 69 showed activity against, both LNCaP and 
PC-3 cell lines, with this activity against PC-3 cell lines absent in the other 
synthesised compounds.  The in silico data suggests that the compounds all exhibit 
a pKD value for their binding within the hARLBD, that is on par with that of 
Bicalutamide (3).  Whilst this in silico data may be used to suggest a mode of action 
for those compounds when tested against the AR containing LNCaP cell lines, this 
is not able to provide a mode of action for the PC-3 cell lines.  
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Chapter 5 
 
5 Antitubercular agents 
 
111 
 
 Chapter overview 
This chapter will begin with an introduction to tuberculosis, focusing on bacterial 
physiology, symptoms of infection and current treatments.  This will then be 
followed by discussion of the design and synthesis of a range 1,4-disubstituted-
1,2,3-triazoles and the investigation into their ability to inhibit the growth of the 
H37Rv strain of Mycobacterium Tuberculosis (Mtb).  By initially examining the 
biological activity of previously discussed triazoles 27 to 46. These compounds 
served as an inspiration for the design and synthesis of the novel compounds 
presented in the latter portion of this chapter.  The compounds featured in Chapter 
5 can be separated into four distinct collections based upon their structures.  The 
first two sets discussed comprise of the compounds previously synthesised in 
Chapter 2 (27 to 46), represented by the general structures 83 and 84 (Figure 5-1).  
The third set of compounds discussed are those bearing a secondary alcohol moiety, 
represented by general structure 85.  The fourth and final set of compounds 
discussed (86) bear a similarity to compounds represented by 83, but with a focus 
on the modification of the alkynyl ‘tail’ region. 
 
 
Figure 5-1 General structures of compounds discussed in Chapter 5 
 
 Tuberculosis  
 
Tuberculosis (TB) is a disease which has presented a persistent threat to mankind 
for centuries and is currently thought to infect roughly 1/3rd of the world’s 
population, as many as 2 billion people.[129]  TB is caused by members of the family, 
Mycobacterium Tuberculosis complex (Mtb).  Mtb poses a large health threat to 
mankind with 1.4 million reported deaths in 2011,[130] this figure makes it the 
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largest killer amongst infectious diseases.  Tuberculosis most often occurs in the 
lungs (pulmonary TB) but may affect any part of the body (extra pulmonary TB).  
Although TB may present without any symptoms, a person infected with 
pulmonary TB may often suffer from a range of different symptoms including; 
cough, fever, weight loss (where the original disease name ‘consumption’ 
originates), breathlessness, and chest pain.[131]  Extrapulmonary TB presents with a 
wide range of symptoms dependant on where the infection has occurred.  These 
symptoms range from swelling of the glands in the neck, armpit or groin; to 
soreness in the spine or large weight bearing joints.[132] 
In healthy individuals with access to well-equipped medical centres and 
professionals, TB poses only a minor threat, for example Australia contributes only 
0.00006% of TB cases worldwide.  However the vast majority of TB afflicted 
people come from developing and third world countries.[133]   
 
 
Figure 5-2 Abundance of TB cases per country, adapted from Corbett et al., 2003[134] 
 
This prevalence and increasing spread of HIV (Human Immunodeficiency Virus) 
has also added to the relative resurgence of TB infection in low socioeconomic 
countries, with individuals affected by HIV essentially unable to fight off TB 
infection.[135]  The inability to defend against infection has meant the TB has 
become the largest cause of death in people infected with HIV, with 1 in 4 
succumbing to the TB infection.[136] 
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TB infection can exist in two distinct forms.  Latent TB infection and active TB 
disease; latent TB infection means the individual is infected with Mtb, but the 
bacteria is dormant, the patient will not present with any of the clinical indications 
of TB and cannot spread the infection to other individuals.  A latent TB infection 
may lay dormant for large periods of time, meaning a person may contract the 
infection and then years, even decades later begin to show signs of the active 
disease.[137]  An individual with active TB disease will present with all the typical 
symptoms and is contagious.  The reason for activation of this latent TB is currently 
unknown.[138]  
 
 Bacterial physiology 
Mtb is a gram positive, slow growing mycobacteria requiring oxygen to grow, with 
a doubling time of 12-24 hours under optimal conditions.[139]  A unique feature of 
this bacterium is an unusually waxy cell wall that is exceptionally strong providing 
a high degree of protection from potentially harmful compounds.[140]  This unique 
cell wall results in poor bacteriological stain uptake and thus specialist stains had 
to be developed such as the Ziehl–Neelsen (ZN) stain which exploits the unique 
properties of Mtb.[141]  The cell wall of the Mtb is comprised of several distinct 
structures (Figure 5-3), the standard phospholipid bilayer followed by a meshwork 
of peptidoglycan.[142] These two layers are then followed by a layer of a unique 
polysaccharide; arabinogalactan.   
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Figure 5-3 Basic structure of Mtb cell wall[143] 
 
This arabinogalactan layer is covalently linked to long fatty acid chains comprised 
of various mycolic acids, generally consisting of a carbon chain with interspersed 
cyclopropyl groups and of the many mycolic acid derivatives.  Mtb produces three 
main types the alpha, methoxy, and keto mycolic acids (Figure 5-4), often 
containing chains of 70-90 carbons in length.[144]  
 
 
Figure 5-4 General structures of the three mycolic acid derivatives 
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The hydrophobic mycolic acid layer acts as a waxy barrier, and is often attributed 
to the survivability of Mtb in otherwise damaging conditions.[145]  The cell wall 
offers protection from many bactericidal agents and organisms that would seek to 
damage or destroy the mycobacteria.  Mtb is unable to be digested by both 
phagocytes and macrophages, primarily due to the waxy cell wall blocking any of 
the bactericidal enzymes that phagocytes may contain, from crossing into the 
mycobacteria.  Interestingly, when under attack by macrophages the mycobacteria 
can draw the host’s natural defences to it by secreting mycobacterial factors.  These 
secretions allow the Mtb to infect the macrophages and turn them into a vehicle to 
further spread the bacterial infection.[141]  The already impressive ability of Mtb to 
resist antibiotics and the body’s natural defences can be increased due to mutations, 
enzymes and ‘exclusion’ systems, this increase can lead to what is called multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).[146]  The 
changes present in these MDR-TB strains mean that they are at least resistant to the 
commonly used isoniazid and rifampicin treatments (Figure 5-5).[147]  Currently, 
5% of TB cases are classified as MDR-TB and unfortunately about 1 in 10 of these 
cases are classified as XDR-TB.  XDR-TB is defined as being resistant to isoniazid 
and rifampicin in addition to any fluoroquinolones,[148] and injectable second line 
drugs used to treat MDR-TB.[149] 
 
 
Figure 5-5 Structure of Isoniazid and Rifampicin 
 
 Treatments 
The first line of defence against Mtb infection is the bacilli Calmette-Guerin (BCG) 
vaccination, although this vaccination only provides limited protection from being 
infected by Mtb (by ≈20%).  The vaccine only moderately reduces the risk of the 
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infection progressing to the disease stage (by ≈60%);[150] unfortunately the 
conferred immunity begins to decrease as time goes on.[151]  Once contracted the 
standard treatment for Mtb infection is a course isoniazid and rifampicin (Figure 
5-5), two ‘front line’ antibiotics, with treatments taking large amounts of time (≈6-
9 months).  If the infection is found in its latent stage it is often easier to treat with 
treatment usually consisting of a single drug (either isoniazid or rifampicin) for a 
period of ≈9 months.  However if the infection progresses to the active disease stage 
treatment becomes more difficult, normally consisting of treatment with 
combinations of multiple drugs for large amounts of time.  MDR-TB and XDR-TB 
become even more problematic to treat; with both possessing resistance to the first 
line drugs, isoniazid and rifampicin.  MDR-TB is often treated with extensive 
combinations of second line drugs requiring long treatment times (often years).[152]  
XDR-TB presents a whole new problem with these ‘strains’ often being resistant 
to large amounts of the second line drugs used to treat MDR-TB, as such the 
treatment of such XDR-TB becomes reliant on test such as the drug susceptibility 
test (DST), which ascertains the drugs the bacteria is resistant to.  However this 
DST is not 100% reliable and can cause problems when determining the best drugs 
to use in each patients infection.[152]  
 
 Pharmaceuticals and their mode of action 
There are a range of common antitubercular pharmaceuticals that are currently used 
to treat Mtb infection.  Unfortunately the mechanism of action of most of these 
compounds remains a mystery, at best there are strong theories suggesting their 
mode of action.[153]  Further complicating this is both the intrinsic (innate) and 
acquired resistance displayed by the Mtb, meaning that as previously discussed 
treatment can become problematic.     
5.2.3.1 Isoniazid 
Isoniazid (Figure 5-5) is one of the most commonly used antitubercular 
pharmaceuticals, being typically used to treat non-drug resistant Mtb infections.  
Isoniazid (isonicotinic acid hydrazide) is administered as a prodrug and is itself not 
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toxic to the bacteria.  Isoniazid enters the Mtb cell by passive diffusion,[154] once 
inside the prodrug is metabolised by the mycobacterial enzyme KatG, a catalase-
peroxidase, forming two radicals (Figure 5-6) which are thought to be the reactive 
intermediates responsible for Isoniazid’s activity.[155]  These reactive intermediates 
have been reported to inhibit a range of essential pathways in Mtb but the main 
method by which they kill is by inhibition of the pathway by which Mtb makes the 
essential mycolic acids.[156]  Although it is known that the active metabolites of 
Isoniazid inhibit the formation of mycolic acids, it is unknown exactly how this is 
achieved.  
 
 
Figure 5-6 Products of Isoniazid metabolism by KatG 
 
5.2.3.2 Rifampicin 
Rifampicin (Figure 5-5) easily diffuses across the Mtb cell wall, this is attributed to 
Rifampicin’s largely lipophilic bulk.[157]  Once inside the cell Rifampicin binds to 
RNA polymerase, inhibiting transcription, ultimately resulting in cell death.[153]  
Although it is known which target Rifampicin binds to it is still unclear exactly how 
this interaction leads to the demise of Mtb.    
5.2.3.3 Bedaquiline 
Isoniazid and Rifampicin have been the golden standards for the treatment of 
tuberculosis, since their initial trials in 1952 and 1983, respectively.  There has been 
a relative lack of novel anti-mycobacterial drugs, coupled with the increase in 
resistance to these drugs mean that new compounds are needed.  For this reason in 
December 2012, Bedaquiline was granted accelerated US Food and Drug 
Administration (FDA) approval.[158]  
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Figure 5-7 Structure of Bedaquiline, a recently approved anti-mycobacterial drug 
  
Bedaquiline is unique among anti-mycobacterial drugs, in that it is the only one 
which targets the synthesis of adenosine triphosphate (ATP) in the Mtb cell.  
Bedaquiline achieves this effect via binding with the ATP synthase complex, 
essentially cutting of the production of energy in the cell.[159]  Bedaquiline is 
considered a first-line anti-mycobacterial drug, and is the first to be approved 
specifically for the treatment of MDR-TB.[160]  Although Bedaquiline provides a 
valuable tool for the treatment of Mtb infection it does not come without risks, the 
most major of these being death, as such Bedaquiline comes with a FDA black box 
warning.[161]    
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 Project aims 
 
This project seeks to determine if 1,4-disubstituted-1,2,3-triazoles present a useful 
core scaffold for the design of novel compounds with antitubercular activity. 
 
1. To investigate the potential anti-mycobacterial activity of previously 
synthesised compounds 27 to 42, against the H37Rv strain of Mtb. 
 
2. From this initial investigation design and synthesis a library of compounds 
based upon the most active ‘head’ regions, which incorporate a variety of 
different ‘tail’ regions derived from aldehydes.  Evaluate the synthesised 
compounds ability to inhibit the growth of Mtb. 
 
3. Utilising the two previous sets of data, design and synthesis a range of 
compounds which incorporate a range of different ‘tail’ regions.  This last set 
will incorporate an amine containing compound which will allow for further 
derivatisation via and amide linkage.  Evaluate the synthesised compounds 
ability to inhibit the growth of Mtb.  
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 Preliminary testing of compounds 
It should be noted that the author did not perform the reported biological testing, 
all antibacterial testing of compounds was done at the National Institute of Allergy 
and Infectious Diseases (NIAID) located at the National Institutes of Health (NIH) 
in Maryland, USA.  The synthesised compounds where tested in a whole cell assay 
against M. tuberculosis H37Rv to determine the minimum inhibitory concentration 
(MIC) that resulted in complete (>99%) inhibition of growth.  Note that all 
compounds were tested against Staphylococcus aureus ATCC 13801, Bacillus 
subtilis, Pseudomonas aeruginosa PA01 and Escherichia coli HB101 bacteria, and 
were selective inhibitors of Mtb. 
Encouraged by the work of Kantevari et al.[162] and Boechat et al.[163] (Figure 5-8) 
who examined triazoles 87 and 88, respectively, which demonstrated good anti-
mycobacterial activity.  The previously synthesised 1,4-disubstituted-1,2,3-
triazoles 27 to 42 were tested for their ability to inhibit the growth of the H37Rv 
strain of Mtb (note further mention of Mtb will refer to this particular strain). 
 
 
Figure 5-8 Compounds made by Kantevari et al. (left) and Boechat et al. (middle) vs compounds from previously 
conducted study (Chapter 2) 
 
Given the structural similarity to established anti-mycobacterial compounds, 
compounds 27 to 46 were submitted and their minimum inhibitory concentrations 
(MIC) were determined.  This allowed a preliminary evaluation to determine if this 
was a potentially fruitful area of investigation.  Note that “MIC” is the minimum 
amount of compound needed to completely inhibit visible growth of the 
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microorganism after overnight incubation.[164]  Given the slow growth rate of Mtb 
the incubation period is typically extended to 1 week rather than 24 hours.[165]  
When assessing MIC values it should be noted that it is not uncommon to see a 
100% variation in values from separate experiments.[166]  Due to the high number 
of MIC experiments and the potential for high variation between replicates, 
individual MIC experiments were not included instead only final MIC values and 
ranges were included.  Before MIC values were obtained, the solubility of the 
synthesised compounds in 0.5% DMSO/Water, at a concentration of 100 μM was 
visually assessed to ensure solubility under antimicrobial assay conditions.  
Isoniazid was used as a control for all of the antibacterial testing, which has an 
extremely low MIC value of 0.02±0.01 μg mL-1.  Of the twenty compounds (27 to 
46), for which the MIC was obtained only five compounds returned results which 
indicated a significant level (≤ 25 μg/mL) of antitubercular activity.  These were, 
27, 28, 31, 33 and 36 (Figure 5-9), of these five compounds 27, 28 and 31 (shown 
in red) exhibited excellent MIC values of <10 μg mL-1.  This was promising for 
compounds which were not originally designed for this purpose, therefore it was 
decided to investigate further compounds which followed this general structure. 
 
 
Figure 5-9 Five active previously synthesised triazoles 
 
It is interesting to note that of the compounds that were submitted, the vast majority 
of compounds which showed activity where those which contained the three 
contiguous aromatic rings.  Compounds following the general structure of 84 and 
85 (Figure 5-10) showing no appreciable activity, apart from the moderately active 
36. 
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Figure 5-10 General structure inactive compounds 
 
 2nd Generation compounds 
With the promising activity of 27, 28, 31, 33 and 36 the previously synthesised 
compounds (Figure 5-9), a new range of compounds were designed (Scheme 5-1).  
This new library of compounds was designed to allow for a range of different 
aromatic groups to evaluate both aryl rings for substitution, electronic and steric 
effects on the biological activity.  These compounds also aimed to incorporate the 
three aromatic rings, which seemed to be a key to the activity of the first series of 
compounds (Scheme 5-1).   
 
 
Scheme 5-1 General synthesis of 2nd generation library, and comparison to previous compounds 
 
This new range of compounds was designed with a range of aldehyde-derived 
alkynes, which would be accessed via a 1,2-Grignard addition to a range of 
benzaldehydes.  This derivatisation from aldehydes provides a secondary alcohol 
which can be utilised as a handle for derivatisation, whilst also incorporating the 
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alcohol seen in the previously evaluated preliminary compounds.  Aryl azides 15 
and 22 were chosen as CuAAc partners for the target alkynes.  The choice of aryl 
azides 15 and 22 (Figure 5-11) as was primarily to allow for comparisons to be 
drawn to the more active preliminary compounds. 
 
 
Figure 5-11 Alkyne derivative and aryl azides 15 and 22 
 
Additionally Mtb has been shown to be able to reduce aryl-nitro groups in vivo to 
the corresponding aniline.  This reduction of the nitro group has in some cases being 
alluded to as a mode of action for published compounds as was reported by Rittel 
et al.[167] and Stover et al.[168] (Figure 5-12).  Thus solidifying the inclusion of 22 
as one of the CuAAc partners 
 
 
Figure 5-12 Lead compounds published by Rittel et al. and Stover et al. 
 
Although these newly proposed compounds now incorporate an alcohol group due 
to being derived from aldehyde, this was not seen as a possible point of issue, and 
could be used as an easy means of structural elaboration in later derivatives.  
Though within the context of this study evaluation of the alcohols was considered 
pertinent to obtain a baseline level of antibacterial activity.  
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Figure 5-13 general structure of products obtained from CuAAc with aldehyde derived alkynes 
 
A set of six aldehydes (89 to 94) where chosen based on differing substitutions and 
substitution patterns.  The five chosen aldehydes all contained aromatic 
substitutions and the majority possess unique substitution patterns, allowing for 
investigation into the effects that the substitution and the substitution pattern have 
on the compounds ability to inhibit Mtb growth.    
The target alkynes could be accessed by a 1,2-Grignard addition to the precursor 
aldehydes.  1,2-Grignard addition was carried out utilising optimised conditions 
from earlier in this document (page 71) and provided the desired alkynes (95 to 99) 
in good to excellent yields (85–98%, Scheme 5-2).  
 
 
Scheme 5-2 1,2-Grignard addition to aldehyde, using previous conditions 
 
Table 5-1 Synthesised alkynes 
Entry Aldehyde Product R1 Yielda (%) 
1 89 95 2-pyrene 85 
2 90 96 C6F5 89 
3 91 97 3,5-BrPh 86 
4 92 98 4-BrPh 98 
5 93 99 4-FPh 91 
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6 94 100 Phenyl 95 
a isolated yield 
 
With the target alkynes synthesised and the aryl azides already on hand the CuAAc 
was then performed.  A range of triazole products were obtained, following the 
general structure presented in Scheme 5-3. 
 
 
Scheme 5-3 Optimised conditions and general structure of triazole product 
 
As a testament to the robust nature of the utilised CuAAc, employing the previously 
optimised conditions resulted in the triazole products being formed in moderate to 
high yield (49–96%, Table 5-2). 
 
Table 5-2 Synthesised triazole products 101 to 112 
Entry Product R1 R2 Yield (%) 
1 101 2-pyrene NO2 49 
2 102 2-pyrene CN 77 
3 103 C6F5 NO2 69 
4 104 C6F5 CN 67 
5 105 3,5-BrPh NO2 94 
6 106 3,5-BrPh CN 96 
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7 107 4-BrPh NO2 73 
8 108 4-BrPh CN 89 
9 109 4-FPh NO2 83 
10 110 4-FPh CN 81 
11 111 Ph NO2 68 
12 112 Ph CN 53 
 
With the triazole products in hand, the ability of these compounds to inhibit the 
growth of Mtb could be assessed.   
 
 Biological evaluation 
 
Of the twelve compounds assessed, six showed an appreciable level of 
antitubercular activity (101, 102, 107, 108, 109 and 110, Figure 5-14), with the 
compounds bearing the dibromo, pentaflouro and hydrogen R1 groups showing no 
activity against Mtb.  Interestingly the results obtained suggested that the activity 
of the compounds is heavily influenced by the R1 substituent located para- to the 
triazole N- originating from the azide component.  The compounds showing 
antitubercular activity were able to be split into three ‘sets’ depending on the R1 
substituent.  The only difference between two compounds of the same ‘set’ being 
the presence of either the nitro (101, 107 and 109) or cyano (102, 108 and 110) 
functional group.  The nitro containing compounds were always more active than 
the cyano derivatives of the same set (e.g. 101 vs 102).  Of the six active compounds 
(Figure 5-14) 101 and 102 (MIC = 4.6 & 17.3 μg mL-1 respectively, shown in red) 
proved to be in general the most active ‘set’ of compounds.  
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Figure 5-14 Compounds displaying antitubercular activity 
 
Interestingly, the most active compounds were those which contained the pyrene 
substituent, suggesting that the unusual pyrene substituent may be well suited for 
use in compounds aiming to combat Mtb.  Though the use of fused aromatic rings 
in therapeutic compounds is uncommon, due to their ability to intercalate DNA.[169]  
Although whether or not it is the pyrene itself having a specific effect or the large 
hydrophobic bulk it imparts the compound, as a large number of adamantly 
containing triazoles previously synthesised by Kantevari et al. also displayed 
similar levels of antitubercular activity. 
Compounds 107 and 108 belonging to the ‘set’ which contained the 4-bromophenyl 
derivatives displayed moderate to high levels of antitubercular activity, although 
neither were as high as the previously mentioned pyrene derivatives.  Again the 
nitro derivative 107 was once again more active than the cyano derivative 108 with 
MIC values of 22 μg mL-1 and 32 μg mL-1, respectively.  Compounds 109 and 110 
belonging to the set which incorporates the 4-flourophenyl component, showed 
moderate activity with MIC values of 9.5 μg mL-1 for 109 and 27 μg mL-1 for 110.           
Interestingly, the effect of the 4-nitro substituent was pronounced, with even the 
least active 4-nitro compound 107 being more active than the majority of the 4-
cyano compounds.  In conjunction with this trend it is also clear that there is a 
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marked difference in the activity that the aryl ‘tail’ substituent imparts, with the 
pyrene containing compounds seeming to have the highest level of activity, 
followed by the 4-fluoro compounds, and the 4-bromo compounds showed the 
lowest level of antitubercular activity. 
 
 3rd Generation compounds 
Although the aldehyde derived compounds presented in Figure 5-14 displayed 
moderate levels of antitubercular activity, they did not match the level of activity 
seen with the simple compounds 27, 28, 31, 33 and 36, which lack the alcohol 
group.  Therefore a new library of compounds was devised, this new library focused 
on derivatising the aryl ring at the 5-position of the triazole core, shown by the 
general structure 86 (Figure 5-15).  In keeping with the activity seen with the first 
set of compounds (Figure 5-9) the aryl azide portion of the library compounds 
would be limited to the phenyl azide (18), nitro trifluoromethyl azide (15) and the 
bis-trifluoromethyl azide (24).  The choice of these azides was such that the 
obtained compounds could be related back to the most active compounds from the 
first set, whilst still allowing investigation into the effects differing the alkyne 
portion would have on the overall antibacterial activity (Figure 5-15). 
      
 
Figure 5-15 General structure of 1st generation compounds (83), general structure of 2nd generation compounds (85) and 
proposed general structure of 3rd generation compound 
 
With the goal of varying the alkyne portion of the synthesised compounds, without 
introducing any extra functionalities; a range of substituted phenyl alkynes were 
purchased from commercial suppliers (Figure 5-16)  
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Figure 5-16 Alkynes and azides used for 3rd generation library 
 
Alkyne 114 containing a fluorine in the 2-position was chosen to investigate the 
effects the position of the halogen substitution, due to previous compounds 
incorporating a halogen substitution showing relatively low MIC values, such as 
28, 36, 107, 108, 109 and 110 although these compound possessed the halogen 
substitution in the 4-position.  Alkyne 115 would allow investigation into the effect 
the positioning of the 4-chlorophenyl moiety would have any antitubercular activity 
of the synthesised compounds, as 28 and 36 had both shown low MIC values but 
had contained the 4-chlorophenyl moiety on the azide component of the CuAAc.  
Phenolic ether 116 would allow the effect that a short lipophilic chain would have 
on the activity of the synthesised compounds, as previously the large lipophilic 
pyrene seen in compounds 101 and 102 had shown to be highly active and as such 
investigation into whether it was overall bulkiness of the hydrophobic group or 
simply the presence of the hydrophobic group itself that was giving these two 
compounds their high level of activity.  Alkyne 116 was chosen to both investigate 
the effect that the possibly reactive amine would have on antitubercular activity, 
but this amine would also serve as a point of derivatisation, via amide formation, 
to allow easy modification of lipophilicity.  
With the alkyne components in hand, three azides were chosen as their reaction 
partners.  The azides were selected based on their previous success, the chosen 
azides being the phenyl azide (18), which had showed excellent activity in the 
preliminary compounds (27).  The nitro trifluoromethyl azide (15), as this had been 
a major focus of this project so far; and the 3,5-bis-trifluoromethyl azide (24), as 
the highly active preliminary compound 31 had incorporated this azide.   
With the azide and alkyne components decided upon the CuAAc was undertaken 
to provide a cross section of each chosen components (Scheme 5-4 and Table 5-3) 
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Scheme 5-4 Generation of 3rd library of compounds 
 
Table 5-3 Synthesised 3rd generation triazole products 
Entry Product R1 R2 R3 R4 
Yielda 
(%) 
1 118 2-F H H H 20 
2 119 4-Cl H H H 40 
3 120 4-OEt H H H 55 
4 121 3-NH2 H H H 50 
5 122 2-F CF3 H CF3 63 
6 123 4-Cl CF3 H CF3 64 
7 124 4-OEt CF3 H CF3 52 
8 125 3-NH2 CF3 H CF3 54 
9 126 2-F H NO2  CF3 70 
10 127 4-Cl H NO2  CF3 40 
11 128 4-OEt H NO2  CF3 67 
12 129 3-NH2 H NO2  CF3 64 
a isolated yield 
131 
 
The CuAAc between each of the chosen alkyne and azide components resulted in 
a library of twelve compounds being generated in low to good yields (20–70%).  
Aryl amine containing compounds 121, 125 and 129 (Figure 5-17) were subjected 
to further derivatisation. 
 
 
Figure 5-17 Three aryl amine containing compounds for further derivatisation 
 
From previously tested compounds it appeared that those possessing a reasonable 
degree of lipophilicity had been amongst the more effective, with 27, 101 and 102 
all showing high levels of antitubercular activity, which is consistent with the waxy 
cell wall of Mtb.  With this apparent trend in mind three separate acyl chlorides 
were chosen to install variable lipophilic regions.  The three acyl chlorides chosen 
were acetyl chloride, octanoyl chloride and benzoyl chloride (130, 131 and 132, 
respectively, Figure 5-18).  Acetyl chloride was chosen to investigate the effect the 
introduction of the amide into the compounds would have, whilst introducing the 
least amount of lipophilicity.  As this effectively serves as an amine coupling unit.  
Octanoyl chloride and benzoyl chloride would both introduce a relatively large 
amount of lipophilic bulk, but now being able to compare the two and suggest 
whether the aromaticity also influenced the compound antitubercular activity.    
 
 
Figure 5-18 130, 131 and 132, the three chosen acyl chlorides 
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With the three acyl chlorides chosen, the desired amide bond was formed via a 
simple N-acylation reaction utilising triethylamine to neutralise the acid formed 
during, which could protonate the aryl amine making it unreactive (Scheme 5-5).  
 
 
Scheme 5-5 General condition used for synthesis of amide derivatives 
 
The desired amide derivatives where generally formed in good to excellent yield 
(75–91%, Table 5-4), although the amide formation between 129 and 131 (Table 
5-4, Entry 8) resulted in a moderate yield of 45%, nevertheless the desired 
compound 142 was isolated for biological evaluation. 
 
Table 5-4 Synthesised amide derivatives 
Entry Product R1 R2 R3 R4 
Yielda 
(%) 
1 135 H H H CH3 86 
2 136 H H H (CH2)6CH3 75 
3 137 H H H Ph 77 
4 138 CF3 H CF3 CH3 85 
5 139 CF3 H CF3 (CH2)6CH3 91 
6 140 CF3 H CF3 Ph 89 
7 141 H NO2 CF3 CH3 78 
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8 142 H NO2 CF3 (CH2)6CH3 45 
9 143 H NO2 CF3 Ph 77 
a isolated yield 
 
With the desired target compounds 118 to 129, and amide derivatives 135 to 143 
synthesised, the antitubercular activity of the compounds could be assessed. 
 
 Biological evaluation 
 
 Selectivity 
It should be noted that the selectivity of all active compounds was evaluated, to do 
this, compounds showing any appreciable activity had their MIC values determined 
for their ability to kill four different bacterial species.  The four chosen bacteria, 
Staphylococcus aureus ATCC 13801, Bacillus subtilis, Pseudomonas aeruginosa 
PA01 and Escherichia coli HB101, the first two bacteria being gram positive and 
the latter two being gram negative.  This mixture of gram positive and negative 
would highlight whether the synthesised compounds targeted one in particular.  
Interestingly when tested against the four species of bacteria the compounds 
exhibited no activity whatsoever, this is an encouraging result as it suggests that 
the synthesised compounds are targeting something unique to Mtb. 
 
 Evaluation 
When comparing the unsubstituted phenyl azide derived 27, to the more complex 
phenyl azide derivatives 118, 119, 120 and 121 (Figure 5-19), it is clear that the 
original parent 27 is the most active of the set.  However 118, 119 and 121 result 
in only a small increase in MIC value, whereas the ethyl ether containing 120 
displays a complete loss of activity.  This change suggests that the halogen and 
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amine substitutions are better tolerated in this scaffold, when compared to the 
introduction of the lipophilic ethyl ether.  
 
 
Figure 5-19 Phenyl azide derived compounds 
 
When comparing the amide derivatives 135, 136 and 137 to the parent aryl amine 
121 (Figure 5-20), the addition of extra hydrophobic bulk raises the MIC values for 
all compounds.  The acetyl derivative 135 has had the lowest negative affect, with 
an MIC value that is close to the original (10±5 and 9±4 μg mL-1, respectively).  
Although the addition of this hydrophobic bulk has lowered the derivatives’ 
antitubercular activity it seems to be to a lesser extent than was seen in the addition 
of the ethyl ether 120. 
 
 
Figure 5-20 Phenyl azide derived, amide containing compounds 
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When comparing the 3,5-bis-trifluromethyl azide derived compounds 122, 123, 
124 and 125, to the parent 31 (Figure 5-21), there is an increase in the MIC.  Whilst 
123 displays a level of activity which is comparable to the parent (MIC = 5±2 vs 
3±2 μg mL-1, respectively), and 124 retains moderate activity (MIC = 15±7 μg mL-
1) the 2-flouro and 3-amino derivatives (122 and 125, respectively) both lose all 
traces of the parent’s antitubercular activity.  
 
 
Figure 5-21 3,5-bis-trifluromethyl azide derived compounds 
 
As seen with the above compounds, in general derivatisation of the parent 31 led 
to a decrease in antitubercular activity, this trend continued with the amide 
derivatives of 125.  Much like the 3-amino parent 125, the amide derivatives 138, 
139 and 140 lose all traces of the antitubercular activity that the parent 31 displayed.  
This result is somewhat surprising as the amide derivatives of phenylazide derived 
27 all retained a good degree of their antitubercular activity. 
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Figure 5-22 3, 5-bis trifluoromethyl azide derived, amide compounds 
 
The derivatives of the 4–nitro-3-trifluoromethyl azide (126, 127, 128 and 129) 
when compared to the original parent 33 (Figure 5-23), all showed improved MIC 
values.  Both 126 and 129 decreased in MIC by more than 10 μg mL-1, down to 13 
μg mL-1 from 25 μg mL-1.  Whereas, 127 and 128 have markedly reduced MIC 
values of 7 and 8 μg mL-1 respectively.    
 
 
Figure 5-23 4-Nitro-3-trifluoromethyl azide derived compounds 
 
As seen with the 3,5-bistrifluoromethyl azide derived, amide compounds (Figure 
5-22), the amide derivatives of 129 also display a complete loss of antitubercular 
activity.  Unlike the amide derivatives seen in Figure 5-22 whose parent 125 also 
displays no antitubercular activity, this loss of activity is strange as the parent amine 
129 displays moderate antitubercular activity but loses this upon formation of the 
amide.  
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Figure 5-24 4-nitro-3-trifluoromethyl azide derived, amide compounds 
 
 Conclusion 
The biological evaluation of these preliminary compounds suggested that the 
simpler tri-aryl compounds were more active against Mtb.  This hypothesis was 
further strengthened by the 2nd and 3rd generation compounds, in which the 3rd 
generation compounds, being based off the simple tri-aryl system were more active 
than the structurally more complex 2nd generation compounds.  Although the more 
lipophilic compounds of the 2nd generation had greater anti-tubercular activity, this 
was not the case with the 3rd generation compounds.  When increasing the 
lipophilicity of the 3rd generation compounds via an amide linkage, the compounds 
seemingly lost their anti-tubercular activity.  Whether this loss of activity is due to 
the incorporation of the amide or the lipophilic bulk is unclear.  What is consistent 
though is the substitution of this point on the aryl ring in not tolerated at all.  
 
 Publications 
The work present in this chapter has led to the publication of the paper listed below. 
 
Altimari, J. M.; Hockey, S. C.; Boshoff, H. I.; Sajid, A.; Henderson, L. C., Novel 
1,4-Substituted-1,2,3-Triazoles as Antitubercular Agents. ChemMedChem 2015, 
10 (5), 787-791 (selected for cover image) 
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6 Conclusions and future work 
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 Concluding statements 
 
With the aim of the project being the investigation into the versatility of the 1,4-
disubstituted-1,2,3-triazole and its application to medicinal chemistry, a range of 
compounds were designed and synthesised with specific goals in mind. 
A synthetic pathway was developed which allowed for the rapid synthesis of a wide 
range of 1,4-disubstituted-1,2,3-trizoles (Scheme 6-1).  This synthetic pathway was 
designed to allow for a range of compounds which mimic the general structure of 
the common pharmaceuticals Flutamide (1) and Bicalutamide (3), to be 
synthesised.  This pathway would also possess a tolerance to a wide range of 
functional groups and allow for the easy generation of subsequent libraries.   
 
 
Scheme 6-1 General 1,4-disubstituted-1,2,3-triazole synthesis 
 
Following this general method, a library of eighteen compounds was synthesised 
with a major focus on compounds which mimic the general structure of the active 
metabolite 2-hydroxyflutamide (2) of the common pharmaceutical Flutamide (1) 
(Figure 6-1).   
 
 
Figure 6-1 Comparison of Flutamide (1) metabolite and mimetic 
 
Of the eighteen synthesised compounds (27–46), four (39, 40, 41 and 42) displayed 
moderate levels of activity against the androgen dependent LNCaP prostate cancer 
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cell line, when tested at static concentrations of 20 & 40 μM.  Although these 
compounds were designed as mimetics of Flutamide (1), they were evaluated 
against Bicalutamide (3), as this is the ‘gold standard’ of non-steroidal prostate 
cancer treatment. Not surprisingly the compounds which displayed the greatest 
activity were those that more closely mimicked Flutamide (1), with respect to their 
aryl ring substituents in both location and identity (e.g. NO2, CF3, CN).  The 
obtained IC50 values for the most active compounds are promising given their 
structural simplicity (Figure 6-2), when compared to the more complex 
Bicalutamide (3).  The ease of synthesis, derivatisation and rapid access mean that 
these compounds are an ideal starting point for future libraries. 
 
 
Figure 6-2 IC50 values for most active compounds 
 
With the biological evaluation of these compounds complete, an in silico study was 
undertaken and the compounds assigned pKD values based on the calculated 
binding strength between themselves and the LBD of the androgen receptor.  
Although there were clear differences in the biological activity of the compounds 
the in silico data didn’t show the more active compounds as having vastly greater 
pKD values, nor greatly different predicted modes of binding. 
With the design and synthesis of the Flutamide (1) mimetics concluded, attention 
was turned to developing a mimetic of the common non-steroidal anti androgen 
Bicalutamide (3).  The designed Bicalutamide (3) mimetics, again incorporated the 
1,4-disubstituted-1,2,3-triazole scaffold (Figure 6-3). 
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Figure 6-3 Designed Bicalutamide (3) mimetic, incorporating the 1,4-disubstituted-1,2,3-triazole 
 
This designed mimetic 63 was accessed in good overall yield (52%, over 5 steps).  
Applying the optimised synthetic pathway to a range of other starting materials, a 
library of eight Bicalutamide (3) inspired compounds was synthesised in good to 
excellent yield over the five steps (41 to 85%).  Of the eight synthesised compounds 
six were tested for their ability to inhibit the growth of both LNCaP and PC-3 
prostate cancer cell lines (Figure 6-5).  The remaining two compounds (70 and 71) 
were developed for further structural elaboration (Figure 6-4). 
 
 
Figure 6-4 Two compounds for further structural elaboration 
 
Of the six tested compounds four displayed good to moderate activity (IC50 = 34–
151 μM) against the LNCaP cell line, whilst only two showed activity (IC50 = 29–
114 μM) against the PC-3 cell line.    
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Figure 6-5 Six compounds tested againt prostate cancer cell lines 
 
Surprisingly the compound which showed the highest level of activity against both 
LNCaP and PC-3 cell line was 69, lacking the 4-fluorine substituent on the sulfonyl 
aryl ring.  Interestingly this compound displayed a greater level of activity against 
the androgen independent PC-3 cell line than it did against the LNCaP cell line 
(IC50 = 29 and 34 μM, respectively).  To support the obtained biological evaluation 
an in silico study was undertaken.  The six compounds were docked into the T877A 
mutant AR isoform, with the compounds assigned pKD values based on the 
calculated binding strength between themselves and the LBD of the androgen 
receptor.  For the in silico study the compounds were tested as their separate 
enantiomers, although they were submitted as a mixture for the biological testing, 
it was hoped that this in silico testing of the separate enantiomers may highlight 
whether one enantiomer was having a more pronounced effect than the other.  
Although there were differences between the pKD values obtained for the 
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enantiomers of each compound, none of the compounds displayed significant 
differences. 
With the design and synthesis and evaluation of a range of novel 1,4-disubstituted 
-1,2,3-triazoles with good to excellent levels of inhibitory action against LNCaP 
and PC-3, attention was turned to other applications for 1,4-disubstitued-1,2,3-
triazole scaffolds. 
After similarities between novel compounds which had displayed good levels of 
antitubercular activity and compounds discussed in Chapter 2, a preliminary 
investigation into the ability of these 1,4-disubstituted-1,2,3-triazole based 
compounds, to inhibit the growth of Mtb, was undertaken.  From this preliminary 
study five compounds (Figure 6-6) with excellent activity (≤ 25 μg mL−1) against 
Mtb were discovered. 
 
 
Figure 6-6 Preliminary compounds displaying excellent levels of antitubercular activity 
 
  Following the promising activity shown by the preliminary compounds a further 
two libraries of compounds were designed and synthesised.  The first library of 
compounds aimed to investigate the effect that different substitution patterns on the 
alkyne portion of the molecule would have on the overall activity of the compounds 
(Scheme 6-2).  
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Scheme 6-2 Design of 2nd compound library 
 
From this designed library six compounds showed moderate to excellent MIC 
values (32 to 4.6 μg mL˗1) when tested against Mtb (Figure 6-7). 
 
 
Figure 6-7 2nd generation compounds showing antitubercular activity 
 
From this a further 3rd generation library was designed and synthesised, focusing 
this time on keeping the original directly linked tri-aromatic system seen in the 
preliminary compounds, whilst also varying the substitutions on the aryl ring at the 
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5-position of the 1,2,3-triazole core (Scheme 6-3).  From this a further twelve 
compounds were synthesised in low to good yields (20-70%). 
 
 
Scheme 6-3 Design and synthesis of 3rd generation compound library 
Of the 21 3rd generation compounds synthesised, over half displayed good to 
excellent MIC values (28 to 5 μg mL˗1).  Although the majority of the phenyl azide 
(18) inspired compounds (118, 119, 121, 135, 136 and 137) displayed excellent 
MIC values (≤ 10 μg mL˗1), none matched the activity shown by the parent 27 (2.1 
μg mL˗1) (Figure 6-8). 
 
 
Figure 6-8 phenyl azide inspired compounds 
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The compounds inspired by the bis-trifluoromethyl derived 31, in general lacked 
any appreciable level of activity against Mtb, with only two of the seven synthesised 
compounds (123 and 124) showing antitubercular activity (Figure 6-9). 
 
Figure 6-9 Bis-trifluoromethyl azide inspired compounds 
 
The compounds inspired by the 4-nitro-3-trifluoromethyl derived 33, all showed an 
increase in their antitubercular activity, with their MIC values decreasing by at least 
50%, suggesting that substitution of the phenyl ring when used in conjunction with 
the 4-nitro-3-trifluoromethyl azide, is well tolerated (Figure 6-10).  
 
 
Figure 6-10 4-Nitro-3-trifluoromethyl azide inspired compounds 
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 Future work 
 
 Chapter 2 
Future work based around derivatisation of the Flutamide (1) mimetic compounds 
(35 to 42), specifically the derivatisation of the alcohol present.  The alcohol present 
a versatile synthetic handle which may be used to attach different groups of interest.  
The attachment of various length/size hydrocarbon chains/groups could be used to 
promote stronger binding of the evaluated ligands, by making use of the 
hydrophobic pocket seen in the ARA.  This handle could also be used to impart 
favourable characteristics to the compounds, such as the attachment of any number 
of organic polymers to increase aqueous solubility[170] or the attachment of 
fluorescent markers to allow visualisation of the compounds in vitro (Figure 
6-11).[171]   
 
 
Figure 6-11 Parent compound (left) and two possible derivatives (middle and right) 
 
With the majority of synthesised compounds showing some level of ability to 
inhibit prostate cancer cell growth in the static tests, it would be interesting to 
investigate the IC50 values for all the synthesised compounds (27 to 46).  This 
investigation into the IC50 values may highlight other compounds which could 
serve as promising leads. 
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To further elucidate trends within compound sets, further physical-chemical 
properties of compounds could be calculated.  Determining parameters such as log 
P, Hammett coefficients and polar surface area for individual compounds may 
allow trends between properties, modelling data and biological activity to be seen 
and utilised.   
 
 Chapter 3 & 4 
Although the compounds were synthesised in good yields, the synthesis itself is not 
stereoselective, meaning that a mixture of the two enantiomers of the synthesised 
compounds is obtained.  This introduction of a stereocentre occurs when 
performing the 1,3-Grignard addition to the ketone seen in intermediates 51 and 78 
(Scheme 6-4).     
 
 
Scheme 6-4 Introduction of stereocentre 
 
Whilst this mixture is still useful for initial testing of biological activity, it would 
be interesting to evaluate the biological activity of each of the individual 
enantiomers.  As such development of a stereoselective method of synthesising the 
target compounds would be useful.  This stereoselective synthesis may prove 
problematic so a more ideal approach may be the derivatisation of either 
intermediates or final compounds using a chiral auxiliary (Figure 6-12).[172]  
Introducing this second chiral centre now renders these compounds diastereomers 
meaning they can now, in theory be separated using chromatographic techniques. 
 
 
Figure 6-12 Introduction of chiral auxiliaries 
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Another point of future work is the utilisation of the aryl bromine handle seen in 
compounds 70 and 71.  As discussed the aryl halide handle is a versatile synthetic 
tool allowing for a wide range of transition metal mediated chemistry to be 
undertaken. 
Future work centred on the biological evaluation of the synthesised compounds, 
may include investigations into the mode of action of the active compounds.  Whilst 
mode of action is complex to determine, such things as where the administered 
compound locates in the cell or the strength of binding between the ligand 
(compound) and the AR; could help shed light on the compounds potential mode 
of action.  Attachment of probes which could be visualised under fluorescent 
microscopy may help locate where in the cell the compounds locate.[173]  Ligand 
binding assays may help determine the strength with which the ligand and receptor 
interact (if there is in fact any interaction at all),[174] and although this value is 
somewhat predicted by the in silico studies, these studies cannot accurately predict 
what occurs in vitro.[175] 
 
 Chapter 5 
Whilst over 50% of the 2nd and 3rd generation compounds showed some level of 
activity against Mtb, it seemed that when introducing the lipophilic region via an 
amide bond the majority of the compounds lost activity.  Whether this loss of 
activity is due to the introduction of the bulky lipophilic region or the presence of 
the amide bond could be further investigated.  To do this the nine amide containing 
derivatives could be synthesised but this time incorporating either an ester linkage 
or ether linkage (Figure 6-13), and the effect that this variation has on the MIC 
values could be obtained.  Another point of future work includes the investigation 
into the spatial substitution of the aryl ring.  Taking the most active compounds and 
altering which position the substitution occurs on the aryl ring, an idea as to whether 
the substituents themselves are the major cause of activity or whether it is the 
positioning and size of the substituents on the aryl ring.  
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Figure 6-13 Ester and ether variation of amide derivatives 
Another source of future work for this portion of the work could be the investigation 
into utilising no aromatic alkyne components, incorporating such ‘tail’ regions as 
alkyl chains, cyclic alkanes and possibly even the promising adamantly group used 
by Kantevari et al.[162] . 
 
Figure 6-14 Possible non-aromatic 'tail' compounds 
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Chapter 7 
7 Experimental 
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All reagents were obtained commercially and used without purification unless 
indicated otherwise. 
NMR experiments were performed on a JEOL JNM-Ex 270 MHz, Eclipse JNM-
ECP 400 MHz FT-NMR or a Bruker AVANCE III 500 MHz FT-NMR 
spectrometer. Samples were dissolved in CDCl3, DMSO-d6 or CD3OD.  1H NMR 
spectra are reported as: chemical shift (ppm), multiplicity (s, singlet; d, doublet; t, 
triplet; m, multiplet; br, broad), J (coupling constant in Hz), integral, assignment.  
19F NMR where corrected using a 0.05% trifluorotoluene (TFT) in Chloroform-d 
standard, purchased from Bruker. 
High-resolution mass spectral data was collected on either an Agilent Technologies 
LC/MSD TOF Mass Spectrometer or a LC Agilent 1200 MS 6520 QTOF with dual 
electrospray ionisation source. Samples were dissolved in MeOH or MeCN at a 
concentration of less than 0.1 mg/mL. 
Thin layer chromatography was performed on Merck TLC silica gel 60 F254 plates, 
and visualised using UV light (λ = 254 nm and 365 nm) and a potassium 
permanganate oxidising dip (KMnO4, H2O, K2CO3). Column chromatography was 
performed using silica gel 60 (230–400 mesh).  
All microwave reactions were closed vessel reactions performed using a CEM 
Discover S-class microwave reactor. 
All melting points were obtained using Stuart SMP30 melting point apparatus. 
Solubility of the compounds was tested by dissolving an amount of the compound 
in DMSO and then taking an aliquot and diluting in H2O to achieve the required 
concentration at 0.5% DMSO in H2O. 
 
General procedure for formation of aryl azides (A) 
To a solution of electron-deficient aniline (1 eq) in H2O/MeCN (1:8, 36 mL) was 
added HCl (10 mL, 18 M) and stirred vigorously for 10 min at room temperature. 
Sodium nitrite (2 eq) was added portion wise and stirred for an additional hour at 
room temperature, the solution was then cooled to 0 °C and sodium azide (2 eq) 
was added portion wise. The resulting solution is then stirred for an additional hour 
and allowed to warm to room temperature. Water (40 mL) is then added to dissolve 
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and remaining solid, the product concentrated in vacuo to remove residual MeCN. 
The aqueous phase is then extracted with CH2Cl2 (4×30 mL), the layers combined 
and washed with brine (1×20 mL), dried (MgSO4 anhydrous) and the solvent 
removed in vacuo to give the desired product. 
 
General experimental procedure for CuAAC reaction (B) 
The azide (1 eq) and alkyne (1 eq) are placed in a microwave reaction vessel, to 
this is added a solution of CuSO4 (10 mol%, 25 mg/mL aqueous solution) followed 
by ascorbic acid (20 mol%, 20 mg/mL aqueous solution) and the total volume 
brought to 3 mL with water. The reaction is then heated to 100 °C using microwave 
irradiation for 30 min. The aqueous phase is then extracted with CH2Cl2 (2×20 mL), 
the layers combined and washed with brine (1×20 mL), dried (MgSO4 anhydrous) 
and the product concentrated in vacuo to give the desired product in >95% crude 
purity by 1H NMR. Note that despite all compounds being >95% pure by 1H NMR 
spectroscopy when isolated as the crude material, the compounds were subjected 
to purification prior to biological evaluation to ensure no residual metals or other 
organic impurities were present. 
 
General experimental procedure for thioether formation (C)  
Acetone was dried by allowing to sit over 3 Å molecular sieves, for no longer than 
24 hours. The dried acetone was added to a three-necked round bottom flask, under 
an inert atmosphere of N2 gas.  The reaction was cooled to 0 °C and whilst gently 
stirring sulfuryl chloride (1 eq) was slowly added via syringe.  This was then 
allowed to warm to 21 °C and stirred for an additional 3 hours.  The reaction was 
again cooled to 0 °C and NEt3 (2 eq) added slowly, this was allowed to stir at 0 °C 
for 10 minutes before the appropriate thiophenol (0.9 eq) was added. This was then 
allowed to warm to 21 °C and stirred for an additional 16 hours.  To the reaction 
mixture water is slowly added until the mixture goes from opaque yellow to a clear 
yellow.  The excess acetone is then removed in vacuo, before extracting from the 
aqueous phase using EtOAc (3×30 mL) and the organic phases combined.  This 
organic phase is then washed with brine (2×20 mL) before being dried over MgSO4, 
filtered and the product concentrated in vacuo to afford the desired product.  The 
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desired crude product was further purified using column chromatography (2:1 
petroleum spirits/ EtOAc) to give the pure product. 
 
General experimental procedure for 1,2-Grignard addition to 
ketone/aldehyde (D) 
The ketone/aldehyde (1 eq) was added to a round bottom flask, to this was added 
LaCl3·2LiCl (0.6 M in THF, 1 eq) and the mixture stirred at 21 °C for 30 minutes.  
The reaction mixture was placed under an inert atmosphere of N2 gas and cooled to 
0 °C, to this cooled solution, ethynylmagnesium bromide (0.5 M in THF, 2 eq) was 
added slowly.  The reaction mixture allowed to stir for 16 hours, after stirring water 
was slowly added (1×50 mL) followed by HCl (2 M, 1×20 mL) and the organic 
product extracted with EtOAc (3×20 mL), the organic phases were combined and 
washed with brine (2×20 mL), before drying over MgSO4, filtering and the product 
concentrated in vacuo.  The desired crude product was then further purified using 
column chromatography (3:1 petroleum spirits/ EtOAc) to give the pure product. 
    
General experimental procedure for oxidation of thioether (E)     
The thioether (1 eq) was added to a round bottom flask and dissolved in an 
appropriate amount of a MeOH/THF/water (1:1:1) mixture.  To this was added 
Oxone® (3 eq) and the reaction stirred at 21 °C for 16 hours.  The reaction mixture 
was then concentrated in vacuo and the organic product extracted using EtOAc 
(3×20 mL) and the organic phases combined.  The organic phase was then washed 
with saturated sodium bicarbonate (1×15 mL) and brine (1×20 mL) before drying 
over MgSO4, filtering and the product concentrated in vacuo.  The afforded product 
is >95% pure by 1H NMR and was able to be used in subsequent steps without 
further purification. 
 
General experimental for amide formation (via acid chloride) (F) 
The amine (1 eq) was added to a round bottom flask and dissolved in DCM, to this 
was added NEt3 (3 eq) under an inert atmosphere of N2 gas.  The reaction mixture 
was then cooled to 0 °C and the appropriate acid chloride (1.5 eq) was slowly 
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added, the reaction mixture was then allowed to warm to 21 °C and stirred for an 
additional 16 hours.  The reaction mixture was quenched by addition of HCl (1 M, 
1×10 mL) and the organic products extracted with EtOAc (3×15 mL).  the organic 
phases were combined and washed with brine (1×20 mL) before drying over 
MgSO4, filtering and the product concentrated in vacuo.  This crude material was 
then redissolved in CHCl3 (1 mL/100 mg) before petroleum spirits was added (10 
mL/100 mg).  the resultant precipitate was isolated by vacuum filtration to give the 
product as a powder in >95% purity by 1H NMR.
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4ǦAzidoǦ1ǦnitroǦ2Ǧ(trifluoromethyl)benzene 15 
 
Prepared via general method (A) 
ν (max) cm-1 2998, 2210, 1552, 1420, 801; 1H NMR (400 MHz, CDCl3) δ 7.45 (1H, 
d, J = 8.4 Hz, Ar-H) 7.28 (1H, d, J = 2.8 Hz) 7.11 (1H, dd, J = 8.4, 2.4 Hz, Ar-H); 
13C NMR (100 MHz, CDCl3) δ 139.4, 132.8, 139.8 (q, JC—F = 31.8 Hz) 128.0, 
123.0, 122.3 (q, JC—F = 272.1 Hz); 19F NMR (470 MHz, CDCl3) δ −62.9; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C7H4F3N4O2 233.0286, found 233.0283. 
 
Azidobenzene 18 
 
Prepared via general method (A) 
1H NMR (400 MHz, CDCl3) δ 7.43-7.39 (2H, m, Ar-H) 7.24-7.20 (1H, m, Ar-H) 
7.11-7.08 (2H, m, Ar-H) 
Matched spectral properties previously reported in the literature.[176] 
 
1-Azido-4-chlorobenzene 19 
 
Prepared via general method (A) 
1H NMR (400 MHz, CDCl3) δ 7.28 (2H, d, J = 8 Hz, Ar-H) 6.92 (2H, d, J = 8 Hz, 
Ar-H) 
Matched spectral properties previously reported in the literature.[176] 
 
 
157 
 
4-Azido-1-chloro-2-(trifluoromethyl)benzene 20 
 
Prepared via general method (A) 
mp 54.3-55.1 °C; ν (max) cm-1 3001, 2110, 1430, 765; 1H NMR (400 MHz, CDCl3) 
δ 7.45 (1H, d, J = 8.8 Hz, Ar-H) 7.28 (1H, d, J = 2.8 Hz, Ar-H) 7.11 (1H, dd, J = 
8.4, 2.4 Hz, Ar-H); 13C NMR (100 MHz, CDCl3) δ 139.4, 132.8, 129.9 (q, JC—F = 
31.7 Hz) 128.0, 122.3 (q, JC—F = 272.1 Hz) 123.0; 19F NMR (470 MHz, CDCl3) δ 
−63.9; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C7H4F3N3 222.0046, found 
222.0039. 
 
4-Azidobenzonitrile 21 
 
Prepared via general method (A) 
1H NMR (400 MHz, CDCl3) δ 7.64 (2H, d, J = 9.6 Hz, Ar-H) 7.10 (2H, d, J = 9.6 
Hz) 
Matched spectral properties previously reported in the literature.[176] 
 
4-Azido-2-(trifluoromethyl)benzonitrile 22 
 
Prepared via general method (A) 
mp 38.2-40.1 °C ; ν (max) cm-1 2254, 2110, 1330; 1H NMR (270 MHz, CDCl3) δ 
7.80 (1H, d, J = 8.1 Hz, Ar-H) 7.35 (1H, s, Ar-H) 7.29 (1H, d, J = 8.4 Hz); 13C 
NMR (100 MHz, CDCl3) δ 145.6, 136.4, 135.0 (q, JC—F = 33.1 Hz) 122.2, 121.9 
(q, JC—F = 272.9 Hz) 117.8 (q, JC—F = 4.8 Hz) 115.1, 105.7; 19F NMR (470 MHz, 
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CDCl3) δ −61.9; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C8H4F3N4 213.0388, 
found 213.0383. 
1-Azido-4-nitrobenzene 23 
 
Prepared via general method (A) 
1H NMR (400 MHz, CDCl3) δ 8.22 (2H, d, J = 10 Hz, Ar-H) 7.13 (2H, d, J = 10, 
Ar-H)  
Matched spectral properties previously reported in the literature.[176] 
 
1-Azido-3,5-bis(trifluoromethyl)benzene 24 
 
Prepared via general method (A) 
1H NMR (270 MHz, CDCl3) δ 7.64 (1H, s, Ar-H) 7.43 (2H, s, Ar-H) 
Matched spectral properties previously reported in the literature.[177] 
 
1Ǧ[4ǦChloroǦ3Ǧ(trifluoromethyl)phenyl]Ǧ4ǦphenylǦ1HǦ1,2,3Ǧtriazole 26 
 
Prepared via general method (B) 
mp 169.1-172.3 °C; ν (max) cm-1 3124, 1495, 1310, 1147, 1037; 1H NMR (400 
MHz, CDCl3) δ 9.50 (1H, s, triazole H), 8.42 (1H, s, Ar-H), 8.32 (1H, dd, J = 8.7, 
2.6 Hz, Ar-H), 8.02 (1H, d, J = 8.7 Hz, Ar-H), 7.95 (2H, d, J =8 Hz, Ar-H), 7.51 
(2H, m, Ar-H), 7.40 (1H, m, Ar-H); 13C NMR (100 MHz, CDCl3) δ 148.22, 136.16, 
133.98, 130.91 (m), 130.47, 129.65, 129.04, 128.53 (q, JC—F = 32 Hz), 125.93, 
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125.70 (m), 122.89 (q, JC—F = 272 Hz), 120.62, 119.75; HRMS (ESI-TOF) m/z: [M 
+ H]+ Calcd for C15H9ClF3N3 324.05099, found 324.05011. 
1,4-Diphenyl-1H-1,2,3-triazole 27 
 
Prepared via general method (B) 
1H NMR (400 MHz, DMSO-d6) δ 9.32 (1H, s, triazole H) 7.98-7.95 (4H, m, Ar-H) 
7.67-7.63 (2H, m, Ar-H) 7.55-7.49 (3H, m, Ar-H) 7.42-7.38 (1H, m, Ar-H) 
Matched spectral properties previously reported in the literature.[178] 
 
1-(4-Chlorophenyl)-4-phenyl-1H-1,2,3-triazole 28 
 
Prepared via general method (B) 
1H NMR (400 MHz, DMSO-d6) δ 9.34 (1H, s, triazole H) 8.01 (2H, d, J = 8.8 Hz, 
Ar-H) 7.96-7.93 (2H, m, Ar-H) 7.73 (2H, d, J = 8.8 Hz, Ar-H) 7.53-7.49 (2H, m, 
Ar-H) 7.40 (1H, t, J = 14.8, 7.2 Hz) 
Matched spectral properties previously reported in the literature.[179] 
 
4-(4-Phenyl-1H-1,2,3-triazol-1-yl)benzonitrile 29 
 
Prepared via general method (B) 
1H NMR (400 MHz, CDCl3) δ 8.31 (1H, s, triazole H) 7.97-7.86 (6H, m, Ar-H) 
7.50-7.39 (3H, m, Ar-H) 
Matched spectral properties previously reported in the literature.[180] 
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1-(4-Nitrophenyl)-4-phenyl-1H-1,2,3-triazole 30 
 
Prepared via general method (B) 
1H NMR (270 MHz, DMSO-d6) δ 9.54 (1H, s, triazole H) 8.53-8.49 (1H, m, Ar-H) 
8.29-8.23 (2H, m, Ar-H) 7.98-7.92 (2H, m, Ar-H) 7.55-7.34 (2H, m, Ar-H) 6.73 
(1H, s, Ar-H) 6.62-6.56 (1H, comp, Ar-H) 
Matched spectral properties previously reported in the literature.[178] 
 
1-[3,5-Bis(trifluoromethyl)phenyl]-4-phenyl-1H-1,2,3-triazole 31 
 
Prepared via general method (B) 
mp 134.5-136.8 °C; ν (max) cm-1 3098, 1612, 1495, 1362, 1227, 1132, 736; 1H 
NMR (400 MHz, DMSO-d6) δ 9.63 (1H, s, Ar-H) 8.68 (2H, s, Ar-H) 8.29 (1H, s, 
Ar-H) 7.95 (2H, t, J = 8 Hz, Ar-H) 7.42 (2H, t, J = 8 Hz, Ar-H); 13C NMR (100 
MHz, DMSO-d6) 148.3, 138.5, 132.5 (q, JC–F = 33 Hz) 130.3, 129.7, 129.1, 125.9, 
123.4 (q, J C–F = 272 Hz) 122.6 (m), 122.0, 121.1 (m), 120.8; 19F NMR (470 MHz, 
CDCl3): δ –63.0; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H10F6N3 
358.07342, found 358.07849. 
 
4-(4-Phenyl-1H-1,2,3-triazol-1-yl)-2-(trifluoromethyl)benzonitrile 32 
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Prepared via general method (B) 
mp 222.8-229.1 °C; ν (max) cm-1 3124, 1495, 1310, 1147, 1037; 1H NMR (400 
MHz, DMSO-d6) δ 9.63 (1H, s, Ar-H) 8.58–8.46 (3H, m, Ar-H) 7.96–7.94 (2H, m, 
Ar-H) 7.54 (2H, t, Ar-H) 7.44–7.41 (1H, m, Ar-H); 13C NMR (100 MHz, DMSO-
d6) δ 148.5, 140.2, 138.1, 133.3 (q, JC–F = 32 Hz) 130.2, 129.7, 129.2, 126.0, 124.2, 
122.7 (q, JC–F = 272 Hz) 120.7, 118.6, 115.6, 108.4; 19F NMR (470 MHz, CDCl3): 
δ −62.2; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H10F3N4 315.08576, found 
315.08448. 
 
1-[4-Nitro-3-(trifluoromethyl)phenyl]-4-phenyl-1H-1,2,3-triazole 33 
 
Prepared via general method (B) 
mp 156.6-158.2 °C; ν (max) cm-1 3124, 1494, 1309, 1135, 727; 1H NMR (400 MHz, 
DMSO-d6) δ 9.51 (1H, s, Ar-H) 8.43 (1H, m, Ar-H) 8.35–8.32 (1H, m, Ar-H) 8.04 
(1H, d, J = 8 Hz, Ar-H) 7.96–7.94 (2H, m, Ar-H) 7.53 (2H, t, J = 8 Hz, Ar-H) 7.41 
(1H, t, J = 8 Hz, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ 148.2, 136.2, 134.0 
130.9, 130.5, 129.7, 129.1, 128.5 (q, JC–F = 31 Hz) 125.9, 125.7, 124.3 (q, JC–F = 
272 Hz) 120.6, 119.8 ; 19F NMR (470 MHz, CDCl3): δ −63.0; HRMS (ESI-TOF) 
m/z: [M + H]+ Calcd for C15H11F3N4O2 335.0750, found 335.0794 
 
2Ǧ(1ǦPhenylǦ1HǦ1,2,3ǦtriazolǦ4Ǧyl)propanǦ2Ǧol 35 
 
Prepared via general method (B) 
1H NMR (400 MHz, DMSO-d6) δ 8.59 (1H, s, triazole H) 7.91 (2H, d, J = 8.4 Hz, 
Ar-H) 7.60-7.56 (2H, m, Ar-H) 7.49-7.45 (1H, comp, Ar-H) 1.54 (6H, s, CH3)    
Matched spectral properties previously reported in the literature.[181] 
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2-[1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl]propan-2-ol 36 
 
Prepared via general method (B) 
1H NMR (270 MHz, CDCl3) δ 7.95 (1H, s, triazole H) 7.56 (2H, d, J = 8.6 Hz, Ar-
H) 7.34 (2H, d, J = 8.6 Hz, Ar-H) 4.67 (1H, br s, OH) 1.60 (6H, s, CH3) 
Matched spectral properties previously reported in the literature.[182] 
 
4-[4-(2-Hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl]benzonitrile 37 
 
Prepared via general method (B) 
mp 108.1-111.2 °C; ν (max) cm-1 3144, 1614, 1510, 1314, 1137, 1025, 695; 1H 
NMR (400 MHz, DMSO-d6) δ 8.78 (1H, s, Ar-H) 8.17 (1H, d, J = 5.4 Hz, Ar-H) 
8.08 (2H, d, J = 5.4 Hz, Ar-H) 3.35 (1H, s, OH) 1.54 (6H, s, CH3); 13C NMR (100 
MHz, DMSO-d6) δ 158.0, 140.3, 134.8, 120.8, 119.7, 118.7, 111.3, 67.5, 31.1; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C12H13N4O 229.10839, found 
229.10718 
 
2-[1-(4-Nitrophenyl)-1H-1,2,3-triazol-4-yl]propan-2-ol 38 
 
Prepared via general method (B) 
1H NMR (400 MHz, DMSO-d6) δ 8.83 (1H, s, triazole H) 8.43 (2H, d, J = 9.2 Hz, 
Ar-H) 8.25 (2H, d, J = 9.2 Hz, Ar-H) 5.34 (1H, s, OH) 1.55 (6H, s, CH3) 
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Matched spectral properties previously reported in the literature.[183] 
2-(1-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)propan-2-ol 39 
 
Prepared via general method (B) 
mp 149.8-150.4 °C; ν (max) cm-1 3290, 3141, 1428, 1275, 1109, 868, 736; 1H NMR 
(400 MHz, DMSO-d6) δ 9.02 (1H, s, Ar-H) 8.66 (2H, s, Ar-H) 8.22 (1H, s, Ar-H) 
5.32 (1H, br s, OH) 1.56 (6H, s, CH3); 13C NMR (100 MHz, DMSO-d6) δ 158.0, 
144.4, 138.7, 132.4 (q, JC–F = 34 Hz) 123.4 (q, JC–F = 272 Hz) 122.1 (m) 121.0 (m) 
120.3, 67.5, 31.0; 19F NMR (470 MHz, CDCl3): δ −61.5; HRMS (ESI-TOF) m/z: 
[M + H]+ Calcd for C13H12F6N3O 340.08791, found 340.08950 
 
2-(1-[4-Chloro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)propan-2-ol 
40 
 
Prepared via general method (B) 
mp 93.7-95.8 °C; ν (max) cm-1 3353, 2979, 1492, 1310, 1142, 1037, 831 736; 1H 
NMR (400 MHz, CDCl3) δ 8.05 (1H, s, Ar-H) 8.00 (1H, d, J = 2 Hz, Ar-H) 7.83 
(1H, dd, J = 8.8 Hz, 2.4 Hz, Ar-H) 7.58 (1H, d, J = 8 Hz, Ar-H) 3.69 (1H, br s, OH) 
1.64 (6H, s, CH3); 13C NMR (100 MHz, DMSO-d6) δ 159.0, 136.4, 133.9, 130.6, 
128.5 (q, JC–F = 31 Hz) 125.6, 122.9 (q, JC–F = 272 Hz) 120.0, 119.7 (q, JC–F = 5 
Hz) 67.5, 31.1; 19F NMR (470 MHz, CDCl3): δ −61.5; HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C12H11ClF3N3NaO 328.04404, found 315.04952 
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4-[4-(2-Hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl]-2-
(trifluoromethyl)benzonitrile 41 
 
Prepared via general method (B) 
mp 112.4-114.2 °C; ν (max) cm-1 3407, 3145, 2981, 1616, 1587, 1365, 1051, 801; 
1H NMR (400 MHz, DMSO-d6) δ 8.23 (1H, s, Ar-H) 8.14–8.11 (2H, m, Ar-H) 8.01 
(1H, d, J = 8 Hz, Ar-H) 1.69 (6H, s, CH3) (OH not observed); 13C NMR (100 MHz, 
DMSO-d6) δ 158.2, 140.4, 138.0, 133.3 (q, JC–F = 16 Hz) 124.0, 120.16, 116.4 (m), 
115.6, 108.0, 67.5, 31.0; 19F NMR (470 MHz, CDCl3): δ −62.2; HRMS (ESI-TOF) 
m/z: [M + H]+ Calcd for C13H12F3N4O 297.09577, found 297.09699 
 
2-(1-[4-Nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)propan-2-ol 42 
 
Prepared via general method (B) 
ν (max) cm-1 3370, 2980, 1492, 1311, 1143, 1037, 831; 1H NMR (400 MHz, 
DMSO-d6) δ 8.94 (1H, s, Ar-H) 8.36 (1H, d, J = 4 Hz, Ar-H) 8.28-8.25 (1H, m, Ar-
H) 7.92 (1H, d, J = 8 Hz, Ar-H) 1.54 (1H, s, OH); 13C NMR (100 MHz, DMSO-
d6) δ 157.9, 136.1, 133.8 (m), 130.5, 128.5 (q, JC–F = 31 Hz) 125.5, 122.8 (q, JC–F 
= 272 Hz) 119.9, 119.5 (m) 67.5, 31.0 ; 19F NMR (470 MHz, CDCl3): δ −63.0; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C12H12F3N4O3 317.08566, found 
317.08856 
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Methyl (2S)Ǧ2Ǧ([(9HǦfluorenǦ9Ǧylmethoxy)carbonyl]amino)pentǦ4Ǧynoate 44 
 
(S)-2-(Fmoc-amino)-4-pentynoic acid, Fmoc-L-2-propargylglycine (335 mg, 1.0 
mmol) was placed in a round bottom flask and dissolved in DCM (5 mL), to this 
was added MeOH (1 mL), EDC•HCl (600 mg, 3.13 mmol), DMAP (36 mg, 0.29 
mmol), this was allowed to stir at 21 °C for 24 hours.  The reaction mixture was 
concentrated in vacuo, the organic products were extracted with DCM (3×15 mL).  
The organic phases were combined and washed with water (2×15 mL) and brine 
(1×15 mL) before drying over MgSO4, filtering and the product concentrated in 
vacuo.  This crude product was further purified using column chromatography (1:9, 
EtOAc/petroleum spirits), to afford the pure product (46%). 
 
1H NMR (270 MHz, CDCl3) δ 7.75 (2H, d, J = 7.5 Hz, Ar-H) 7.61 (2H, d, J = 7.0 
Hz, Ar-H) 7.42-7.28 (4H, comp, Ar-H, note 2 sets of dd unresolved) 5.78 (1H, d, J 
= 8.1 Hz, NH) 4.56 (1H, m, CH) 4.40 (2H, d, J = 7.0 Hz, CH2) 4.23 (1H, t, J = 7.0 
Hz, CH) 3.78 (3H, s, CH3) 2.78 (2H, s, CH2) 2.08 (1H, s, C≡CH);    
Matched spectral properties previously reported in the literature.[184] 
 
Methyl (2S)-2-([(9H-fluoren-9-ylmethoxy)carbonyl]amino)-3-(1-[4-nitro-3-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)propanoate 45 
 
Prepared via general method (B) 
mp 141.3-142.3 °C; ν (max) cm-1 3352, 3066, 2852, 1718, 1492, 1289, 1142, 1036, 
739, 536; 1H NMR (400 MHz, DMSO-d6) δ 8.79 (1H, s, ArH) 8.29 (1H, d, J = 5 
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Hz, ArH) 8.22–8.20 (1H, m, ArH) 7.95 (2H, t, J = 10 Hz, ArH) 7.87 (2H, d, J = 5 
Hz, ArH) 7.64 (2H, dd, J = 5 Hz, 2.5 Hz, ArH) 7.39–7.36 (2H, m, ArH) 7.29, 7.24 
(2H, m, ArH) 4.51–4.47 (1H, m, CH) 4.29 (2H, d, J = 5 Hz, CH2) 4.18 (1H, t, J = 
5 Hz CH) 3.67 (3H, s, CH3); 13C NMR (100 MHz, DMSO-d6) δ 172.3, 156.5, 145.0, 
144.3, 141.3, 136.1, 133.9, 130.7, 128.5 (q, JC–F = 32 Hz) 128.1, 127.6, 125.7, 
125.6, 122.8 (q, JC–F = 272 Hz) 122.4, 120.7, 119.7 (m) 66.3, 54.1, 52.7, 47.1, 27.7 
; 19F NMR (470 MHz, CDCl3): δ −62.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd 
for C28H23F3N5O6 582.1595, found 582.1624 
 
Methyl (2S)-3-(1-[4-cyano-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)-
2-([(9H-fluoren-9-ylmethoxy)carbonyl]amino)propanoate 46 
 
Prepared via general method (B) 
mp 82.5-83.9 °C; ν (max) cm-1 3367, 2954, 1719, 1509, 1467, 1147, 1032, 760; 1H 
NMR (500 MHz, DMSO-d6) δ 8.94 (1H, s, ArH) 8.45–8.38 (3H, m, ArH) 7.95 (2H, 
d, J = 10 Hz, ArH) 7.86 (2H, d, J = 10 Hz, ArH) 7.63 (2H, t, J = 5 Hz, ArH) 7.38 
(2H, t, J = 10 Hz, ArH) 7.27 (2H, dd, J = 5 Hz, 10 Hz, ArH) 4.53–4.48 (1H, m, 
CH) 4.28 (2H, d, J = 10 Hz, CH2) 4.18–4.15 (1H, m, CH) 3.67 (3H, s, CH3); 13C 
NMR (100 MHz, DMSO-d6) δ 172.2, 156.5, 145.3, 144.3, 144.2, 141.3, 140.2, 
138.1, 133.2 (q, JC–F = 33 Hz) 128.2, 127.6, 125.7, 124.1, 122.7, 122.6 (q, JC–F = 
272 Hz) 120.7, 118.4, 115.6, 66.3, 54.1, 52.8, 47.1, 27.7; 19F NMR (470 MHz, 
CDCl3): δ −61.0; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C29H23F3N5O4 
562.16967, found 562.17244 
 
1-[(4-Fluorophenyl)sulfanyl]propan-2-one 53 
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Prepared via general method (C) 
1H NMR (500 MHz, DMSO-d6) δ 7.40-7.37 (2H, m, Ar-H) 7.17-7.13 (2H, m, Ar-
H) 3.95 (2H, s, CH2) 2.20 (3H, s, CH3) 
Matched spectral properties previously reported in the literature.[185] 
 
1-(4-Fluorobenzenesulfonyl)propan-2-one 52 
 
Prepared via general method (E) 
1H NMR (270 MHz, CDCl3) δ 7.89-7.81 (2H, m, Ar-H) 7.21-7.15 (2H, m, Ar-H) 
4.71 (2H, s, CH2) 2.21 (3H, s, CH3) 
Matched spectral properties previously reported in the literature.[186] 
 
1-[(4-Fluorophenyl)sulfanyl]-2-methylbut-3-yn-2-ol 60 
 
Prepared via general method (D) 
ν (max) cm-1 3450, 3212, 1865, 1239, 1156, 556; 1H NMR (270 MHz, CDCl3) δ 
7.47-7.42 (2H, m, Ar-H) 7.00-6.93 (2H, m, Ar-H) 3.33 (1H, d, J = 13.5 Hz, 
SO2CHH) 3.09 (1H, d, J = 13.5 Hz, SO2CHH) 2.39 (1H, s, C≡CH) 1.55 (3H, s, 
CH3); 13C NMR (125 MHz, DMSO-d6) δ 161.20 (d, JC-F = 241 Hz) 133.1, 131.7 (d, 
JC-F = 31 Hz) 116.3 (d, JC-F = 87 Hz) 88.3, 74.0, 66.9, 47.7, 29.3; 19F NMR (470 
MHz, CDCl3): δ −116.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C29H23F3N5O4 
562.16967, found 562.17244 
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1-(4-Fluorobenzenesulfonyl)-2-methylbut-3-yn-2-ol 51 
 
Prepared via general method (D) 
ν (max) cm-1 3500, 3372, 1765, 1349, 1246, 456; 1H NMR (270 MHz, DMSO-d6) 
δ 7.97 (2H, m, ArH), 7.23 (2H, m, ArH), 3.57 (1H, d, J = 13.5 Hz, SO2CHH), 3.44 
(1H, d, J = 13.5 Hz, SO2CHH), 2.37 (1H, s, C≡CH), 1.60 (3H, s, CH3); 13C NMR 
(67.5 MHz, DMSO-d6) δ 166 (d, JC-F = 255.0 Hz), 131.4 (d, JC-F = 10 Hz), 166.6 
(d, JC-F = 89.0 Hz), 88.9, 73.9, 65.8, 64.6, 30.5; 19F NMR (470 MHz, CDCl3): δ 
−106.0; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C11H12FO3S 243.0486, found 
243.0467 
 
4-(4-[1-(Benzenesulfonyl)-2-hydroxypropan-2-yl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 63 
 
Prepared via general method (B) 
mp 205-206.3 °C (decomp); ν (max) cm-1 3470, 3374, 1614, 1506, 1355, 1180, 
1139; 1H NMR (500 MHz, DMSO-d6) δ 8.91 (1H, s, Ar-H) 8.46-8.43 (3H, m, Ar-
H) 7.80-7.77 (2H, m, Ar-H) 7.30-7.27 (2H, m, Ar-H) 5.89 (1H, br s, OH) 4.00-3.93 
(2H, m, CH2) 1.72 (3H, s, CH3); 13C NMR (67.5 MHz, DMSO-d6) δ 167.1, 163.4, 
154.3, 140.1, 138.1, 137.4 (d, JC-F = 3 Hz), 133.6, 133.1, 131.6 (d, JC-F = 10 Hz), 
124.0, 122.6 (q, JC-F = 273 Hz), 121.5, 118.4 (q, JC-F = 47 Hz), 116.5 (d, JC-F = 23 
Hz), 115.6, 108.2 (q, JC-F = 2 Hz), 68.3, 65.8, 28.8; 19F NMR (470 MHz, CDCl3): 
δ −61.89, -106.79; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C19H14F4N4NaO3S 
477.0615, found 477.0643 
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1-(Benzenesulfonyl)-2-(1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-
triazol-4-yl)propan-2-ol 65 
 
Prepared via general method (B) 
mp 211-213 °C (decomp); ν (max) cm-1 3473, 3073, 1591, 1493, 1313, 1237, 1141, 
838; 1H NMR (500 MHz, , DMSO-d6) δ 8.76 (1H, s, Ar-H) 8.27-8.20 (2H, m, Ar-
H) 7.98 (1H, d, J = 10 MHz, Ar-H) 7.79-7.77 (2H, m, Ar-H) 7.30-7.26 (2H, m, Ar-
H) 5.84 (1H, s, OH) 3.99-3.93 (2H, m, CH2) 1.72 (3H, s, CH3); 13C NMR (125 
MHz, DMSO-d6) δ 165.7, 163.7, 153.4, 136.8, 135.5, 133.4, 131.2 (d, JC-F = 12.5 
Hz) 130.2, 130.0 (q, JC-F = 37.5 Hz) 124.9, 123.4, 122.2 (q, JC-F = 250 Hz) 120.7, 
119.0 (q, JC-F = 12.5 Hz) 115.9 (d, JC-F = 25 Hz) 67.7, 65.3, 28.2; 19F NMR (470 
MHz, CDCl3): δ −60.6, -104.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C18H15F4N4O5S 475.0694, found 475.0713 
 
Ethyl 4-(4-[1-(4-fluorobenzenesulfonyl)-2-hydroxypropan-2-yl]-1H-1,2,3-
triazol-1-yl)benzoate 66 
 
Prepared via general method (B) 
mp 170-172 °C; ν (max) cm-1 1714, 1590, 1278, 1140, 1037, 840, 768, 481; 1H 
NMR (500 MHz, DMSO-d6) δ 8.65 (1H, s, triazole-H5), 8.16 (2H, d, J = 10 Hz, 
Ar-H), 8.03 (2H, d, J = 10 Hz, Ar-H), 7.80 (2H, m, Ar-H), 7.29 (2H, dd (app. t), J 
= 10 Hz, Ar-H), 5.81 (1H, s, OH), 4.36 (2H, q, J = 5 Hz, CH2CH3), 3.96 (2H, dd, J 
= 15 Hz, SO2CH2), 1.72 (3H, s, CH3), 1.36 (3H, t, J = 5 Hz, CH2CH3); 13C NMR 
(125 MHz, DMSO-d6) δ 165.3, 165.1 (d, JC-F = 250 Hz), 153.8, 140.1, 137.3 (d, 
J4C-F = 5 Hz), 131.5 (d, JC-F = 35 Hz), 131.4, 129.9, 120.7, 120.0, 116.4 (d, JC-F = 
90 Hz), 122.2, 68.2, 65.7, 61.6, 28.7, 14.6; 19F NMR (470 MHz, CDCl3): δ −110.4; 
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HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C20H21FN3O5S 434.1180, found 
434.1162 
4-(4-[1-(4-Fluorobenzenesulfonyl)-2-hydroxypropan-2-yl]-1H-1,2,3-triazol-1-
yl)benzoic acid 67 
 
mp 253.5-256 °C (decomp); ν (max) cm-1 1690, 1109, 1026, 850, 745, 477; 1H 
NMR (500 MHz, CD3OD) δ 13.21(1H, br, COOH), 8.63 (1H, s, triazole-H5), 8.19-
8.11 (3H, m, Ar-H), 7.99 (2H, d, J = 5 Hz, Ar-H), 7.30-7.26 (2H, m, Ar-H) 7.79 
(2H, dd, J = 5, 10 Hz, ArH), 7.30 (2H, dd, J = 5 Hz, ArH) 5.80 (1H, s, OH), 3.95 
(2H, d, J = 15, 20 Hz, SO2CH2), 1.72 (3H, s, CH3); 13C NMR (125 MHz, DMSO-
d6) δ 165.7, 163.7, 153.4, 136.8, 135.5, 133.4, 131.2 (d, JC-F = 12.5 Hz) 130.2, 130.0 
(q, JC-F = 37.5 Hz) 124.9, 123.4, 122.2 (q, JC-F = 250 Hz) 120.7, 119.0 (q, JC-F = 
12.5 Hz) 115.9 (d, JC-F = 25 Hz), 68.2, 65.7, 28.5; 19F NMR (470 MHz, CDCl3): δ 
−110.56; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C18H17FN3O5S 406.0867, 
found 406.0835 
 
4-(4-[1-(Benzenesulfonyl)-2-hydroxypropan-2-yl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 68 
 
Prepared via general method (B) 
mp 160.3-162.1°C; ν (max) cm-1 1312, 1138, 1049, 1028, 735; 1H NMR (500 MHz, 
DMSO-d6) δ 8.92 (1H, s, ArH), 8.47 (1H, s, triazole-H5), 8.42 (2H, m, Ar-H), 7.73 
(2H, m, ArH), 7.55 (1H, dd, J = 5, Ar-H), 7.47 (2H, dd, J = 10 Hz, Ar-H), 5.87 (1H, 
s, OH), 3.94 (2H, dd, J = 15, 25 Hz, SO2CH2), 1.73 (3H, s, CH3); 13C NMR (125 
MHz, DMSO-d6) δ 154.3, 141.0, 140.0, 138.0, 133.7, 133.2 (q, JC-F = 32.5 Hz), 
129.3, 128.2, 123.9, 122.5 (q, JC-F = 272.5 Hz), 121.3, 118.3 (q, JC-F = 15 Hz), 
115.5, 108.1, 68.2, 65.6, 28.6; 19F NMR (470 MHz, CDCl3): δ −64.0; HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C19H16F3N4O3S 437.0890, found 437.0921 
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1Ǧ(Benzenesulfonyl)Ǧ2Ǧ(1Ǧ[4ǦnitroǦ3Ǧ(trifluoromethyl)phenyl]Ǧ1HǦ1,2,3Ǧ
riazolǦ4Ǧyl)propanǦ2Ǧol 69 
 
Prepared via general method (B) 
mp 140.8-142.9 °C; ν (max) cm-1 1493, 1309, 1141, 1034, 752, 446; 1H NMR (500 
MHz, DMSO-d6) δ 8.78 (1H, s, Ar-H), 8.28 (1H, m, triazole-H5), 8.23-8.18 (1H, 
m, ArH), 7.98 (1H, d, J = 10 MHz, Ar-H), 7.74 (2H, m, Ar-H), 7.58-7.54 (1H, m, 
Ar-H), 7.50-7.45 (1H, m, ArH), 5.81 (1H, s, OH), 3.93 (2H, dd, J = 15, 25 Hz, 
CH2), 1.73 (3H, s, CH3); 13C NMR (67.5 MHz, DMSO-d6) δ 154.0, 141.0, 136.0, 
133.8, 133.1, 129.3, 127.6, 124.2, 122.2 (q, JC-F = 273 Hz), 119.6 (q, JC-F = 5.4 Hz), 
119.0, 69.9, 64.8, 60.5, 30.2; 19F NMR (470 MHz, CDCl3): δ −66.3; HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C18H16F3N4O5S 457.0788, found 457.0728 
 
4-(4-[1-(4-Bromobenzenesulfonyl)-2-hydroxypropan-2-yl]-1H-1,2,3-triazol-1-
yl)-2-(trifluoromethyl)benzonitrile 70 
 
Prepared via general method (B) 
mp 233.2-235.1 °C; ν (max) cm-1 1507, 1398, 1200, 798, 678, 306; 1H NMR (500 
MHz, DMSO-d6) δ 8.84 (1H, s, triazole H) 8.46-8.43 (3H, m, Ar-H) 7.63-7.58 (4H, 
m, Ar-H) 5.93 (1H, s, OH) 3.98 (2H, s, CH2) 1.71 (3H, s, CH3); 13C NMR (125 
MHz, DMSO-d6) δ 153.9, 139.9, 139.8, 138.0, 133.3 (q, JC-F = 32.5 Hz) 132.2, 
130.4, 127.8, 123.8, 122.5 (q, JC-F = 272.5 Hz) 121.4, 118.1, 115.5, 108.1, 68.0, 
65.6, 28.8; 19F NMR (470 MHz, CDCl3): δ −65.0; HRMS (ESI-TOF) m/z: [M + 
H]+ Calcd for C29H23F3N5O4 562.16967, found 562.17244 
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1Ǧ(4ǦBromobenzenesulfonyl)Ǧ2Ǧ(1Ǧ[4ǦnitroǦ3Ǧ(trifluoromethyl)phenyl]Ǧ1HǦ
1,2,3ǦriazolǦ4Ǧyl)propanǦ2Ǧol 71 
 
Prepared via general method (B) 
mp 248.1-249.3 °C; ν (max) cm-1 1493, 1309, 1141, 1034, 752, 446; 1H NMR (500 
MHz, DMSO-d6) δ 8.83 (1H, s, triazole H) 8.45-8.42 (3H, m, Ar-H) 8.31 (1H, s, 
Ar-H) 7.60 (4H, s, Ar-H) 5.91 (1H, s, OH) 3.96 (2H, s, CH2) 1.70 (3H, s, CH3); 13C 
NMR (62.5 MHz, DMSO-d6) δ 154.1, 140.1, 139.9, 138.1, 133.4 (q, JC-F = 30.5 
Hz) 132.3, 130.5, 123.9, 122.6 (q, JC-F = 252.0 Hz) 121.5, 118.2 (q, JC-F = 4.5 Hz) 
115.6, 108.2, 68.2, 65.8, 28.9; 19F NMR (470 MHz, CDCl3): δ −63.4; HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C29H23F3N5O4 562.16967, found 562.17244 
 
4-Azidobenzoic acid 73 
 
Prepared via general method (A) 
1H NMR (500 MHz, DMSO-d6) δ 12.97 (1H, s, COOH) 7.97 (2H, d, J = 8.5 Hz, 
Ar-H) 7.22 (2H, d, J = 8.5 Hz, Ar-H) 
Matched spectral properties previously reported in the literature.[187] 
 
Ethyl 4Ǧazidobenzoate 74 
 
4-Azidobenzoic acid (73) (1 g, 6.1 mmol) was added to a round bottom flask and 
dissolved in EtOH (40 mL), to this was added sulphuric acid (18.4 M, 0.5 mL), the 
reaction mixture was then refluxed for 24 hours.  Excess EtOH was removed in 
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vacuo and the organic product redissolved in DCM (20 mL), the organic layer was 
then washed with water (1×15 mL) and brine (1×15 mL).  The organic layer was 
then dried over MgSO4, filtered and concentrated in vacuo, to give the product as a 
yellow oil (0.97 g, 83%) in >95% purity as determined by 1H NMR.  This was then 
used without further purification.  
1H NMR (500 MHz, CDCl3) δ 8.03 (2H, d, J = 9 Hz, Ar-H) 7.05 (2H, d, J = 9 Hz, 
Ar-H) 4.37 (2H, q, J = 14, 7 Hz, CH2) 1.39 (3H, t, J = 7.5 Hz, CH3)  
Matched spectral properties previously reported in the literature.[188] 
 
1-(Phenylsulfanyl)propan-2-one 76 
 
Prepared via general method (C) 
1H NMR (500 MHz, DMSO-d6) δ 7.34-7.29 (4H, comp, Ar-H) 7.21-7.18 (1H, m, 
Ar-H) 4.00 (2H, s, CH2) 2.23 (3H, s, CH3) 
Matched spectral properties previously reported in the literature.[189] 
 
2-Methyl-1-(phenylsulfanyl)but-3-yn-2-ol 77 
 
Prepared via general method (D) 
ν (max) cm-1 3050, 2890, 2120, 1552, 1089; 1H NMR (500 MHz, DMSO-d6) δ 
7.45-7.41 (2H, comp, Ar-H) 7.30-7.14 (3H, comp, Ar-H) 3.36 (1H, d, J = 13.5 Hz, 
CH2) 3.27 (1H, br s, OH) 3.18 (1H, d, J = 13.2 Hz) 2.41 (1H, s, C≡CH) 1.56 (3H, 
s, CH3); 13C NMR (125 MHz, DMSO-d6) δ 135.9, 129.6, 128.6, 126.5, 87.3, 75.1, 
72.4, 43.7, 28.7; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C11H13OS 193.0687, 
found 193.0691 
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1-(Benzenesulfonyl)-2-methylbut-3-yn-2-ol 78 
 
Prepared via general method (D) 
ν (max) cm-1 3480, 3272, 1717, 1306, 1145, 950, 734, 456; 1H NMR (400 MHz, 
DMSO-d6) δ 7.91 (2H, d, J = 8 Hz, ArH), 7.61 (1H, dd, J = 8 Hz, ArH), 7.51 (2H, 
dd, J = 8Hz, ArH), 4.14 (1H, br s, OH), 3.56 (1H, d, J = 12 Hz, SO2CHH), 3.42 
(1H, d, J = 12 Hz, SO2CHH), 2.34 (1H, s, CCH), 1.98 (3H, s, CH3); 13C NMR (100 
MHz, DMSO-d6) δ 140.3, 134.2, 129.3, 128.3, 84.1, 77.4, 73.9, 66.5, 30.4; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C11H13O3S 225.0580, found 225.0584 
 
1-[(4-Bromophenyl)sulfanyl]propan-2-one 80 
 
Prepared via general method (C) 
1H NMR (500 MHz, DMSO-d6) δ 7.49 (2H, d, J = 8.5 Hz) 7.25 (2H, d, J = 8.5 Hz) 
4.05 (2H, s, CH2) 2.21 (3H, s, CH3) 
Matched spectral properties previously reported in the literature.[189] 
 
1-[(4-Bromophenyl)sulfanyl]-2-methylbut-3-yn-2-ol 81 
 
Prepared via general method (C) 
ν (max) cm-1 3000, 1103, 987, 883, 732, 350; 1H NMR (400 MHz, CDCl3) δ 7.37 
(2H, d, J = 8.8 Hz, Ar-H) 7.29 (2H, d, J = 8 Hz, Ar-H) 3.33 (1H, d, J = 13.6 Hz, 
CH2) 3.13 (1H, d, J = 13.6 Hz, CH2) 2.95 (1H, br s, OH) 2.41 (1H, s, C≡CH) 1.56 
(3H, s, CH3); 13C NMR (125 MHz, DMSO-d6) δ 203.9,137.7, 132.1, 130.2, 119.1, 
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71.6, 51.0, 44.6, 27.0; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C11H12BrOS 
270.9792, found 270.9803 
 
1-(4-Bromobenzenesulfonyl)-2-methylbut-3-yn-2-ol 82 
 
Prepared via general method (D) 
ν (max) cm-1 1501, 1489, 1254, 1110, 701, 554; 1H NMR (500 MHz, CDCl3) δ 7.82 
(2H, d, J = 9 Hz, Ar-H) 7.70 (2H, d, J = 9 Hz, Ar-H) 3.59 (1H, d, J = 14.5 Hz, CH2) 
3.46 (1H, d, J = 14.5 Hz, CH2) 2.42 (1H, s, C≡CH) 1.60 (3H, s, CH3); 13C NMR 
(125 MHz, DMSO-d6) δ 139.2, 132.5, 129.9, 129.4, 83.9, 74.0, 65.6, 64.5, 30.4; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C11H12BrO3S 302.9691, found 
302.9701 
 
1Ǧ(PyrenǦ2Ǧyl)propǦ2ǦynǦ1Ǧol 95 
 
Prepared via general method (C) 
mp 155.1-156.7 °C; ν (max) cm-1 3870, 3750, 3566, 2364, 1699, 1418, 1027, 740, 
707; 1H NMR (500 MHz, DMSO-d6) δ 8.62 (1H, d, J = 10 Hz, Ar-H) 8.36 (1H, d, 
J = 10 Hz, Ar-H) 8.31 (3H, apparent t, J = 5 Hz, Ar- H) 8.25 (1H, d, J = 10 Hz, Ar-
H) 8.17 (2H, apparent s, Ar-H) 8.09 (1H, t, J = 5 Hz, Ar-H) 6.34 (1H, dd, J = 5, 3 
Hz, CH) 6.25 (1H, d, J = 5.5 Hz, OH) 3.50 (1H, s, CH); 13C NMR (125 MHz, 
DMSO-d6) δ 135.6, 131.3, 131.1, 130.7, 127.9, 127.7, 127.7, 127.3, 126.7, 125.8, 
125.7, 125.1, 124.7, 124.5, 124.2, 86.1, 76.9, 61.5; HRMS (ESI-TOF) m/z: [M + 
H]+ Calcd for C19H13O 257.0961, found 257.0994 
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1-(Pentafluorophenyl)prop-2-yn-1-ol 96 
 
Prepared via general method (C) 
1H NMR (270 MHz, CDCl3) δ 5.73 (1H, s, CH) 3.74 (1H, s, OH) 2.62 (1H, d, J = 
2.4 Hz, C≡CH); 13C NMR (100 MHz, CDCl3) δ 146.1, 143.6, 142.1, 138.5, 136.4, 
117.1, 83.4, 75.1, 61.1 due to the complexity in the 13C NMR arising from the 
multiple C-F groups resolution of the C-F multiplets was not possible; 19F NMR 
(470 MHz, CDCl3): δ; −141.5, −153.0, −161.0; HRMS (ESI-TOF) m/z: [M + H]+ 
Calcd for C9H4F5O 223.0182, found 223.0193 
 
1-(3,5-Dibromophenyl)prop-2-yn-1-ol 97 
 
Prepared via general method (C) 
mp 68.5-69.1 °C; ν (max) cm-1 3844, 3724, 2361, 1694, 1548, 1426, 1029, 708, 
406; 1H NMR (270 MHz, CD3OD) δ 7.65 (3H, s, Ar-H) 5.39 (1H, s, CH) 4.86 (1H, 
s, OH) 3.08 (1H, s, CH); 13C NMR (100 MHz, CDCl3) δ 143.6, 134.0, 128.5, 123.1, 
82.3, 76.0, 62.9; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C9H7Br2O 288.8858, 
found 288.8832 
 
1-(4-Bromophenyl)prop-2-yn-1-ol 98 
 
Prepared via general method (C) 
1H NMR (270 MHz, CDCl3) δ 7.44 (2H, d, J = 8.6, Ar-H) 7.31 (2H, d, J = 8.4, Ar-
H) 5.31 (1H, s, CH) 4.02 (1H, s, OH) 2.65 (1H, s, C≡CH) 
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Matched spectral properties previously reported in the literature.[190] 
 
1-(4-Fluorophenyl)prop-2-yn-1-ol 99 
 
Prepared via general method (C) 
1H NMR (270 MHz, CDCl3) δ 7.48-7.43 (2H, m, Ar-H) 7.03-6.96 (2H, m, Ar-H) 
5.35 (1H, d, J = 2.2 Hz, CH) 4.00 (1H, br s, OH) 2.62 (1H, d, J = 2.2 Hz, C≡CH) 
Matched spectral properties previously reported in the literature.[190] 
 
1-Phenylprop-2-yn-1-ol 100 
 
Prepared via general method (C) 
1H NMR (270 MHz, CDCl3) δ 7.57-7.53 (2H, m, Ar-H) 7.42-7.33 (3H, m, Ar-H) 
5.46 (1H, d, J = 2.2 Hz, CH) 3.72 (1H, s, OH) 2.66 (1H, d, J = 2.4 Hz, C≡CH) 
Matched spectral properties previously reported in the literature.[191] 
 
(1Ǧ[4ǦNitroǦ3Ǧ(trifluoromethyl)phenyl]Ǧ1HǦ1,2,3ǦtriazolǦ4Ǧyl)(pyrenǦ2Ǧ
yl)methanol 101 
 
Prepared via general method (B) 
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mp 180.3-182.8 °C; ν (max) cm-1 3902, 3801, 3566, 2342, 1868, 1733, 1540, 1396, 
1060, 1027, 743, 703, 419; 1H NMR (500 MHz, DMSO-d6) δ 8.93 (1H, s, Ar-H) 
8.53 (1H, d, J = 9 Hz, Ar-H) 8.41- 8.17 (11H, m, Ar-H) 8.12-8.06 (1H, m, Ar-H) 
7.91 (1H, d, J = 8.5 Hz, Ar-H) 6.98 (1H, d, J = 4.5 Hz, OH) 6.58 (1H, d, J = 4.5 
Hz, CH); 13C NMR (125 MHz, DMSO-d6) δ 153.6, 137.5, 136.1, 135.4, 133.6, 
131.3, 130.7, 130.6, 128.4, 127.9, 127.8, 127.64, 127.60, 126.8, 126.7, 125.8, 
125.75, 125.6, 125.4, 125.2, 125.1, 124.5, 124.4, 124.2, 123.9, 121.7, 119.7, 65.9; 
Note: due to the complexity in the 13C NMR arising from the CF3 group and the 
pyrene resolution of the C-F multiplets was not possible.  19F NMR (470 MHz, 
CDCl3): δ −61.49; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C26H18F3N4O3 
491.1326, found 491.1358 
 
4-(4-[Hydroxy(pyren-2-yl)methyl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 102 
 
Prepared via general method (B) 
mp 133.4-135.4 °C; ν (max) cm-1 3902, 3801, 2364, 1792, 1653, 1396, 1026, 740, 
717, 444; 1H NMR (270 MHz, DMSO-d6) δ 9.06 (1H, s, Ar-H) 8.52 (2H, m, Ar-H) 
8.46 (1H, d, J = 8.6, Ar-H) 8.37 (2H, d, J = 3Hz, Ar-H) 8.30 (3H, m, Ar-H) 8.21 
(1H, s, Ar-H) 8.18 (2H, s, Ar-H) 8.07 (1H, t, J = 7.8 Hz, Ar-H) 6.98 (1H, d, J = 4.6 
Hz, OH) 6.63 (1H, d, J = 4.6, CH); 13C NMR (67.5 MHz, CDCl3) δ 136.3, 131.5, 
131.3, 130.5, 128.4, 128.0, 127.9, 127.4, 126.4, 125.8, 125.7, 125.6, 125.2, 125.0, 
124.9, 124.7, 124.6, 123.9, 122.9, 122.6, 122.5, 118.1, 62.9; 19F NMR (470 MHz, 
CDCl3): δ −60.85; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C27H18F3N4O 
471.1427, found 471.1458 
 
 
179 
 
(1-[4-Nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3- 
triazol-4-yl)(pentafluorophenyl)methanol 103 
 
Prepared via general method (B) 
mp 148.0-149.8 °C; ν (max) cm-1 3345, 2900, 1313, 1214, 1183, 1123, 990, 851; 
1H NMR (270 MHz, DMSO-d6) δ 9.07 (1H, s, Ar-H) 8.40 (1H, d, J = 2.7 Hz, Ar-
H) 8.32 (1H, d, J = 2.7 Hz, Ar-H) 8.29 (1H, d, J = 2.7 Hz, Ar-H) 7.97 (1H, d, J = 
8.1 Hz, Ar-H) 6.83 (1H, d, J = 5.4 Hz, CH) 6.30 (1H, d, J = 2.7 Hz, OH); 13C NMR 
(100 MHz, DMSO-d6) δ 150.4, 146.2 (m) 143.8 (m) 138.9 (m) 136.4 (m) 136.1, 
133.9, 131.0, 128.5 (q, J C-F = 31 Hz) 125.9, 122.9 (q, J C-F = 272 Hz) 121.1, 120.0 
(m) 117.2 (m); 19F NMR (470 MHz, CDCl3): δ −63.1, −142.7, −153.1, −161.0; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H7F8N4O3 455.0385, found 
455.0410 
 
4-(4-[Hydroxy(pentafluorophenyl)methyl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 104 
 
Prepared via general method (B) 
mp 153.6-155.3 °C; ν (max) cm-1 3384, 1616, 1506, 1312, 1124, 996; 1H NMR 
(270 MHz, DMSO-d6) δ 9.07 (1H, s, Ar-H) 8.58 (1H, s, Ar-H) 8.53 (1H, d, J = 8.1 
Hz, Ar-H) 8.41 (1H, d, J = 10.8 Hz, Ar-H) 6.89 (1H, d, J = 5.4 Hz, CH) 6.31 (1H, 
d, J = 5.4 Hz, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ 150.8, 146.2 (m) 143.8 
(m) 140.2, 138.8 (m) 138.0, 136.4 (m) 133.26 (q, J C-F = 32 Hz) 124.3, 123.6 (q, J 
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C-F = 273 Hz) 122.3, 118.8 (q, J C-F = 5 Hz) 117.1 (m) 115.5, 108.4; 19F NMR (470 
MHz, CDCl3): δ −62.2, −142.7, −152.7, −160.8 ; HRMS (ESI-TOF) m/z: [M + H]+ 
Calcd for C17H7F8N4O 435.04866, found 435.04435 
 
(3,5ǦDibromophenyl)((1Ǧ[4ǦnitroǦ3Ǧ(trifluoromethyl)phenyl]Ǧ1HǦ1,2,3ǦtriazolǦ
4Ǧyl))methanol 105 
 
Prepared via general method (B) 
mp 167.2-168 °C; ν (max) cm-1 3449, 2853, 1615, 1585, 1313, 1183, 1143, 1082, 
841, 740; 1H NMR (400 MHz, DMSO-d6) δ 9.06 (1H, s, Ar-H) 8.56 (1H, d, J = 2.7 
Hz, Ar-H) 8.51-8.49 (1H, m, Ar-H) 8.41 (1H, d, J = 5.4 Hz, Ar-H) 7.76 (1H, m, 
Ar-H) 7.68 (2H, m, Ar-H) 6.53 (1H, d, J = 2.7 Hz, CH) 6.00 (1H, d, J = 2.7 Hz, 
OH); 13C NMR (100 MHz, DMSO-d6) δ 152.7, 148.6, 138.0, 133.2 (q, J C-F = 33 
Hz) 132.8, 129.1, 124.4, 122.9, 122.6 (q, J C-F = 272 Hz) 122.1, 118.8, 115.6, 66.98; 
19F NMR (470 MHz, CDCl3): δ −60.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C16H10Br2F3N4O3 520.9066, found 520.9054 
 
4-(4-[(3,5-Dibromophenyl)(hydroxy)methyl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 106 
 
Prepared via general method (B) 
mp 164.6-165.4 °C; ν (max) cm-1 3381, 3074, 1615, 1467, 1355, 1184, 1143, 998, 
666, 50; 1H NMR (500 MHz, DMSO-d6) δ 9.06 (1H, s, ArH) 8.56 (1H, s, ArH) 
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8.50 (1H, d, J = 8 Hz, ArH) 8.41 (1H, d, J = 8 Hz, ArH) 7.76 (1H, s, ArH) 7.68 
(1H, s, ArH) 6.53 (1H, d, J = 4 Hz, CH), 6.00 (1H, d, J = 4 Hz, OH); 13C NMR 
(100 MHz, DMSO-d6) δ 152.7, 148.6, 140.3, 139.0, 133.2 (q, J C-F = 32 Hz) 132.8, 
129.1, 124.4, 122.9, 122.6 (q, J C-F = 272 Hz), 122.1, 118.8 (m) 115.6, 67; 19F NMR 
(470 MHz, CDCl3): δ −59.1; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C17H10Br2F3N4O 500.9168, found 500.9214 
 
(4-Bromophenyl)((1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4- 
yl))methanol 107 
 
Prepared via general method (B) 
mp 66.5-67.5 °C; ν (max) cm-1 3353, 3153, 1490, 1290, 1143, 1036, 825; 1H NMR 
(270 MHz, CDCl3) δ 8.00 (1H, s, Ar-H) 7.83-7.74 (2H, m, Ar-H) 7.63 (1H, d, J = 
10 Hz, Ar-H) 7.49 (2H, J = 8.1 Hz, Ar-H) 6.06 (1H, s, CH), OH not observed; 13C 
NMR (100 MHz, DMSO-d6) δ 153.2, 143.5, 136.2, 133.8, 131.6, 129.3, 128.4 (q, 
J C-F = 31 Hz) 125.8, 122.9 (q, J C-F = 272 Hz) 121.5, 120.9, 119.9 (q, J C-F = 6 Hz) 
67.7; 19F NMR (470 MHz, CDCl3): δ −63.0; HRMS (ESI-TOF) m/z: [M + H]+ 
Calcd for C16H11BrF3N4O3 442.9961, found 442.9924 
 
4-(4-[(4-Bromophenyl)(hydroxy)methyl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 108 
 
Prepared via general method (B) 
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mp 68.0-69.3 °C; ν (max) cm-1 3359, 3143, 1615, 1509, 1402, 1183, 1010, 738; 1H 
NMR (270 MHz, CDCl3) δ 8.19 (1H, s, Ar-H) 8.08-7.98 (2H, m, Ar-H) 7.86 (1H, 
s, Ar-H) 7.53 (2H, d, J = 8.1 Hz, Ar-H) 7.38 (2H, d, J = 8.1 Hz, Ar-H) 6.09 (1H, s, 
CH) 2.94 (1H, br s, OH); 13C NMR (100 MHz, DMSO-d6) δ 153.6, 143.4, 140.3, 
138.0, 133.2 (q, J C-F = 33 Hz) 131.7, 129.4, 124.3, 122.6 (q, J C-F = 273 Hz) 121.8, 
121.0, 118.7, 115.6, 108.2, 67.7; 19F NMR (470 MHz, CDCl3): δ −62.2; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C17H10BrF3N4ONa 444.9823, found 444.9846 
 
(4-Fluorophenyl)((1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4- 
yl))methanol 109 
 
Prepared via general method (B) 
ν (max) cm-1 3352, 2924, 1604, 1539, 1312, 1226, 1144, 1037, 829, 731; 1H NMR 
(500 MHz, CDCl3) δ 8.04 (1H, s, ArH) 7.87-7.84 (2H, m, ArH) 7.67 (1H, d, J = 10 
Hz, ArH) 7.50-7.47 (2H, m, ArH) 7.08 (2H, t, J = 10 Hz, ArH) 6.12 (1H, s, CH) 
No OH peak observed; 13C NMR (125 MHz, DMSO-d6) δ 162.6 (q, J C-F = 245 Hz) 
137.3, 135.4, 133.0, 132.6, 130.0 (q, J CF= 32.5 Hz) 128.2 (d, J C-F=8.75 Hz) 126.7, 
124.3, 122.0 (q, J C-F = 272.5) 119.6 (m) 115.6 (d, J C-F = 21.3 Hz) 53.4; 19F NMR 
(470 MHz, CDCl3): δ −63.1,−113.7; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C16H11F4N4O3 383.0762, found 383.0775 
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4-(4-[(4-Fluorophenyl)(hydroxy)methyl]-1H-1,2,3-triazol-1-yl)-2-
(trifluoromethyl)benzonitrile 110 
 
Prepared via general method (B) 
ν (max) cm-1 3403, 3107, 1654, 1504, 1320, 1150, 990, 831; 1H NMR (500 MHz, 
CDCl3) δ 8.20 (1H, s, ArH) 8.08 (1H, d, J = 10 Hz, ArH) 8.01 (1H, d, J = 5 Hz, 
ArH) 7.98 (1H, s, ArH) 7.43 (2H, t, J = 10 Hz, ArH) 7.01 (2H, t, J = 10 Hz, ArH) 
6.09 (1H, s, CH) No OH observed; 13C NMR (125 MHz, CDCl3) δ 162.5 (d, J C-F 
= 250 Hz) 153.2, 139.6, 137.2, 136.6, 134.8 (q, J C-F = 33.75 Hz) 128.3 (d, J C-F = 
8.75 Hz) 123.0, 121.6 (q, J C-F = 272.5 Hz) 119.6, 118.3 (m) 115.6 (d, J C-F = 22.5 
Hz) 114.4, 109.6, 68.2; 19F NMR (470 MHz, CDCl3): δ −62.2, −113.6; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C17H11F4N4O 363.0864, found 363.0875 
 
(1Ǧ[4ǦNitroǦ3Ǧ(trifluoromethyl)phenyl]Ǧ1HǦ1,2,3ǦtriazolǦ4Ǧyl)methanol 111 
 
Prepared via general method (B) 
ν (max) cm-1 3368, 2822, 2233, 1613, 1444, 1312, 1180, 1083, 995, 844, 638, 480; 
1H NMR (500 MHz, CDCl3) δ 8.93 (1H, s, Ar-H) 8.53 (1H, d, J = 1.5 Hz, Ar-H) 
8.48 (1H, dd, J = 2, 8.5 Hz, Ar-H) 8.36 (1H, d, J = 8.5, Ar-H) 7.50 (2H, d, J = 7.5 
Hz, Ar-H) 7.36 (2H, t, J = 7.5 Hz, Ar-H) 7.28 (1H, t, J = 7.5 Hz, Ar-H) 6.04 (1H, 
d, J = 4.5 Hz, OH) 5.96 (1H, d, J = 4 Hz, CH); 13C NMR (125 MHz, CDCl3) δ 
153.9, 143.9, 140.4, 137.8, 136.7, 133.2 (q, J C-F = 32.5 Hz) 128.6, 127.7, 127.0, 
124.3, 118.7 (q, J4= 3.75 Hz) 68.5; 19F NMR (470 MHz, CDCl3): δ −60.1; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C16H12F3N4O3 365.0856, found 365.0845 
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4-[4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl]-2-(trifluoromethyl)benzonitrile 
112 
 
Prepared via general method (B) 
ν (max) cm-1 3541, 3203, 1748, 1504, 1320, 1150, 980, 835; 1H NMR (500 MHz, 
DMSO-d6) δ 8.79 (1H, s, Ar-H) 8.35 (1H, d, J = 2.5, Ar- H) 8.26 (1H, ) 7.92 (1H, 
d, J = 8.5 Hz, Ar-H) 7.49 (2H, d, J = 7.5 Hz, Ar-H) 7.36 (2H, apparent t, J = 7 Hz, 
Ar-H) 7.29-7.25 (1H, m, Ar-H) 5.98 (1H, d, J = 4.5 Hz, OH) 5.94 (1H, d, 4.5, CH); 
13C NMR (125 MHz, DMSO-d6) δ 136.3, 136.11, 133.7, 133.7, 128.6, 128.2, 128.1 
(q, J = 255, 102.5 Hz) 127.6, 127.0, 125.7, 125.6; 19F NMR (470 MHz, CDCl3): δ 
−62.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C17H12F3N4O 345.0958, found 
345.0942 
 
4-(2-Fluorophenyl)-1-phenyl-1H-1,2,3-triazole 118 
 
Prepared via general method (B) 
mp 87.1-88.3 °C; ν (max) cm-1 2980, 2450, 1789, 1546, 1109, 983, 754, 589, 450; 
1H NMR (270 MHz, DMSO-d6) δ 9.34 (1H, s, Ar-H) 9.09 (1H, s, Ar-H) 8.18-8.21 
(1H, m, Ar-H) 8.03 (1H, d, J = 10 Hz, Ar-H) 7.62-7.65 (1H, m, Ar-H) 7.37-7.55 
(2H, m, Ar-H) 7.16-7.18 (1H, m, Ar-H) 6.74-6.78 (1H, m, Ar-H); 13C NMR (100 
MHz, DMSO-d6) δ 159.0 (d, J C-F = 100 Hz) 157.8, 141.4, 137.0, 130.6 130.1 (d, J 
C-F = 60 Hz) 129.3 128.2, 125.5, 122.3, 120.8, 119.2, 116.6 (d, J C-F = 20 Hz) 115.7; 
19F NMR (470 MHz, CDCl3): δ −113.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd 
for C14H10FN3 240.09315, found 240.09284 
 
 
185 
 
4-(4-Chlorophenyl)-1-phenyl-1H-1,2,3-triazole 119 
 
Prepared via general method (B) 
mp 216.5-218.4 °C; ν (max) cm-1 3604, 3102, 2567, 1301, 976, 644, 518; 1H NMR 
(500 MHz, DMSO-d6) δ 9.37 (1H, s, Ar-H) 7.94-7.98 (4H, m, Ar-H) 7.52-7.67 (5H, 
m, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ 146.7, 137.0, 133.2, 130.4, 129.6, 
129.3, 127.5, 120.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C14H10ClN3 
256.06360, found 256.06370 
 
4-(4-Ethoxyphenyl)-1-phenyl-1H-1,2,3-triazole 120 
 
Prepared via general method (B) 
mp 162.5-164.7 °C; ν (max) cm-1 3201, 2954, 2100, 1578, 1100, 920, 650, 340; 1H 
NMR (270 MHz, DMSO-d6) δ 9.19 (1H, s, Ar-H) 7.92-7.96 (2H, m, Ar-H) 7.84-
7.87 (2H, m, Ar-H) 7.60-7.66 (2H, m, Ar-H) 7.48-7.54 (1H, m, Ar-H) 7.03-7.06 
(2H, m, Ar-H) 4.08 (2H, q, J =8.1 Hz, CH2) 1.35 (3H, t, J = 8.1 Hz, CH3); 13C NMR 
(67.5 MHz, DMSO-d6) δ 159.1, 147.9, 137.3, 130.5, 129.2, 127.3, 123.1, 120.5, 
119.1, 115.4, 63.7, 15.2; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H15N3O 
266.12879, found 266.12862 
 
3-(1-Phenyl-1H-1,2,3-triazol-4-yl)aniline 121 
 
Prepared via general method (B) 
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mp 121.4-122.6 °C, ν (max) cm-1 3344, 2969, 2931, 2360, 1378, 1108, 816, 624; 
1H NMR (270 MHz, DMSO-d6) δ 9.15 (1H, s, Ar-H) 7.94-7.98 (2H, m, Ar-H) 7.59-
7.65 (2H, m, Ar-H) 7.47-7.53 (1H, m, Ar-H) 7.21 (1H, t, J = 2.7 Hz, Ar-H) 7.03-
7.15 (2H, m, Ar-H) 6.55-6.59 (1H, m, NH); 13C NMR (67.5 MHz, DMSO-d6) δ 
149.5, 148.5, 137.2, 131.1, 130.4, 129.9, 129.0, 120.4, 119.6, 114.4, 113.7, 111.0; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C14H12N4 237.11347, found 237.11310 
 
1Ǧ[3,5ǦBis(trifluoromethyl)phenyl]Ǧ4Ǧ(2Ǧfluorophenyl)Ǧ1HǦ1,2,3Ǧtriazole 122 
 
Prepared via general method (B) 
mp 166.3-168.1 °C; ν (max) cm-1 3321. 2899, 1789, 1407, 1011, 746, 685, 534, 
390; 1H NMR (500 MHz, DMSO-d6) δ 8.50 (1H, d, J = 3 Hz, Ar-H) 8.41 (1H, td, 
J = 1.5, 7.5 Hz, Ar-H) 8.35 (2H, s, Ar-H) 8.00 (1H, s, Ar-H) 7.40-7.45 (1H, m, Ar-
H) 7.46 (1H, td, J = 1.5, 7.5 Hz, Ar-H) 7.22-7.26 (1H, m, Ar-H); 13C NMR (125 
MHz, DMSO-d6) δ 160.4, 157.9, 141.9, 138.4, 132.4 (q, J C-F = 37.5 Hz) 130.9, 
128.2, 125.6, 123.4 (q, J C-F = 337.5 Hz) 123.0 (d, J C-F = 12.5 Hz) 122.6, 121.5, 
118.1 (d, J C-F = 12.5 Hz) 116.7 (d, J C-F = 25 Hz); 19F NMR (470 MHz, CDCl3): δ 
−63.0, -114.1; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H8F7N3 376.06792, 
found 376.06813 
 
1-[3,5-Bis(trifluoromethyl)phenyl]-4-(4-chlorophenyl)-1H-1,2,3-triazole 123 
 
Prepared via general method (B) 
mp 187.2-189.7 °C; ν (max) cm-1 3354, 2890, 2108, 1657, 1209, 983, 650, 421; 1H 
NMR (500 MHz, DMSO-d6) δ 9.67 (1H, s, Ar-H) 8.67 (2H, s, Ar-H) 8.31 (1H, s, 
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Ar-H) 7.95-7.97 (2H, m, Ar-H) 7.60-7.62 (2H, m, Ar-H); 13C NMR (125 MHz, 
DMSO-d6) δ 206.9, 147.1, 138.3, 133.5, 132.4 (q, J C-F = 25 Hz) 129.7, 129.1, 
127.5, 123.3 (q, J C-F = 275 Hz) 122.7, 121.2, 121.1; 19F NMR (470 MHz, CDCl3): 
δ −61.4; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H8ClF6N3 392.03837, 
found 392.03837 
 
1-[3,5-Bis(trifluoromethyl)phenyl]-4-(4-ethoxyphenyl)-1H-1,2,3-triazole 124 
 
Prepared via general method (B) 
mp 141.3-142.9 °C; ν (max) cm-1 3054, 2245, 1604, 1348, 1001, 546, 482; 1H NMR 
(500 MHz, DMSO-d6) δ 9.50 (1H, s, Ar-H) 8.66 (2H, s, Ar-H) 8.29 (1H, s, Ar-H) 
7.85 (2H, d, J = 10 Hz, Ar-H) 7.08 (2H, d, J = 5 Hz, Ar-H) 4.09 (2H, q, J = 5 Hz, 
CH2) 1.36 (3H, t, J = 5 Hz, CH3); 13C NMR (125 MHz, DMSO-d6) δ 159.3, 148.2, 
138.4, 132.4 (q, J =37.5 Hz) 127.2, 123.3 (q, J =275 Hz) 122.6, 122.4, 120.9, 119.6, 
115.4, 63.6, 15.1; 19F NMR (470 MHz, CDCl3): δ −61.4; HRMS (ESI-TOF) m/z: 
[M + H]+ Calcd for C18H13F6N3O 402.10356, found 402.10316 
 
3-(1-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)aniline 125 
 
Prepared via general method (B) 
mp 163.5-164.7 °C; ν (max) cm-1 3348, 2358, 1633, 1395, 1017, 773, 512, 402; 1H 
NMR (270 MHz, DMSO-d6) δ 9.41 (1H, s, Ar-H) 8.68 (2H, s, Ar-H) 8.27 (1H, s, 
Ar-H) 7.01-7.21 (4H, m, Ar-H) 6.59 (1H, d, J = 8.1 Hz, Ar-H) 5.26 (2H, br-s, NH2); 
13C NMR (67.5 MHz, DMSO-d6) δ 149.7, 149.0, 138.4, 132.3 (q, J C-F = 20.25 Hz) 
130.7, 130.0, 123.3 (q, J C-F = 148.5 Hz) 122.3, 121.0, 120.3, 114.6, 113.6, 111.0; 
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19F NMR (470 MHz, CDCl3): δ −61.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C16H10F6N4 373.08824, found 373.08835 
 
4-(2-Fluorophenyl)-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazole 
126 
 
Prepared via general method (B) 
mp 171.5-173.2 °C; ν (max) cm-1 3320, 2700, 1899, 1726, 1340, 1100, 988, 712, 
542, 400; 1H NMR (500 MHz, DMSO-d6) δ 9.48 (1H, s, Ar-H) 8.65-8.70 (2H, m, 
Ar-H) 8.45-8.50 (1H, m, Ar-H) 8.20-8.22 (1H, m, Ar-H) 7.38-7.52 (3H, m, Ar-H) 
; 13C NMR (125 MHz, DMSO-d6) δ 160.1, 158.1, 146.7, 142.0, 139.7, 133.7, 131.0, 
128.2, 125.7, 125.6, 123.7 (q, J C-F = 25 Hz) 123.0, 120.1, 117.9 (d, J C-F = 12.5 Hz) 
116.7 (d, J C-F = 25 Hz); 19F NMR (470 MHz, CDCl3): δ −62.6, −113.7; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C15H8F4N4O2 353.06561, found 353.06694 
 
4-(4-Chlorophenyl)-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazole 
127 
 
Prepared via general method (B) 
mp 175.6-176.8 °C; ν (max) cm-1 3203, 2834, 2100, 1734, 1507, 1208, 985, 750, 
430; 1H NMR (500 MHz, DMSO-d6) δ 9.55 (1H, s, Ar-H) 8.42 (1H, d, J =5 Hz, 
Ar-H) 8.32 (1H, dd, J =2.5, 5 Hz, Ar-H) 8.05 (1H, d, J =5 Hz, Ar-H) 7.95-7.97 (2H, 
m, Ar-H) 7.60-7.62 (2H, m, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ 147.0, 136.0, 
133.9, 133.4, 130.9, 129.7, 129.3, 128.5 (q, J C-F=25 Hz) 127.5, 125.7, 122.8 (q, J 
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C-F=275 Hz) 121.0, 119.8; 19F NMR (470 MHz, CDCl3): δ −61.5; HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C15H8ClF3N4O2 369.03606, found 369.03598 
 
4-(4-Ethoxyphenyl)-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazole 
128 
 
Prepared via general method (B) 
mp 158.3-160.2 °C; ν (max) cm-1 3189, 2617, 1476, 1241, 982, 754, 498, 354; 1H 
NMR (270 MHz, DMSO-d6) δ 9.38 (1H, s, Ar-H) 8.40 (1H, s, Ar-H) 8.29-8.32 (1H, 
m, Ar-H) 8.02 (1H, d, J = 10 Hz, Ar-H) 7.84-7.86 (2H, m, Ar-H) 7.06-7.07 (2H, m, 
Ar-H) 4.09 (2H, d, J = 10 Hz, CH2) 1.36 (3H, t, J = 5 Hz, CH3); 13C NMR (125 
MHz, DMSO-d6) δ 159.2, 148.1, 136.1, 133.9, 130.6, 128.4 (q, J C-F=25 Hz) 127.2, 
125.5, 122.9 (q, J C-F=275 Hz) 122.7, 119.5, 119.4, 115.4, 63.6, 15.1; 19F NMR 
(470 MHz, CDCl3): δ −61.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C17H13F3N4O3 379.10125, found 379.10135 
 
3-(1-[4-Nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl)aniline 129 
 
Prepared via general method (B) 
mp 181.0-183.4 °C; ν (max) cm-1 3349, 2333, 1591, 1492, 1260, 1077, 749; 1H 
NMR (500 MHz, DMSO-d6) δ 9.36 (1H, s, Ar-H) 8.43 (1H, s, Ar-H) 8.33 (1H, d, 
J =5 Hz, Ar-H) 8.01 (1H, d, J = 5 Hz, Ar-H) 7.22 (1H, s, Ar-H) 7.14 (1H, t, J = 10 
Hz, Ar-H) 7.05 (1H, d, J =5 Hz, Ar-H) 6.58-6.61 (1H, m, Ar-H) 5.29 (2H, br-s, 
NH2); 13C NMR (125 MHz, DMSO-d6) δ 149.8, 149.0, 136.2, 133.9, 130.9, 130.8, 
130.1, 128.5 (q, J C-F=37.5 Hz) 125.6, 123.0 (q, J C-F=337.5 Hz) 120.1, 119.8 (q, J 
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C-F=12.5 Hz) 114.7, 113.8, 111.2; 19F NMR (470 MHz, CDCl3): δ −61.5; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C15H10F3N5O2 350.08594, found 350.08574 
 
N-[3-(1-Phenyl-1H-1,2,3-triazol-4-yl)phenyl]acetamide 135 
 
Prepared via general method (F) 
mp 145.3-147.0 °C ; ν (max) cm-1 3299, 2166, 1489, 1478, 1356, 998, 701 
1H NMR (500 MHz, DMSO-d6) δ 10.89 (1H, s, NH) 9.26 (1H, s, triazole H) 8.24 
(1H, s, Ar-H) 8.00 (2H, m, Ar-H) 7.66-7.51 (5H, comp, Ar-H) 7.41 (1H, t, J = 8 
Hz, Ar-H) 2.08 (3H, s, CH3); 13C NMR (100 MHz, DMSO-d6) δ 169.0, 147.9, 
140.5, 137.2, 131.2, 130.5, 130.5, 129.9, 129.3, 120.9, 120.6, 120.2, 116.4, 24.6; 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C29H23F3N5O4 562.16967, found 
562.17244 
 
N-[3-(1-Phenyl-1H-1,2,3-triazol-4-yl)phenyl]octanamide 136 
 
Prepared via general method (F) 
mp 138.0-140.9 °C; ν (max) cm-1 3254, 2958, 2900, 2460, 1300, 1100, 796, 524, 
301; 1H NMR (500 MHz, DMSO-d6) δ 10.03 (1H, s, NH) 9.27 (1H, s, Ar-H) 8.27 
(1H, s, Ar-H) 7.98-8.00 (2H, m, Ar-H) 7.51-7.66 (5H, m, Ar-H) 2.34 (2H, t, J = 5 
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Hz, CH2) 1.60-1.63 (2H, m, CH3) 1.26-1.32 (8H, m, CH2); 13C NMR (125 MHz, 
DMSO-d6) δ 171.9, 147.8, 140.4, 137.1, 131.1, 130.4, 129.8, 129.2, 120.7, 120.5, 
120.1, 119.4, 116.3, 36.9, 31.7, 29.1, 29.0, 25.6, 22.5, 14.4; HRMS (ESI-TOF) m/z: 
[M + H]+ Calcd for C22H26N4O 363.21794, found 363.21642 
 
N-[3-(1-Phenyl-1H-1,2,3-triazol-4-yl)phenyl]benzamide 137 
 
Prepared via general method (F) 
mp 162.5-164.1 °C; ν (max) cm-1 3543, 3001, 2790, 2265, 1204, 800, 540, 480; 1H 
NMR (500 MHz, DMSO-d6) δ 10.42 (1H, s, NH) 9.31 (1H, s, Ar-H) 8.48 (1H, s, 
Ar-H) 7.99-8.03 (4H, m, Ar-H) 7.81 (1H, d, J = 10, Ar-H) 7.47-7.67 (8H, m, Ar-
H); 13C NMR (125 MHz, DMSO-d6) δ 166.1, 147.8, 140.2, 137.1, 135.3, 132.1, 
131.1, 130.4, 129.8, 129.2, 128.9, 128.2, 121.4, 120.8, 120.5, 120.1, 117.8; HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C21H16N4O 341.13969, found 341.13954 
 
N-(3-(1-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-
yl)phenyl)acetamide 138 
 
Prepared via general method (F) 
mp 201.2-203.6 °C; ν (max) cm-1 3321, 2454, 1600, 1620, 1100, 731, 560, 389; 1H 
NMR (270 MHz, DMSO-d6) δ 10.11 (1H, s, Ar-H) 9.58 (1H, s, Ar-H) 8.70 (2H, s, 
Ar-H) 8.28 (2H, d, J = 5.4 Hz, Ar-H) 7.57 (2H, t, J =5.4 Hz, Ar-H) 7.41-7.45 (1H, 
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m, Ar-H) 2.09 (3H, s, CH3) ; 13C NMR (67.5 MHz, DMSO-d6) δ 169.0, 148.3, 
140.6, 138.5, 132.5 (q, J C-F = 20.25 Hz) 130.7, 130.0, 123.4 (q, J C-F=182.3 Hz) 
122.5, 121.2, 121.1, 120.8 119.7, 116.4, 24.6; 19F NMR (470 MHz, CDCl3): δ 
−61.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C18H12F6N4O 415.09881, found 
415.09884 
 
N-(3-(1-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-
yl)phenyl)heptanamide 139 
 
Prepared via general method (F) 
mp 147.2-148.9 °C; ν (max) cm-1 3290, 2418, 1589, 1401, 1117, 780, 487, 441; 1H 
NMR (500 MHz, DMSO-d6) δ 10.05 (1H, s, NH) 9.60 (1H, s, Ar-H) 8.72 (2H, s, 
Ar-H) 8.32 (2H, d, J = 20 Hz, Ar-H) 7.57-7.59 (2H, m, Ar-H) 7.44 (1H, t, J = 10 
Hz, Ar-H) 2.34 (2H, t, J = 10 Hz, CH2) 1.60-1.63 (3H, m, CH3) 1.23-1.32 (10H, m, 
CH2); 13C NMR (125 MHz, DMSO-d6) δ 175.0, 171.9, 148.2, 140.5, 138.4, 132.3 
(q, J C-F = 25 Hz) 130.6, 129.9, 123.3 (q, J C-F = 275 Hz) 122.5, 121.2, 120.8, 120.6, 
119.6, 116.4, 36.9, 34.1, 31.7, 29.1, 28.9, 25.6, 25.0, 22.5, 14.4; 19F NMR (470 
MHz, CDCl3): δ −61.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C24H24F6N4O 
499.19271, found 499.19381 
 
N-(3-(1-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-
yl)phenyl)benzamide 140 
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Prepared via general method (F) 
mp 217.3-218.9 °C; ν (max) cm-1 3398, 3101, 2500, 1340, 1105, 701, 370; 1H NMR 
(400 MHz, DMSO-d6) δ 10.44 (1H, s, Ar-H) 9.64 (1H, s, Ar-H) 8.72 (2H, s, Ar-H) 
8.54 (1H, s, Ar-H) 8.28 (1H, s, Ar-H) 8.02-8.04 (2H, m, Ar-H) 7.79-7.81 (1H, m, 
Ar-H) 7.51-7.67 (5H, m, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ 166.2, 148.3, 
140.3, 138.5, 135.3, 132.5 (q, J C-F = 30 Hz) 132.2, 130.7, 130.0, 129.0, 128.3, 
123.4 (q, J C-F=270 Hz) 122.5, 121.4, 121.1, 120.9, 117.9; 19F NMR (470 MHz, 
CDCl3): δ −61.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C23H14F6N4O 
477.11446, found 477.11318 
 
N-(3-(1-[4-Nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-
yl)phenyl)acetamide 141 
 
Prepared via general method (F) 
mp 181.7-182.8 °C; ν (max) cm-1 3401, 2334, 1899, 1620, 1507, 1205, 1050, 752, 
510, 402; 1H NMR (500 MHz, DMSO-d6) δ 10.11 (1H, s, -NH) 9.47 (1H, s, Ar-H) 
8.45 (1H, br-s, Ar-H) 8.35 (1H, d, J =5 Hz, Ar-H) 8.28 (1H, s, Ar-H) 8.02 (1H, d, 
J = 10 Hz, Ar-H) 7.55-7.60 (2H, m, Ar-H) 7.41-7.45 (1H, m, Ar-H); 13C NMR (125 
MHz, DMSO-d6) δ 169.0, 148.2, 140.6, 136.2, 133.9, 130.9, 130.0, 128.5 (q, J C-
F=37.5 Hz) 125.8, 124.3, 122.9 (q, J C-F=350 Hz) 120.9, 120.7 119.9 (q, J C-F=12.5 
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Hz) 119.6, 116.4, 24.6; 19F NMR (470 MHz, CDCl3): δ −61.5; HRMS (ESI-TOF) 
m/z: [M + H]+ Calcd for C17H12F3N5O3 392.09650, found 392.09680 
 
N-(3-(1-[4-Nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-
yl)phenyl)octanamide 142 
 
Prepared via general method (F) 
mp 151.4-153.5 °C; ν (max) cm-1 3365, 2221, 1602, 1500, 1200, 1021, 690; 1H 
NMR (400 MHz, DMSO-d6) δ 10.03 (1H, s, NH) 9.48 (1H, s, Ar-H) 8.46 (1H, s, 
Ar-H) 8.30-8.36 (2H, m, Ar-H) 8.03 (1H, d, J =4 Hz, Ar-H) 7.55-7.60 (2H, m, Ar-
H) 7.40-7.45 (1H, m, Ar-H) 2.34 (2H, t, J =8 Hz, CH2) 1.62 (3H, t, J = 8 Hz, CH3) 
1.26-1.31 (8H, m, CH2); 13C NMR (100 MHz, DMSO-d6) δ 172.0, 148.2, 140.6, 
136.2, 133.9, 130.9, 130.0, 128.5 (q, J C-F=30 Hz) 125.8, 123.0 (q, J C-F=270 Hz) 
120.8, 120.6, 119.9, 119.7, 116.5, 37.0, 31.8, 29.1, 29.1, 25.7, 22.7, 14.5; 19F NMR 
(470 MHz, CDCl3): δ −61.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C23H24F3N5O3 476.19040, found 476.19070 
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N-(3-(1-[4-Nitro-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-
yl)phenyl)benzamide 143 
 
Prepared via general method (F) 
mp 216.0-218.1 °C; ν (max) cm-1 3455, 3001, 2467, 1290, 1108, 801, 590; 1H NMR 
(400 MHz, DMSO-d6) δ 10.43 (1H, s, Ar-H) 9.51 (1H, s, Ar-H) 8.46-8.52 (2H, m, 
Ar-H) 8.36 (1H, d, J = 5.4 Hz, Ar- H) 8.01-8.03 (3H, m, Ar-H) 7.79-7.82 (1H, m, 
Ar-H) 7.48-7.67 (6H, m, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ 166.2, 148.2, 
140.4, 136.2, 135.3, 133.9, 132.2, 130.9, 129.9, 129.0, 128.3, 125.8, 121.5, 121.0, 
120.7, 119.8, 117.9; 19F NMR (470 MHz, CDCl3): δ −61.5; HRMS (ESI-TOF) m/z: 
[M + H]+ Calcd for C22H14F3N5O3 454.11215, found 454.11235 
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